create table tnmList(pk INTEGER, description TEXT);

INSERT INTO tnmList(pk, description) VALUES (10, 'Gastric Cancer');
INSERT INTO tnmList(pk, description) VALUES (20, 'Colorectal Cancer');
--INSERT INTO tnmList(pk, description) VALUES (30, 'Esophageal Squamous Cell Cancer');
INSERT INTO tnmList(pk, description) VALUES (40, 'TNM for Carcinoma of Breast');
INSERT INTO tnmList(pk, description) VALUES (50, 'Lung Cancer');
INSERT INTO tnmList(pk, description) VALUES (60, 'Prostate Cancer');
INSERT INTO tnmList(pk, description) VALUES (70, 'Bladder Cancer');
--INSERT INTO tnmList(pk, description) VALUES (80, 'TNM Anatomic Groups for Prognostic Cancer');
INSERT INTO tnmList(pk, description) VALUES (90, 'Testicular Cancer');

create table tnmT(listID INTEGER, code TEXT, description TEXT);

INSERT INTO tnmT(listID, code, description) VALUES(10, 'TX','Primary tumor cannot be assessed');
INSERT INTO tnmT(listID, code, description) VALUES(10, 'TO','No evidence of primary tumor');
INSERT INTO tnmT(listID, code, description) VALUES(10, 'Tis','Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria');
INSERT INTO tnmT(listID, code, description) VALUES(10, 'T1','Tumor invades lamina propria, muscularis mucosae, or submucosa');
INSERT INTO tnmT(listID, code, description) VALUES(10, 'T1a','Tumor invades lamina propria or muscularis mucosae');
INSERT INTO tnmT(listID, code, description) VALUES(10, 'T1b','Tumor invades submucosa');
INSERT INTO tnmT(listID, code, description) VALUES(10, 'T2','Tumor invades muscularis propria*');
INSERT INTO tnmT(listID, code, description) VALUES(10, 'T3','Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structucres??');
INSERT INTO tnmT(listID, code, description) VALUES(10, 'T4','Tumor invades serosa (visceral peritoneum) or adjacent structures??');
INSERT INTO tnmT(listID, code, description) VALUES(10, 'T4a','Tumor invades serosa (visceral peritoneum)');
INSERT INTO tnmT(listID, code, description) VALUES(10, 'T4b','Tumor invades adjacent structures');

create table tnmN(listID INTEGER, code TEXT, description TEXT);

INSERT INTO tnmN(listID, code, description) VALUES(10, 'NX','Regional lymph node(s) cannot be assessed');
INSERT INTO tnmN(listID, code, description) VALUES(10, 'NO','No regional lymph node metastasiso');
INSERT INTO tnmN(listID, code, description) VALUES(10, 'N1','Metastasis in L-2 regional lymph nodes');
INSERT INTO tnmN(listID, code, description) VALUES(10, 'N2','Metastasis in 3-6 regional lymph nodes');
INSERT INTO tnmN(listID, code, description) VALUES(10, 'N3','Metastasis in seven or more regional lymph nodes');
INSERT INTO tnmN(listID, code, description) VALUES(10, 'N3a','Metastasis in 7-15 regional lymph nodes');
INSERT INTO tnmN(listID, code, description) VALUES(10, 'N3b','Metastasis in 16 or more regional lymph nodes');

create table tnmM(listID INTEGER, code TEXT, description TEXT);

INSERT INTO tnmM(listID, code, description) VALUES(10, 'MO','No distant metastasis');
INSERT INTO tnmM(listID, code, description) VALUES(10, 'M1','Distant metastasis');

create table tnmG(listID INTEGER, code TEXT, description TEXT);

create table tnmStage(listID INTEGER, t_code TEXT, n_code TEXT, m_code TEXT, g_code TEXT, stage TEXT);

INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'Tis','NO','MO','Stage 0');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T1','NO','MO','Stage IA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T2','NO','MO','Stage IB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T1','N1','MO','Stage IB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T3','NO','MO','Stage IIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T2','N1','MO','Stage IIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T1','N2','MO','Stage IIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T4a','NO','MO','Stage IIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T3','N1','MO','Stage IIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T2','N2','MO','Stage IIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T1','N3','MO','Stage IIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T4a','N1','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T3','N2','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T2','N3','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T4b','NO','MO','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T4b','N1','MO','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T4a','N2','MO','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T3','N3','MO','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T4b','N2','MO','Stage IIIC');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T4b','N3','MO','Stage IIIC');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'T4a','N3','MO','Stage IIIC');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(10, 'Any T','Any N','M1','Stage IV');


INSERT INTO tnmT(listID, code, description) VALUES(20, 'TX','Primary tumor cannot be assessed');
INSERT INTO tnmT(listID, code, description) VALUES(20, 'TO','No evidence of primary tumor');
INSERT INTO tnmT(listID, code, description) VALUES(20, 'Tis','Carcinoma in situ: intraepithelial or invasion of lamina propria*');
INSERT INTO tnmT(listID, code, description) VALUES(20, 'T1','Tumor invades submucosa');
INSERT INTO tnmT(listID, code, description) VALUES(20, 'T2','Tumor invades muscularis propria');
INSERT INTO tnmT(listID, code, description) VALUES(20, 'T3','Tumor invades through the muscularis propria into pericolorectal tissues');
INSERT INTO tnmT(listID, code, description) VALUES(20, 'T4a','Tumor penetrates to the surface of the visceral peritoneum?');
INSERT INTO tnmT(listID, code, description) VALUES(20, 'T4b','Tumor directly invades or is adherent to other organs or structures??');


INSERT INTO tnmN(listID, code, description) VALUES(20, 'NX','Regional lymph nodes cannot be assessed');
INSERT INTO tnmN(listID, code, description) VALUES(20, 'NO','No regional lymph node metastasis');
INSERT INTO tnmN(listID, code, description) VALUES(20, 'N1','Metastasis in 1-3 regional lymph nodes');
INSERT INTO tnmN(listID, code, description) VALUES(20, 'N1a','Metastasis in one regional lymph node');
INSERT INTO tnmN(listID, code, description) VALUES(20, 'N1b','Metastasis in 2-3 regional lymph nodes');
INSERT INTO tnmN(listID, code, description) VALUES(20, 'N1c','Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional nodal metastasis');
INSERT INTO tnmN(listID, code, description) VALUES(20, 'N2','Metastasis in four or more regional lymph nodes');
INSERT INTO tnmN(listID, code, description) VALUES(20, 'N2a','Metastasis in 4-6 regional lymph nodes');
INSERT INTO tnmN(listID, code, description) VALUES(20, 'N2b','Metastasis in seven or more regional lymph nodes');

INSERT INTO tnmM(listID, code, description) VALUES(20, 'MO','No distant metastasis');
INSERT INTO tnmM(listID, code, description) VALUES(20, 'M1','Distant metastasis');
INSERT INTO tnmM(listID, code, description) VALUES(20, 'M1a','Metastasis confined to one organ or site (eg: liver, lung, ovary, nonregional node)');
INSERT INTO tnmM(listID, code, description) VALUES(20, 'M1b','Metastases in more than one organ/site or the peritoneum');

INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'Tis','NO','MO','Stage 0');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T1','NO','MO','Stage I');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T2','NO','MO','Stage I');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T3','NO','MO','Stage IIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T4a','NO','MO','Stage IIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T4b','NO','MO','Stage IIC');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T1','N1','M0','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T1','N1c','M0','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T2','N1','M0','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T2','N1c','M0','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T1','N2a','M0','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T3','N1','M0','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T3','N1c','M0','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T4a','N1','M0','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T4a','N1c','M0','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T2','N2a','M0','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T3','N2a','M0','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T1','N2b','M0','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T2','N2b','M0','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T4a','N2a','M0','Stage IIIC');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T3','N2b','M0','Stage IIIC');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T4a','N2b','M0','Stage IIIC');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T4b','N1-N2','M0','Stage IIIC');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'Any T','Any N','M1a','Stage IVA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'Any T','Any N','M1b','Stage IVB');

INSERT INTO tnmT(listID, code, description) VALUES(40, 'TX ','Primary tumor cannot be assessed');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'TO','No evidence of primary tumor');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'Tis','Carcinoma in situ');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'T1','Tumor ?20 mm in greatest dimension');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'Tlmi','Tumor ?1 mm in greatest dimension');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'T1a','Tumor >1 mm but ?5 mm in greatest dimension');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'T1b','Tumor >5 mm but ?10 mm in greatest dimension');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'T1c','Tumor >10 mm but ?20 mm in greatest dimension');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'T2','Tumor >20 mm but ?50 mm in greatest dimension');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'T3','Tumor >50 mm in greatest dimension');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'T4?','Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules)');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'T4a','Extension to the chest wall, not including only pectoralis muscle adherence/invasion');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'T4b','Ulceration and/or ipsilateral satellite nodules and/or edema (including peau d''orange) of the skin, which do not meet the criteria for inflammatory carcinoma');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'T4c','Both T4a and T4b');
INSERT INTO tnmT(listID, code, description) VALUES(40, 'T4d','Inflammatory carcinoma§');

INSERT INTO tnmN(listID, code, description) VALUES(40, 'pNX','Regional lymph nodes cannot be assessed (eg, previously removed, or not removed for pathologic study)');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN0','No regional lymph node metastasis identified histologically');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN0(i- )','No regional lymph node metastases histologically, negative immunohistochemistry (IHC)');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN0(i+)','Malignant cells in regional lymph node(s) no greater than 0.2 mm (detected by H&E or IHC including isolated tumor cell clusters (ITC))');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN0(mol-)','No regional lymph node metastases histologically, negative molecular findings (RT-PCR)??');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN0(mol+)','Positive molecular findings (RT-PCR)??, but no regional lymph node metastases detected bV histology or IHC');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN1','Micrometastases; or metastases in 1-3 axillary lymph nodes; and/or in internal mammary nodes with metastases detected by sentinel lymph node biop-sy but not clinically detected ??');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN 1mi','Micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0 mm');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN 1a','Metastases in 1-3 axillary lymph nodes, at least one metastasis greater than 2.0 mm');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN 1b','Metastases in internal mammary nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected ??');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN 1c','Metastases in 1-3 axillary lymph nodes and in internal mammary or macrometastases detected by sentinel lymph node biopsy but lymph nodes with micrometastases not clinically detected');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN2','Metastases in 4-9 axillary lymph nodes; or in clinically detected?? internal mammary lymph nodes in the absence of axillary lymph node metastases');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN2a','Metastases in 4-9 axillary lymph nodes (at least one tumor deposit greater than 2.0 mm)-..-');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN2b','Metastases in clinically detectedoo internal mammary lymph nodes in the absence of axillary lymph node metastases');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN3','Metastases in ten or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or in clinically detectedoo ipsilateral internal mammary lymph nodes in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected ??; or in ipsilateral supraclavicular lymph nodes');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN3a','Metastases in ten or more axillary lymph nodes (at least one tumor deposit greater than 2.0 mm); or metastases to the infraclavicular (level III axillary lymph) nodes');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN3b','Metastases in clinically detected?? ipsilateral internal mammary lymph nodes in the presence of one or more positive axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected ??');
INSERT INTO tnmN(listID, code, description) VALUES(40, 'pN3c','Metastases in ipsilateral supraclavicular lymph nodes');

INSERT INTO tnmM(listID, code, description) VALUES(40, 'MO','No clinical or radiographic evidence of distant metastases');
INSERT INTO tnmM(listID, code, description) VALUES(40, 'M1','Distant detectable metastases as determined by classic clinical and radiographic means');

INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'Tis','pNO','MO','Stage 0');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T1','pNO','MO','Stage IA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'TO','pNNmi','MO','Stage IB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T1','pN1mi','MO','Stage IB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'TO','pN1','MO','Stage IIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T1','pN1','MO','Stage IIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T2','pNO','MO','Stage IIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T2','pN1','MO','Stage IIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T3','pNO','MO','Stage IIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'TO','pN2','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T1','pN2','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T2','pN2','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T3','pN1','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T3','pN2','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T4','pNO','MO','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T4','pN1','MO','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'T4','pN2','MO','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'Any T','pN3','MO','Stage IIIC');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(20, 'Any T','pAny N','M1','Stage IV');


INSERT INTO tnmT(listID, code, description) VALUES(50, 'T1','Tumor ?3 cm diameter, surrounded by lung or visceral pleura, without invasion more proximal than lobar bronchus');
INSERT INTO tnmT(listID, code, description) VALUES(50, 'T1a','Tumor ?2 cm in diameter');
INSERT INTO tnmT(listID, code, description) VALUES(50, 'T1b','Tumor >2 cm but ?3 cm in diameter');
INSERT INTO tnmT(listID, code, description) VALUES(50, 'T2','Tumor >3 cm but ?7 cm, or tumor with any of the following features: Involves main bronchus, >2 cm distal to carina Invades visceral pleura Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung');
INSERT INTO tnmT(listID, code, description) VALUES(50, 'T2a','Tumor >3 cm but ?5 cm');
INSERT INTO tnmT(listID, code, description) VALUES(50, 'T2b','Tumor >5 cm but ?7 cm');
INSERT INTO tnmT(listID, code, description) VALUES(50, 'T3','Tumor >7 cm or any of the following: Directly invades any of the following: chest wall, diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium, main bronchus <2 cm from carina (without involvement of carina) Atelectasis or obstructive pneumonitis of the entire lung Separate tumor nodules in the same lobe');
INSERT INTO tnmT(listID, code, description) VALUES(50, 'T4','Tumor of any size that invades the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, or with separate tumor nodules in a different ipsilateral lobe');

INSERT INTO tnmN(listID, code, description) VALUES(50, 'N0','No regional lymph node metastases');
INSERT INTO tnmN(listID, code, description) VALUES(50, 'N1','Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension');
INSERT INTO tnmN(listID, code, description) VALUES(50, 'N2','Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)');
INSERT INTO tnmN(listID, code, description) VALUES(50, 'N3','Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)');

INSERT INTO tnmM(listID, code, description) VALUES(50, 'MO','No distant metastasis');
INSERT INTO tnmM(listID, code, description) VALUES(50, 'M1','Distant metastasis');
INSERT INTO tnmM(listID, code, description) VALUES(50, 'M1a ','Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural or pericardial effusion');
INSERT INTO tnmM(listID, code, description) VALUES(50, 'Mlb','Distant metastasis (in extrathoracic organs)');

INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T1a','N0','M0','Stage IA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T1b','N0','M0','Stage IA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T2a','N0','M0','Stage IB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'Tla','N1','MO','Stage IIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T1b','N1','MO','Stage IIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T2a','N1','MO','Stage IIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T2b','NO','MO','Stage IIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T2b','N1','MO','Stage IIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T3','NO','MO','Stage IIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'Tla','N2','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'Tlb','N2','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T2a','N2','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T2b','N2','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T3','N1','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T3','N2','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T4','N0','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T4','N1','MO','Stage IIIA');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'T4','N2','MO','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'Any T','N3','MO','Stage IIIB');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'Any T','Any N','M1a','Stage IV');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(50, 'Any T','Any N','M1b','Stage IV');


INSERT INTO tnmT(listID, code, description) VALUES(70, 'TX','Primary tumor cannot be assessed');
INSERT INTO tnmT(listID, code, description) VALUES(70, 'TO','No evidence of primary tumor');
INSERT INTO tnmT(listID, code, description) VALUES(70, 'Ta','Noninvasive papillary carcinoma');
INSERT INTO tnmT(listID, code, description) VALUES(70, 'Tis','Carcinoma in situ: "flat tumor"');
INSERT INTO tnmT(listID, code, description) VALUES(70, 'T1','Tumor invades subepithelial connective tissue');
INSERT INTO tnmT(listID, code, description) VALUES(70, 'T2','Tumor invades muscularis propria');
--INSERT INTO tnmT(listID, code, description) VALUES(70, 'pT2a','Tumor invades superficial muscularis propria (inner half)');
--INSERT INTO tnmT(listID, code, description) VALUES(70, 'pT2b','Tumor invades deep muscularis propria (outer half)');
INSERT INTO tnmT(listID, code, description) VALUES(70, 'T3','Tumor invades perivesical tissue');
--INSERT INTO tnmT(listID, code, description) VALUES(70, 'pT3a','Microscopically');
--INSERT INTO tnmT(listID, code, description) VALUES(70, 'pT3b',' Macroscopically (extravesical mass) .');
INSERT INTO tnmT(listID, code, description) VALUES(70, 'T4','Tumor invades any of the following: prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall');
INSERT INTO tnmT(listID, code, description) VALUES(70, 'T4a','Tumor invades prostatic stroma, uterus, vagina');
INSERT INTO tnmT(listID, code, description) VALUES(70, 'T4b','Tumor invades pelvic wall, abdominal wall');

INSERT INTO tnmN(listID, code, description) VALUES(70, 'NX',' Lymph nodes cannot be assessed');
INSERT INTO tnmN(listID, code, description) VALUES(70, 'N0','No lymph node metastasis');
INSERT INTO tnmN(listID, code, description) VALUES(70, 'N1','Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node)');
INSERT INTO tnmN(listID, code, description) VALUES(70, 'N2','Multiple regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node metastasis)');
INSERT INTO tnmN(listID, code, description) VALUES(70, 'N3','Lymph node metastasis to the common iliac lymph nodes');

INSERT INTO tnmM(listID, code, description) VALUES(70, 'M0','No distant metastasis');
INSERT INTO tnmM(listID, code, description) VALUES(70, 'M1','Distant metastasis');

INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'Ta','N0','M0','Stage 0a');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'Tis','N0','M0','Stage 0is');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'T1','N0','M0','Stage I');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'T2a','N0','M0','Stage II');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'T2b','N0','M0','Stage II');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'T3a','N0','M0','Stage III');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'T3b','N0','M0','Stage III');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'T4a','N0','M0','Stage III');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'T4b','N0','M0','Stage IV');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'Any T','N1','M0','Stage IV');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'Any T','N2','M0','Stage IV');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'Any T','N3','M0','Stage IV');
INSERT INTO tnmStage(listID, t_code, n_code, m_code, stage) VALUES(70, 'Any T','Any N','M1','');


create table ECOGTCGroup(GroupId INTEGER, title TEXT);
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(100,'Leukopenia');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(110,'Thrombocytopenia');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(120,'Anemia');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(130,'Hemorrhage (Clinical)');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(140,'Infection');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(150,'Fever in absence of infection');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(160,'GU');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(170,'GI');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(180,'Liver');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(190,'Pulmonary');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(200,'Cardiac');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(210,'Blood Pressure');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(220,'Skin');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(230,'Allergy');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(240,'Phlebitis');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(250,'Local');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(260,'Alopecia');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(270,'Weight gain/loss');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(280,'Neurologic Sensory');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(290,'Neurologic Motor');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(300,'Neurologic Psych');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(310,'Neurologic Clinical');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(320,'Metabolic');
INSERT INTO ECOGTCGroup(GroupId, title) VALUES(330,'Coagulation');

create table ECOGTCSubGroup(SubGroupId INTEGER, GroupId INTEGER, title TEXT);
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(10,100,'WBC x 10^^^');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(11,100,'Granulocytes/Bands');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(12,100,'Lymphocytes');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(13,110,'Plt x 10^^^');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(14,120,'Hgb');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(15,130,'Hemorrhage (Clinical)');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(16,140,'Infection');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(17,150,'Fever in absence of infection');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(18,160,'Creatinine');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(19,160,'Proteinuria');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(20,160,'Hematuria');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(21,160,'BUN');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(22,170,'Nausea');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(23,170,'Vomiting');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(24,170,'Diarrhea');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(25,170,'Stomatitis');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(26,180,'Bilirubin');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(27,180,'Transaminase (SGOT, SGPT)');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(28,180,'Alk Phos or 5''nucleotidase');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(29,180,'Liver - clinical');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(30,190,'Pulmonary');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(31,200,'Cardiac dysrhythmias');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(32,200,'Cardiac function');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(33,200,'Cardiac—ischemia');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(34,200,'Cardiac –pericardial');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(35,210,'Hypertension');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(36,210,'Hypotension');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(37,220,'Skin');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(38,230,'Allergy');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(39,240,'Phlebitis');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(40,250,'Local');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(41,260,'Alopecia');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(42,270,'Weight gain/loss');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(43,280,'neuro—sensory');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(44,280,'neuro—vision');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(45,280,'neuro—haering');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(46,290,'neuro—motor');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(47,290,'neuro—constipation');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(48,300,'neuro—mood');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(49,310,'neuro—cortical');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(50,310,'neuro—cerebellar');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(51,310,'neuro—headache');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(52,320,'Hyperglycemia');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(53,320,'Hypoglycemia');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(54,320,'Amylase');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(55,320,'Hypercalcemia');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(56,320,'Hypocalcemia');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(57,320,'Hypomagnesemia');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(58,330,'Fibrinogen');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(59,330,'Prothrombin time');
INSERT INTO ECOGTCSubGroup(SubGroupId, GroupId, title) VALUES(60,330,'Partial thromboplastin time');



create table ECOGTCOptions(SubGroupId INTEGER, title TEXT, grade INTEGER);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(10,'>= 4.0',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(11,'>= 2.0',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(12,'>= 2.0',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(13,'WNL',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(14,'WNL',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(15,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(16,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(17,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(18,'WNL',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(19,'No Change',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(20,'neg',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(21,'< 1.5 x N',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(22,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(23,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(24,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(25,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(26,'WNL',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(27,'WNL',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(28,'WNL',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(29,'no change from baseline',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(30,'none or no change',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(31,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(32,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(33,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(34,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(35,'none or no change',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(36,'none or no change',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(37,'none or no change',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(38,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(39,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(40,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(41,'no loss',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(42,'< 5.0%',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(43,'none or no change',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(44,'none or no change',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(45,'none or no change',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(46,'none or no change',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(47,'none or no change',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(48,'No Change',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(49,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(50,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(51,'none',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(52,'<116',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(53,'>64',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(54,'WNL',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(55,'<10.6',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(56,'>8.4',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(57,'>1.4',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(58,'WNL',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(59,'WNL',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(60,'WNL',0);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(10,'3.0 – 3.9',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(11,'1.5 – 1.9',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(12,'1.5 – 1.9',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(13,'75.0 – normal',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(14,'10.0 – normal',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(15,'mild, no transfusion',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(16,'mild, no active Rx',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(17,'37.1^degC - 38.0^degC ^nl98.7^degF- 100.4^degF',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(18,'< 1.5 x N',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(19,'1+ or <0.3g% or <3g/l',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(20,'micro only',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(21,'1.5 - 2.5 x N',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(22,'able to eat reasonable intake',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(23,'1 episode in 24 hours',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(24,'increase of 2-3 stools/day over pre-Rx',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(25,'painless ulcers, erythema, or mild soreness',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(27,'<= 2.5xN',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(28,'<= 2.5xN',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(30,'asymptomatic, with abnormality in PFTs',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(31,'asymptomatic, transient, requiring no therapy',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(32,'asymptomatic, decline of resting ejection fraction by less than 20% of baseline value',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(33,'non-specific T-wave flattening',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(34,'asymptomatic effusion, no intervension required',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(35,'asymptomatic, transient increase by >20 mm Hg(D) or to >150/100 if previously WNL. No treatment required',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(36,'changes requiring no therapy (including transient orthostatic hypotension)',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(37,'scattered macular or papular eruption or erythema that is asymptomatic',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(38,'transient rash, drug fever < 38ºC, 100.4ºF',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(39,'arm',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(40,'pain',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(41,'mild hair loss',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(42,'5.0 - 9.9%',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(43,'mild paresthesias; loss of deep tendon reflexes',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(45,'asymptomatic, hearing loss on audiometry only',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(46,'subjective weakness; no objective findings',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(47,'mild',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(48,'mild anxiety or depression',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(49,'mild somnolence or agitation',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(50,'slight incoordination, dysdiadockinesis',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(51,'mild',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(52,'116 - 160 ',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(53,'55-64 ',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(54,'<1.5xN ',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(55,'10.6 - 11.5 ',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(56,'8.4 - 7.8 ',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(57,'1.4 - 1.2',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(58,'0.99-0.75xN ',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(59,'1.01-1.25xN',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(60,'1.01-1.66xN',1);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(10,'2.0 – 2.9',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(11,'1.0 – 1.4',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(12,'1.0 – 1.4',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(13,'50.0 – 74.9',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(14,'8.0 – 10.0',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(15,'gross, 1-2 units transfusion/episode',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(16,'Moderate, localized infection requires active Rx',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(17,'38.1^degC - 40.0^degC ^nl100.5^degF - 104.0^degF',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(18,'1.5 - 3.0 x N',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(19,'2-3+ or 0.3 - 1.0g% or 3 - 10g/l',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(20,'gross, no clots',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(21,'2.6 - 5 x N',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(22,'intake significantly decreased but can eat',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(23,'2-5 episodes in 24 hours',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(24,'increase of 4-6 stools/day, or nocturnal stools, or moderate cramping',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(25,'painful erythema, edema, or ulcers, but can eat',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(26,'<1.5 x N',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(27,'2.6 - 5.0 x N',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(28,'2.6 - 5.0 x N',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(30,'dyspnea on significant exertion',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(31,'recurrent or persistent, no therapy required',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(32,'asymptomatic, decline of resting ejection fraction by more than 20% of baseline value',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(33,'asymptomatic, ST and T wave changes suggesting ischemia',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(34,'pericarditis (rub, chest pain, ECG changes)',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(35,'recurrent or persistent increase by >20 mm Hg',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(36,'requires fluid replacement or other therapy but not hospitalization',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(37,'scattered macular or papular eruption or erythema with pruritus or other associated symptoms',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(38,'urticaria, drug fever $ 38EC, 100.4EF, mild bronchospasm',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(39,'thrombophlebitis, leg',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(40,'pain and swelling, with inflammation or phlebitis',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(41,'pronounced or total hair loss',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(42,'10.0 - 19.9%',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(43,'mild or moderate objective sensory loss; moderate paresthesias',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(45,'tinnitus',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(46,'mild objective weakness without significant impairment of function',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(47,'moderate',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(48,'moderate anxiety or depression',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(49,'moderate somnolence or agitation',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(50,'intention tremor, dysmetria, slurred speech, nystagmus',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(51,'moderate or severe but transient',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(52,'161 - 250 ',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(53,'40-54 ',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(54,'1.5-2.0xN ',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(55,'11.6 - 12.5 ',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(56,'7.7 - 7.0',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(57,'1.1 - 0.9',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(58,'0.74-0.50xN ',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(59,'1.26-1.50xN',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(60,'1.67-2.33xN',2);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(10,'1.0 – 2.9',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(11,'0.5 – 0.9',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(12,'0.5 – 0.9',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(13,'25.0 – 49.9',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(14,'6.5 – 7.9',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(15,'gross, 3-4 units transfusion/episode',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(16,'severe, systemic infection requires active Rx, specify site',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(17,'> 40.0^degC (> 104.0^degF) for less than 24 hours',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(18,'3.1-6.0xN',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(19,'4+ or >1.0g% or >10g/l',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(20,'gross + clots',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(21,'5.1-10xN',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(22,'no significant intake',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(23,'6-10 episodes in 24 hours',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(24,'increase of 7-9 stools/day or incontinence, or severe cramping',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(25,'painful erythema, edema or ulcers, and cannot eat',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(26,'1.5-3.0xN',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(27,'5.1-20.0xN',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(28,'5.1-20.0xN',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(29,'precoma',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(30,'dyspnea at normal level of activity',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(31,'requires treatment',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(32,'mild CHF, responsive to therapy',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(33,'angina without evidence for infarction',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(34,'symptomatic effusion; drainage required',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(35,'requires therapy',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(36,'requires therapy and hospitalization; resolves within 48 hours of stopping the agent',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(37,'generalized symptomatic macular, papular or vesicular eruption',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(38,'serum sickness, bronchospasm, requires parenteral meds',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(39,'hospitalization',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(40,'ulceration',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(42,'>= 20%',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(43,'severe objective sensory loss or paresthesias that interfere with function',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(44,'symptomatic subtotal loss of vision',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(45,'hearing loss interfering with function but correct- able with hearing aid',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(46,'objective weakness with impairment of function',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(47,'severe',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(48,'severe anxiety or depression',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(49,'severe somnolence, agitation, confusion, disorientation or hallucinations',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(50,'locomotor ataxia',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(51,'unrelenting and severe',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(52,'251 - 500 ',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(53,'30-39 ',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(54,'2.1-5.0xN ',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(55,'12.6 - 13.5 ',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(56,'6.9 - 6.1',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(57,'0.8 - 0.6',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(58,'0.49-0.25xN ',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(59,'1.51-2.00xN',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(60,'2.34-3.00xN',3);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(10,'< 1.0',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(11,'< 0.5',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(12,'< 0.5',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(13,'< 25.0',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(14,'< 6.5',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(15,'massive, >4 units transfusion/episode',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(16,'life-threatening, sepsis, specify site',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(17,'>40.0^degC (104.0^degF) for >24 hrs or fever with hypotension',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(18,'>6.0 x N',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(19,'nephrotic syndrome',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(20,'requires transfusion',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(21,'>10 x N',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(23,'>10 episodes in 24 hrs or',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(24,'increase of $10 stools/day or grossly bloody diarrhea, or need for parenteral support',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(25,'requires parenteral or enteral support',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(26,'>3.0 x N',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(27,'>20.0 x N',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(28,'>20.0 x N',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(29,'hepatic coma',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(30,'dyspnea at rest',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(31,'requires monitoring, or',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(32,'hypotension or ventricular tachycardia or fibrillation',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(33,'acute myocardial infarction',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(34,'tamponade; drainage urgently required',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(35,'hypertensive crisis',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(36,'requires therapy and hospitalization for >48 hours after stopping the agent',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(37,'exfoliative dermatitis or ulcerating dermatitis',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(38,'anaphylaxis',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(39,'embolus',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(40,'plastic surgery indicated',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(44,'blindness',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(45,'deafness, not correctable',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(46,'paralysis',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(47,'ileus >96 hours',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(48,'suicidal ideation',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(49,'coma, seizures, toxic psychosis',4);
INSERT INTO ECOGTCOptions(SubGroupId, title, grade) VALUES(50,'cerebellar necrosis',4);



create table PatientType(pk INTEGER PRIMARY KEY, title TEXT);
create table CancerType(pk INTEGER, PatientTypeId INTEGER, title TEXT);
create table SubCancerType1(pk INTEGER PRIMARY KEY, CancerTypeId INTEGER, title TEXT);
create table SubCancerType2(pk INTEGER PRIMARY KEY, SubCancerTypeId1 INTEGER, title TEXT);
create table RegimenDetail(pk INTEGER PRIMARY KEY, SubCancerTypeId2 INTEGER, disp_name TEXT, name TEXT, schedule TEXT, emetogenic_potential TEXT, reference TEXT, dosage_modifications TEXT, brand_names TEXT);


INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (1, 47, 'CNS Tumors');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (2, 48, 'Head & Neck Malignancies');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (3, 49, 'Anal Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (4, 50, 'Colon and rectal Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (5, 51, 'Esophegeal Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (6, 52, 'Gastric Cancer');
--INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (7, 53, 'Gastric Carcinoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (8, 54, 'Gastrointestinal Stromal Tumor (GIST)');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (9, 55, 'Biliary Tract Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (10, 55, 'Hepatocellular Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (11, 56, 'Pancreatic Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (12, 57, 'Non-Small Cell');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (13, 58, 'Small Cell');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (14, 59, 'Thymoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (15, 60, 'HER-2 Neu Negative');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (16, 61, 'HER-2 Neu Positive');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (17, 62, 'Hormonal Therapy');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (18, 63, 'Cervical');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (19, 64, 'Endometrial');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (20, 65, 'Ovarian');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (21, 66, 'Bladder');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (22, 67, 'Kidney');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (23, 68, 'Harmone-Refractory');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (24, 68, 'Hormonal');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (25, 69, 'Testicular');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (26, 70, 'Sarcoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (27, 71, 'Kaposi''s Sarcoma- AIDS Related');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (28, 72, 'Unknown Primary');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (29, 73, 'AIDS-Related');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (30, 74, 'Hodgkin''s');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (31, 75, 'Non-Hodgkin''s');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (32, 76, 'Acute Lymphocytic Leukemia (ALL)');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (33, 77, 'Acute Myeloid Leukemia (AML)');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (34, 78, 'Chronic Lymphocytic Leukemia (CLL)');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (35, 79, 'Chronic Myeloid Leukemia (CML)');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (36, 80, 'Hairy Cell Leukemia');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (37, 81, 'Myeloma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (38, 82, 'CNS Tumors');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (39, 83, 'Neuroblastoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (40, 84, 'Retinoblastoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (41, 85, 'Hepatoblastoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (42, 86, 'Wilms'' Tumor');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (43, 87, 'Osteosarcoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (44, 88, 'Soft tissue and Bone');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (45, 89, 'Hodgkin''s');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (46, 90, 'Non-Hodgkin''s');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (47, 91, 'Acute Lymphocytic Leukemia');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (48, 92, 'Acute Myeloid Leukemia');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (47, 1, 'CNS Tumors');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (48, 2, 'Head & Neck Malignancies');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (49, 3, 'Anal Cancer');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (50, 3, 'Colon and rectal Cancer');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (51, 3, 'Esophegeal Cancer');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (52, 3, 'Gastric Cancer');
--INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (53, 3, 'Gastric Carcinoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (54, 3, 'Gastrointestinal Stromal Tumor (GIST)');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (55, 3, 'Hepatobiliary');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (56, 3, 'Pancreatic Cancer');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (57, 4, 'Non-Small Cell');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (58, 4, 'Small Cell');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (59, 4, 'Thymoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (60, 5, 'HER-2 Neu Negative');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (61, 5, 'HER-2 Neu Positive');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (62, 5, 'Hormonal Therapy');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (63, 6, 'Cervical');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (64, 6, 'Endometrial');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (65, 6, 'Ovarian');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (66, 7, 'Bladder');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (67, 7, 'Kidney');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (68, 7, 'Prostate');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (69, 7, 'Testicular');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (70, 8, 'Sarcoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (71, 9, 'Kaposi''s Sarcoma- AIDS Related');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (72, 10, 'Unknown Primary');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (73, 11, 'AIDS-Related');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (74, 11, 'Hodgkin''s');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (75, 11, 'Non-Hodgkin''s');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (76, 12, 'Acute Lymphocytic Leukemia (ALL)');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (77, 12, 'Acute Myeloid Leukemia (AML)');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (78, 12, 'Chronic Lymphocytic Leukemia (CLL)');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (79, 12, 'Chronic Myeloid Leukemia (CML)');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (80, 12, 'Hairy Cell Leukemia');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (81, 13, 'Myeloma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (82, 14, 'CNS Tumors');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (83, 15, 'Neuroblastoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (84, 16, 'Retinoblastoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (85, 17, 'Hepatoblastoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (86, 18, 'Wilms'' Tumor');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (87, 19, 'Osteosarcoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (88, 19, 'Soft tissue and Bone');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (89, 20, 'Hodgkin''s');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (90, 20, 'Non-Hodgkin''s');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (91, 21, 'Acute Lymphocytic Leukemia');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (92, 21, 'Acute Myeloid Leukemia');
INSERT INTO PatientType (pk, title) VALUES (1, 'Adult');
INSERT INTO PatientType (pk, title) VALUES (2, 'Pediatric');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (1, 1, 'CNS Tumors');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (2, 1, 'Head & Neck Malignancies');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (3, 1, 'Gastro Intestinal');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (4, 1, 'Thoracic');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (5, 1, 'Breast Cancer');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (6, 1, 'Gynecologic Malignancy');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (7, 1, 'Urinary Tract');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (8, 1, 'Sarcoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (9, 1, 'Kaposi''s Sarcoma- AIDS Related');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (10, 1, 'Unknown Primary');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (11, 1, 'Lymphoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (12, 1, 'Leukemia');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (13, 1, 'Myeloma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (14, 2, 'CNS Tumors');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (15, 2, 'Neuroblastoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (16, 2, 'Retinoblastoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (17, 2, 'Hepatoblastoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (18, 2, 'Wilms'' Tumor');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (19, 2, 'Sarcoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (20, 2, 'Lymphoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (21, 2, 'Leukemias');

INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (1, 1, 'Bevacizumab/Irinotecan', '<b>Bevacizumab/Irinotecan</b>', '<b>Bevacizumab</b> 15 mg/kg IV<br> Repeat Every 21 Days<br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> with enzyme-inducing antiepileptic drugs, days 1, 8, 22, 29<br> <b>OR</b><br> <b>Irinotecan</b> 125 mg/m<sup>2</sup> with non-enzyme-including antiepileptic drugs, IV, days 1, 8, 22, 29<br> Repeat every 6 weeks', 'Moderate', 'Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. $J Clin Oncol. 2007;25(30):4722-4279.$', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', 'Bevacizumab : Avastin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (2, 1, 'PCV', '<b>PCV</b>', '<b>Procarbazine</b> 60 mg/m<sup>2</sup>/d PO, days 8-21<br> <b>Lomustine</b> 110 mg/m<sup>2</sup> PO, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, days 8, 29<br> Repeat every 6 weeks upto 7 cycles ', 'Moderate-High', 'Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluromethylornithine- procarbazine, N-(2-chloroethyl)-N'' -cyclohexyl- N-nitrosuera, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. $Clin Cancer Res.2000;6(10):3878-3884.$', '<b>Hepatic Impairment</b><ul><li>Lomustine:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Lomustine:<br>If CrCl < 60 mL/min, do not use</li><li>Procarbazine:<br>If CrCl < 30 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Lomustine : CCNU<br>Procarbazine : Matulane<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (3, 1, 'Temozolomide+RT', '<b>Temozolomide+RT</b>', '<b>Temozolomide</b> 75 mg/m<sup>2</sup> daily along with radiation<br> <b>FOLLOWED 28 DAYS LATER BY</b><br><b>Temozolomide<sup>e</sup></b> 150 mg/m<sup>2</sup> daily for 5 days<br>Repeat every 28 days.', 'Moderate for IV<br> <=75 mg/m<sup>2</sup> PO is minimal-low;<br> >75 mg/m<sup>2</sup> PO is moderate-high   ', 'Stupp R, et al.  Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma.$N Engl J Med 2005; 352:987-996$', '<b>Hepatic Impairment</b><ul><li>Temozolomide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Temozolomide : Temodar');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (4, 1, 'BCNU (Carmustine)', '<b>BCNU (Carmustine)</b>', '<b>Carmustine</b> 200 mg/m<sup>2</sup> IV over 30-60 minutes<br> Repeat every 8 weeks ', 'High', 'Selker RG, Sharipo WR, Burger p, et al. The Brain tumor cooperative group NIH Trial 87-01: a randomized comparision of surgery, external radiotherapy, and carmustine versus surgery, interstital radiotherapy, and carmustine. $Neurosurgery.2002;51(2):343-355; discussion 355-357.$', '<b>Hepatic Impairment</b><ul><li>Carmustine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carmustine:<br>If CrCl < 60 mL/min, do not use</li></ul>', 'Carmustine : BCNU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (5, 1, 'Bevacizumab', '<b>Bevacizumab</b>', '<b>Bevacizumab</b> 10 mg/kg IV<br> Repeat every 14 days on a 28-day cycle<br><b>OR</b><br><b>Bevacizumab</b> 15 mg/kg IV<br> Repeat every 21 days ', 'Low', 'Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab plus irinotecan at tumor progression in recuurent glioblastoma. $J Clin Oncol. 2009;27(5):740-745.$                                                           Raizer JJ, Grimm S, et al. Aphase 2 trial of single-agent bevacizumab plus irinotecan at tumor progression in recurrent high- grade schedule for patients with recurrent high- grade gliomas. $Cancer.2010;116(22):597-5305.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Bevacizumab : Avastin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (6, 1, 'Temozolomide', '<b>Temozolomide</b>', '<b>Temozolomide</b> 150 mg/m<sup>2</sup> every day for 5 days per 28-day cycle<br> ', 'Moderate for IV<br> >75 mg/m<sup>2</sup> PO is moderate-high   ', 'Gállego Pérez-Larraya J, et al.Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.$J Clin Oncol. 2011 Aug 1;29(22):3050-5. doi: 10.1200/JCO.2011.34.8086. Epub 2011 Jun 27$', '<b>Hepatic Impairment</b><ul><li>Temozolomide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Temozolomide : Temodar');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (7, 2, 'Carboplatin/Fluorouracil/Cetuximab', '<b>Carboplatin/Fluorouracil/Cetuximab</b>', '<b>Carboplatin</b> AUC of 5, day 1<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days for a maximum of 6 cycles<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV load over 4 hours, day 1, cycle 1 <b>THEN</b> 250 mg/m<sup>2</sup> IV over 1 hour, every week.', 'Moderate', 'Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. $N Engl J Med. 2008;359(11):1116-1127.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Carboplatin : Paraplatin<br>Cetuximab : Erbitux<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (8, 2, 'CF', '<b>CF</b>', '<b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>5-Fluorouracil</b> 1000 mg/m<sup>2</sup>/day CIVI, days 1-4<br> Repeat every 21 days', 'High', 'Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. $J Clin Oncol. 2005;23(15):3562-3567.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (9, 2, 'Cisplatin/Fluorouracil/Cetuximab', '<b>Cisplatin/Fluorouracil/Cetuximab</b>', '<b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days for a maximuum of 6 cycles<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV load over 4 hours, day 1, cycle 1. <b>THEN</b> 250 mg/m<sup>2</sup> IV over 1 hour, every week', 'High', 'Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. $N Engl J Med. 2008;359(11):1116-1127.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Cetuximab : Erbitux<br>Cisplatin : CDDP<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (10, 2, 'Cisplatin + radiation', '<b>Cisplatin + radiation</b>', '<b>Cisplatin</b> 75 mg/m<sup>2</sup>  IV, days 1,22, 43 concomitantly with radiation', 'High', 'Franchin G, Minatel E, Politi D, et al. Postoperative reduced dose of cisplatin concomitant with radiatoin therapy in high-risk head and neck squamous cell carcinoma. $Cancer. 2009;115(11):2464-2471.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (11, 2, 'CP', '<b>CP</b>', '<b>Cisplatin</b> 75 mg/m<sup>2</sup>, day 1 and<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> over 3 hours on day 1<br> Repeat cycle every 21 days', 'High', 'Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. $J Clin Oncol. 2005;23(15):3562-3567.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cisplatin : CDDP<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (12, 2, 'TPF', '<b>TPF</b>', '<b>Docetaxel<sup>b</sup></b> 75mg/m<sup>2</sup> IV over 1 hour, day1<br> <b>Cisplatin</b> 75mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Fluorouraacil</b> 750 mg/m<sup>2</sup>/d, days 1-5<br> Repeat every 21 days<br> <b>OR</b><br> <b>Docetaxel<sup>b</sup></b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days for 3 cycles', 'High', 'Vermorken JB, Remenar E, Van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. $N Engl J Med. 2007;357(17):1695-1704.$<br> Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. $N Engl J Med. 2007;357(17):1705-1715.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (13, 2, 'Cetuximab', '<b>Cetuximab</b>', '<b>Cetuximab</b> 400 mg/m<sup>2</sup> loading dose over 120 minutes, <b>THEN</b> 250 mg/m<sup>2</sup> over 60 minutes, every 7 days', 'Low', 'Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival datat from a phase 3 randomised trial, and relation between cetuximab-induced rash and surival. $Lancet Oncol.2010;11(1):21-28.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Cetuximab : Erbitux');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (14, 5, '5-Fluorouracil + Cisplatin', '<b>5-Fluorouracil + Cisplatin</b>', '<b>5-Fluorouracil</b>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5<br><b>Cisplatin</b>100 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle on weeks 1, 5, 8, and 11.', 'High', '$Kies MS, et al. Cancer 1987;60:2156-2160.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (15, 5, 'Irinotecan + Cisplatin', '<b>Irinotecan + Cisplatin</b>', '<b>Irinotecan</b>65 mg/m<sup>2</sup> IV weekly for 4 weeks<br><b>Cisplatin</b>30 mg/m<sup>2</sup> IV weekly for 4 weeks<br>Repeat cycle every 6 weeks.', 'High', '$Ilson DH, et al. J Clin Oncol 1999;17:3270-3275.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (16, 5, 'Paclitaxel + Cisplatin', '<b>Paclitaxel + Cisplatin</b>', '<b>Paclitaxel</b>200 mg/m<sup>2</sup> IV over 24 hours on day 1<br><b>Cisplatin</b>75 mg/m<sup>2</sup> IV on day 2<br>Repeat cycle every 21 days. G-CSF support is recommended.', 'High', '$Ilson DH, et al. J Clin Oncol 1998;16:1826-1834.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cisplatin : CDDP<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (17, 5, 'Capecitabine + Oxaliplatin', '<b>Capecitabine + Oxaliplatin</b>', '<b>Capecitabine</b>1,000 mg/m<sup>2</sup> PO bid on days 1-14<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle every 21 days.', 'Moderate', '$Van Meerten E, et al. Br J Cancer 2007;96:1348-1352.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Capecitabine : Xeloda<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (18, 5, 'ECF', '<b>ECF</b>', '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Cisplatin</b>60 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>200 mg/m<sup>2</sup>/day IV continuous infusion for 24 weeks.<br>Repeat cycle every 21 days.', 'High', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP<br>Epirubicin : Ellence, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (19, 5, 'EOF', '<b>EOF</b>', '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>200 mg/m<sup>2</sup>/day IV continuous infusion for 24 weeks<br>Repeat cycle every 21 days.', 'Moderate', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', '<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Epirubicin : Ellence, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (20, 5, 'ECX', '<b>ECX</b>', '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Cisplatin</b>60 mg/m<sup>2</sup> IV on day 1<br><b>Capecitabine</b>625 mg/m<sup>2</sup> PO bid continuously<br>Repeat cycle every 21 days.', 'High', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Capecitabine : Xeloda<br>Cisplatin : CDDP<br>Epirubicin : Ellence, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (21, 5, 'EOX', '<b>EOX</b>', '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br><b>Capecitabine</b>625 mg/m<sup>2</sup> PO bid times 21 days<br>Repeat cycle every 21 days.', 'Moderate', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Capecitabine : Xeloda<br>Epirubicin : Ellence, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (22, 5, 'Paclitaxel', '<b>Paclitaxel</b>', '<b>Paclitaxel</b>250 mg/m<sup>2</sup> IV over 24 hours on day 1<br>Repeat cycle every 21 days. G-CSF support is recommended.', 'Moderate', '$Ajani JA, et al. Semin Oncol 1995;22 (Suppl 6):35-40.$', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (23, 6, 'DCF', '<b>DCF</b>', '<b>Docetaxel</b> 75mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 1-3 hours, day 1<br> <b>Fluorouracil</b> 750 mg/m<sup>2</sup>/d CIVI, days 1-5<br> Repeat every 21 days', 'High', 'Van Custem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus florouracil compared with cisplatin and flouorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. $J Clin Oncol. 2006;24(31):4991-4997$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Docetaxel : Taxotere<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (24, 6, 'Docetaxel/Cisplatin', '<b>Docetaxel/Cisplatin</b>', '<b>Docetaxel</b> 85 mg/m<sup>2</sup> IV over 1 hour, day 1,<br> <b>FOLLOWED BY</b><br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1<br> Repeat every 21 days for a maximum of 8 cycles', 'High', 'Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. $Ann Oncol. 2000;11(3):301-306$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (25, 6, 'ECF', '<b>ECF</b>', '<b>Epirubicin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 60 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 200 mg/m<sup>2</sup>/d CIVI, for up to 6 months<br> Repeat every 21 days for a maximum of 8 cycles', 'High', 'Waters JS, Norman A, Cunningham D, et al. Long-term survival afer epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. $Br J Cancer. 1999;80(1-2):269-272.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP<br>Epirubicin : Ellence, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (26, 6, 'ELF', '<b>ELF</b>', '<b>Leucovorin calcium</b> 300 mg/m<sup>2</sup>/d IV over 10 minutes, <b>FOLLOWED BY</b><br> <b>Etoposide</b> 120 mg/m<sup>2</sup>/d IV over 50 minutes,<br> <b>THEN</b><br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup>/d IV  bolus<br> Give all agents on days 1-3; repeat every 22 days', 'Low', 'Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional flurorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gasttrointestinal Tract Cancer Cooperative Group. $J Clin Oncol. 2000;18(41):2648-2657$', '<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Etoposide : VP-16<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (27, 6, '5-FU/LV and Radiation', '<b>5-FU/LV and Radiation</b>', '<b>Fluorouracil</b> 425 mg/m<sup>2</sup>/d for 5 days<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d for 5 days,<br> <b>FOLLOWED BY</b><br> <b>RT</b> 4,500 cGy (180cGy/d), 5 days a week for 5 weeks<br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup>/d IV, on the first 4 and last 3 days of RT<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d, on the first 4 and last 3 days of RT,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 425 mg/m<sup>2</sup>/d for 5 days<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d for 5 days<br>repeat 28 days X 2 cycles', 'Low', 'Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy afer surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. $N Engl J Med. 2001;345(10):725-730.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (28, 6, 'Trastuzumab + Cisplatin + Capecitabine or Fluorouracil', '<b>Trastuzumab + Cisplatin + Capecitabine or Fluorouracil</b>', '<b>Trastuzumab</b> 8 mg/kg IV, day 1 of the first cycle <b>THEN</b>  6 mg/kg IV, day 1<br><br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1. <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14 <br> Repeat  every 21 days<br> <b>OR</b><br> <b>Fluorouracil</b> 800 mg/m<sup>2</sup>/d CIVI for 5 days of each 3-week cycle<br> Repeat for 6 cycles', 'High day 1, low for the remaining treatment days', 'Bang YJ, Van Cutsem E, Feyereislava A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 open-label, randomised controlled trial. $Lancet. 2010;376(99742):687-697.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Capecitabine : Xeloda<br>Cisplatin : CDDP<br>Fluorouracil : 5-FU<br>Trastuzumab : Herceptin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (29, 6, 'Capecitabine', '<b>Capecitabine</b>', '<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> days 1-14,  <br> Repeat every 21 days for  6 cycles', 'Low', 'Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. $Ann Oncol. 2004;15(9):1344-1347.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Capecitabine : Xeloda');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (30, 6, 'Epirubicin + Oxaliplatin + Capecitabine (EOX)', '<b>Epirubicin + Oxaliplatin + Capecitabine (EOX)</b>', '<b>Epirubicin</b> 50 mg/m2 IV bolus d1 q3w x 8 cycles<br>
<b>Oxaliplatin</b> 130 mg/m2 iv over 2 hours d1 q3w x 8 cycles<br>
<b>Capecitabine</b> 625 mg/m2 po bid x 6 months.', 'High', 'Cunningham D et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. $N Eng J Med 2008; 358:36.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Capecitabine : Xeloda<br>Epirubicin : Ellence, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (31, 10, 'GEMOX', '<b>GEMOX</b>', '<b>Gemcitabine</b>1,000 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>100 mg/m<sup>2</sup> IV on day 2<br>Repeat cycle every 2 weeks.', 'Moderate', '$Taieb J, et al. Cancer 2003;98:2664-2670.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Gemcitabine : Gemzar, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (32, 10, 'FOLFOX4', '<b>FOLFOX4', '<b>Oxaliplatin</b>85 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>400 mg/m<sup>2</sup> IV bolus, followed by 600 mg/m<sup>2</sup> IV continuous infusio for 22 hours on days 1 and 2<br><b>Leucovorin</b>200 mg/m<sup>2</sup> IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil<br>Repeat cycle every 2 weeks.', 'Moderate', '$Qin S, et al. J Clin Oncol 2010;28:303S (abstract 408).$', '<b>Hepatic Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (33, 10, 'Bevacizumab + Erlotinib', '<b>Bevacizumab + Erlotinib</b>', '<b>Bevacizumab</b>10 mg/kg IV on days 1 and 14<br><b>Erlotinib</b>150 mg PO daily<br>Repeat cycle every 28 days.', 'Low', '$Thomas MB, et al. J Clin Oncol 2009;27:843-850.$', '<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li></ul>', 'Bevacizumab : Avastin<br>Erlotinib : Tarceva');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (34, 10, 'Sorafenib', '<b>Sorafenib</b>', '<b>Sorafenib</b>400 mg PO bid.', 'Low', '$Llovet J, et al. N Engl J Med 2008;359:378-390.$', '<b>Hepatic Impairment</b><ul><li>Sorafenib:<br>If Child-Pugh A or B, no dose reduction     <br>                                                 If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sorafenib:<br>No dose reduction </li></ul>', 'Sorafenib : Nexavar');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (35, 10, 'Doxorubicin', '<b>Doxorubicin</b>', '<b>Doxorubicin</b>20-30 mg/m<sup>2</sup> IV weekly<br>Repeat cycle every week.', 'Moderate', '$Venook AP. J Clin Oncol 1994;12:1323-1334.$', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (36, 10, 'Cisplatin', '<b>Cisplatin</b>', '<b>Cisplatin</b>80 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle every week.', 'High', '$Okada S, et al. Oncology 1993;50:22-26.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (37, 10, 'Capecitabine', '<b>Capecitabine</b>', '<b>Capecitabine</b>1,000 mg/m<sup>2</sup> PO bid on days 1-14<br>Repeat cycle every 21 days. PO bid on days 1-14.', 'Moderate', '$Patt YZ, et al. Cancer 2004;101:578-586.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Capecitabine : Xeloda');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (38, 10, 'Bevacizumab', '<b>Bevacizumab</b>', '<b>Bevacizumab</b>10 mg/kg IV on day 1<br>Repeat cycle every 14 days.', 'Low', '$Siegel AB, et al. J Clin Oncol 2008;26:2992-2998.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Bevacizumab : Avastin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (39, 9, 'Gemcitabine + Cisplatin', '<b>Gemcitabine + Cisplatin</b>', '<b>Gemcitabine</b> 1,250 mg/m<sup>2</sup> IV on Day 1, 8<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV on Day 1<br> Repeat cycle every 21 days', 'Low', '$Thongprasert S, et al. Ann Oncol 2005;16:279-281$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (40, 9, 'Gemcitabine + Capecitabine', '<b>Gemcitabine + Capecitabine</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on Day 1, 8<br> <b>Capecitabine</b> 650 mg/m<sup>2</sup> PO BID on Days 1-14<br> Repeat cycle every 21 days', 'Moderate', '$Knox JJ, et al. J Clin Oncol 2005;23:2332-2338.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Capecitabine : Xeloda<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (41, 9, 'Gemcitabine + Oxaliplatin', '<b>Gemcitabine + Oxaliplatin</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on Day 1<br> <b>Oxaliplatin</b> 100 mg/m<sup>2</sup> on Day 2<br> Repeat cycle every 14 days', 'Moderate', '$Andre T, et al. Ann Oncol 2004;15:1339-1343.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Gemcitabine : Gemzar, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (42, 9, '5-Fluorouracil + Cisplatin', '<b>5-Fluorouracil + Cisplatin</b>', '<b>5-FU</b> 400 mg/m<sup>2</sup> on Day 1<br> <b>FOLLOWED BY</b> 600 mg/m<sup>2</sup> continuous infusion over 22 hours on days 1 and 2<br> <b>Cisplatin</b> 50 mg /m<sup>2</sup> IV on day 2<br> Repeat cycle every 21 days', 'High', '$Taieb J, et al. Ann Oncol 2002;13:1192-1196.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (43, 9, 'Capecitabine + Cisplatin', '<b>Capecitabine + Cisplatin</b>', '<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> PO bid on days 1-14<br> <b>Cisplatin</b> 60 mg/m<sup>2</sup> IV on day 2<br> Repeat cycle every 21 days', 'High', '$Hong YS, et al. Cancer Chemother Pharmacol 2007;60:321-328.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Capecitabine : Xeloda<br>Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (44, 9, 'Capecitabine + Oxaliplatin', '<b>Capecitabine + Oxaliplatin</b>', '<b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid on days 1-14<br> <b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV on day 1<br> Repeat cycle every 21 days', 'Moderate', '$Nehis O, et al. Br J Cancer 2008;98:309-315.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Capecitabine : Xeloda<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (45, 9, 'Capecitabine', '<b>Capecitabine</b>', '<b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid on days 1-14<br> Repeat cycle every 21 days', 'Moderate', '$Patt YZ, et al. Cancer 2004;101:578-586.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Capecitabine : Xeloda');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (46, 9, 'Docetaxel', '<b>Docetaxel</b>', '<b>Docetaxel</b> 100 mg/m<sup>2</sup> IV on day 1<br> Repeat cycle every 21 days', 'Moderate', '$Papakostas P, et al. Eur J Cancer 2001;37:1833-1838.$', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (47, 9, 'Gemcitabine', '<b>Gemcitabine</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on days 1 and 8<br> Repeat cycle every 21 days', 'Moderate', '$Park JS, et al. Jpn J Clin Oncol 2005;35:68-73.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (48, 11, 'FOLFIRINOX', '<b>FOLFIRINOX</b>', '<b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV over 2 hours <b>FOLLOWED BY Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours with the addition, after 30 minutes <b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes; <b>IMMEDIATELY FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, <b>THEN</b><br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> IV over 46 hours<br> Repeat cycle every 2 weeks', 'Moderate', 'Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. $N Engl J Med. 2011;364(19):1817-1825.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (49, 11, 'Gemcitabine/Capecitabine', '<b>Gemcitabine/Capecitabine</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes, days 1, 8<br> <b>Capecitabine</b> 650 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat every 21 days.', 'Low', 'Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. $J Clin Oncol. 2007;25(16):221-2217.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Capecitabine : Xeloda<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (50, 11, 'Gemcitabine/Erlotinib', '<b>Gemcitabine/Erlotinib</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes once weekly for 7 weeks,<br> <b>FOLLOWED BY</b> 1 week of rest<br> <b>Erlotinib</b> 100 <b>OR</b> 150 mg/d PO<br> Repeat subsequent cycles once weekly for 3 consecutive weeks out of every 4 weeks', 'Low', 'Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer institute of Canada Clinical Trials Group. $J Clin Oncol. 2007;25(15):1960-1966.$', '<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Erlotinib : Tarceva<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (51, 11, 'GEMOX', '<b>GEMOX</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>, day 1 as 100-minute infusion<br> <b>Oxaliplatin</b> 100 mg/m<sup>2</sup>, day 2 as 2-hour infusion<br> Repeat every 14 days', 'Moderate', 'Louvet C, Labianca R, Hammel P, at al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. $J Clin Oncol. 2005;23(15):3509-3516.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Gemcitabine : Gemzar, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (52, 11, 'Gemcitabine', '<b>Gemcitabine</b>', '<b>Gemcitabine 1,000 mg/m<sup>2</sup> IV over 30 minutes once weekly for 7 weeks,<br> <b>FOLLOWED BY</b> 1 week of rest<br> Repeat subsequent cycles once weekly for 3 consecutive weeks out of every 4 weeks', 'Low', 'Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survivial and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. $J Clin Oncol. 1997;15(6):2403-2413.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (53, 4, 'Cetuximab/Irinotecan', '<b>Cetuximab/Irinotecan</b>', '<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose,<b>THEN</b> 250 mg/m<sup>2</sup> IV every 7 days<br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> IV every 21 days<br> <b>OR</b> 180 mg/m<sup>2</sup> IV every 14 days', 'Moderate', 'Cunningham D, Humblet Z, Siena S,et al. Cetuximab monothherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. $N Engl J Med. 2004;351(4):337-345.$', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', 'Cetuximab : Erbitux');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (54, 4, '5-FU/LV (Mayo regimen)', '<b>5-FU/LV (Mayo regimen)</b>', '<b>Fluorouracil</b> 370mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1-5<br> <b>FOLLOWING Leucovorin calcium</b> 200 mg/m<sup>2</sup>/d IV bolus, days 1-5<br> Repeat at 4 and 8 weeks, and every 5 weeks thereafter', 'Low ', 'Poon MA, O''Connell MJ, Moertel CG. Biochemical modulation of fluorouracil: evidence of significant improvement of surival and quality of life in patients with advanced colorectal carcinoma. $J Clin Oncol. 1989;7(10):1407-1418$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (55, 4, '5-FU/LV (Roswell Park regimen)', '<b>5-FU/LV (Roswell Park regimen)</b>', '<b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1,8, 15, 22, 29, 35<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup>/d IV over 2 hours, days 1, 8, 15, 22, 29, 35<br> Repeat every 8 weeks', 'Low', 'Petreli N, Douglass HO Jr, Herrera L, et al. The modulation of fluroouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. $J Clin Oncol. 1989;7(10):1419-1426$<br> Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previoulsy untreated patients with advanced colorectal carcinoma. $J Clin Oncol. 1987;5(10):1559-1565.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (56, 4, '5-FU/LV + Bevacizumab', '<b>5-FU/LV + Bevacizumab</b>', '<b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1,8, 15, 22, 29, 35<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup>/d IV over 2 hours, days 1, 8, 15, 22, 29, 35<br> Repeat every 8 weeks<br> <b>Bevacizumab</b> 5mg/kg IV<br> Repeat every 14 days', 'Low', 'Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumb to flurouracil/leucovorin improves survival for patients with metastatic colorectal cancer. $J Clin Oncol. 2005;23(16):3706-3712.$<br> Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin; an active regimen for firstline metastatic colorectal cancer. $J Clin Oncol. 2005;23(15):3502-3508$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Bevacizumab : Avastin<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (57, 4, 'FLOX', '<b>FLOX</b>', '<b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV over 2 hours, days 1, 15, 29<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup> IV over 2 hours, days 1, 8, 15, 22, 29, 36<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup> IV bolus 1 hour after the infusion begins, days 1, 8, 15, 22,    29, 36<br> Repeat every 8 weeks for 3 cycles', 'Moderate', 'Kuebler JP, Wieand HS, O''Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. $J Clin Oncol. 2007;25(16):2198-2204.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (58, 4, 'FOLFIRI', '<b>FOLFIRI</b>', '<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours during irinotecan infusion,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus,<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours<br> Repeat every 14 days', 'Moderate', 'Tournigand C, Andre T, Achille E, et al. FOLFIRI  followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. $J Clin Oncol. 2004;22(2):229-237$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (59, 4, 'FOLFIRI + Bevacizumab', '<b>FOLFIRI + Bevacizumab</b>', '<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours, day 1<br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, day 1<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours, day 1<br> <b>Bevacizumab</b> 5 mg/kg IV, day 1<br> Repeat every 14 days', 'Moderate', 'Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. $J Clin Oncol. 2007;25(30):4779-4786.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Bevacizumab : Avastin<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (60, 4, 'FOLFIRI + Cetuximab', '<b>FOLFIRI + Cetuximab</b>', '<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours during irinotecan infusion,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus,<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours<br> Repeat every 14 days<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose, <b>THERE AFTER</b> 250mg/m<sup>2</sup> IV weekly', 'Moderate', 'Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. $J Clin Oncol. 2007;25:4000 (abstract).$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Cetuximab : Erbitux<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (61, 4, 'FOLFOX4', '<b>FOLFOX4</b>', '<b>Day 1</b><br><b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV AND <br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br><b>Day 2</b><br><b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br> Repeat  every 14 days', 'Moderate', 'Richard M. Goldberg, et al.Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer.$http://jco.ascopubs.org/content/24/25/4085.abstract$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (62, 4, 'FOLFOX4 + Bevacizumab', '<b>FOLFOX4 + Bevacizumab</b>', '<b>Day 1</b><br><b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV <b>AND</b><br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours, <br><b>Bevacizumab</b> 5 mg/kg IV.<br><b>Day 2</b><br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV over 120 minutes, day 2, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br> Repeat  every 14 days <br> Repeat every 14 days', 'Moderate', 'Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. $J Clin Oncol. 2008;26(18)2013-2019.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Bevacizumab : Avastin<br>Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (63, 4, 'FOLFOX4 + panitumumab ', '<b>FOLFOX4 + panitumumab</b> ', '<b>Panitumumab</b> 6 mg/kg IV over 60 minutes <br> <b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV, day 1<br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV on day 1<br> <b>FOLLOWED BY Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, <b>FOLLOWED BY Fluorouracil</b> 600mg/m<sup>2</sup> IV infusion over 22 hours on days 1 and 2<br> Repeat cycle every 14 days', 'Moderate', 'Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. $J Clin Oncol. 2010;28(31):4697-4705.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (64, 4, 'FOLFOX6', '<b>FOLFOX6</b>', '<b>Oxaliplatin</b> 100mg/m<sup>2</sup> IV over 2 hours, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours during oxaliplatin infusion,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours;<br> Repeat every 14 days', 'Moderate', 'Tournigand C, Andre T, Achille E, et al. FOLFIRI  followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. $J Clin Oncol. 2004;22(2):229-237$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (65, 4, 'Modified FOLFOX6', '<b>Modified FOLFOX6</b>', '<b>Leucovorin</b> 350 mg/m<sup>2</sup> IV over 2 hrs before 5-FU, d1<br>
5-FU 400 mg/m<sup>2</sup> IV bolus d1 followed by 2400 mg/m2 iv over 46 hrs<br>
<b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV d1
Q2w until progression or unacceptable toxicity', 'Moderate', 'Hochster, HS et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. $J Clin Oncol 2008; 26:3523$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (66, 4, 'XELIRI', '<b>XELIRI</b>', '<b>Irinotecan</b> 250 mg/m<sup>2</sup> IV over 30-90 minutes, day 1<br> <b>Cappecitabine 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat cycle every 21 days', 'Moderate', 'Patt YZ, Lee F, Liebman JE, et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer. $Am J Clin Oncol. 2007;30(4):350-357$', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (67, 4, 'XELOX', '<b>XELOX</b>', '<b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV, day 1<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid from evening day 1 to 14<br> Repeat every 21 days', 'Moderate', 'Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin); active first-line therapy for patients with metastatic colorectal cancer. $J Clin Oncol. 2004;22(11):2084-2091$', '<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (68, 4, 'XELOX + Bevacizumab', '<b>XELOX + Bevacizumab</b>', ' <b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV, day 1<br><b>Bevacizumab</b> 7.5 mg/kg IV, day 1<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid from evening day 1 to 14<br> Repeat every 21 days<br> Repeat every 21 days', 'Moderate', 'Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. $J Clin Oncol. 2008;26(18)2013-2019.$', '<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Bevacizumab : Avastin<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (69, 4, 'Capecitabine', '<b>Capecitabine</b>', '<b>Capecitabine</b> 1,000- 1,250 mg/m<sup>2</sup>/d PO bid, days 1-14, <b>FOLLOWED BY</b> 7 days rest<br> Repeat every 21 days', 'Low', 'Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III Study. $J Clin Oncol. 2001;19(21):4097-4106$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Capecitabine : Xeloda');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (70, 4, 'Cetuximab', '<b>Cetuximab</b>', '<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose over 120 minutes, <b>FOLLOWED BY</b> 250 mg/m<sup>2</sup> IV over 60 minutes<br> Repeat every 7 days', 'Low', 'Erbitux [package insert]. $Branchburg, NJ, and Princeton, NJ: ImClone Systems/ Bristol-Myers Squibb; 2011.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Cetuximab : Erbitux');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (71, 4, '5-FU', '<b>5-FU</b>', '<b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-5<br> Repeat every 28 days', 'Low', 'Kemeny N, Israel K, Niedzwieki D, et al. Randomized study of continuous-infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. $J Clin Oncol. 1990;8(2):313-318.$<br> Schmoll HJ. Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents. $lEur J Cancer. 1996;32A(suppl 5):S18-S22.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (72, 4, 'Irinotecan', '<b>Irinotecan</b>', '<b>Irinotecan</b> 125 mg/m<sup>2</sup>/d IV over 90 minutes, days 1,8, 15,22 <b>FOLLOWED BY</b> 2 weeks rest<br> Repeat every 6 weeks<br> <b>OR</b><br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> IV over 90 minutes<br> Repeat every 21 days', 'Moderate', 'Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. $J Clin Oncol. 1997;15(1):251-260$<br> Camptosar [package insert]. New York, NY: Pfizer; 2010.<br> Conti JA, Kemeny NE, jSaltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. $J Clin Oncol. 1996;14(3):709-715.$<br> Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. $Lancet. 1998;352(9138):1413-1418.$', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (73, 4, 'Panitumumab', '<b>Panitumumab</b>', '<b>Panitumumab</b> 6 mg/kg IV over 60 minutes<br> Repeat every 14 days', 'Low', 'Eric Van Cutsem, et al. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer.$http://jco.ascopubs.org/content/25/13/1658.abstract$ ', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (74, 4, 'Regorafenib', '<b>Regorafenib</b>', '<b>Regorafenib</b>160 mg po daily 3 weeks on and 1 week off', 'Low', 'Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Wilhelm SM, et al. $Int J Cancer. 2011 Jul 1;129(1):245-55. doi: 10.1002/ijc.25864$ 
', '<b>Hepatic Impairment</b><ul><li>Regorafenib:<br>No dose adjustment is recommended in patients with mild or moderate hepatic impairment. <br>Closely monitor patients with hepatic impairment for adverse reactions. <br>;
Stivarga is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C), as it has not been studied in this population.</li></ul><b>Renal Impairment</b><ul><li>Regorafenib:<br>No dose adjustment is recommended for patients with mild renal impairment. <br>Limited pharmacokinetic data are available from patients with moderate renal impairment (CLcr 30-59 mL/min). <br>Stivarga has not been studied in patients with severe renal impairment or end-stage</li></ul>', 'Regorafenib : Stivarga');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (75, 3, 'Fluorouracil/Mitomycin C', '<b>Fluorouracil/Mitomycin C</b>', '<b>5-Fluorouracil</b> 1,000 mg/m<sup>2</sup>/day CIVI,  days 1-4 and 29-32<br> <b>Mitomycin C</b> 10 mg/m<sup>2</sup> IV  days 1 and 29 and radiation concurrently.', 'Low', 'Ajani JA, Winter KA, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. $JAMA. 2008;299(16):1914-1921.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (76, 3, '5-FU + Cisplatin (Metastatic) ', '<b>5-FU + Cisplatin (Metastatic) </b>', '<b>Fluorouracil</b> 1000 mg/m<sup>2</sup>/d civi d1-5<br>
<b>Cisplatin (CDDP) 100 mg/m<sup>2</sup> IV d2 
Q4w', 'High', 'Faivre, C et al. 5-fluorouracile and cisplatin combination chemotherapy for metastatic squamous-cell anal cancer. $Bull Cancer 1999; 86:861$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (77, 8, 'Imatinib', '<b>Imatinib</b>', '<b>Imatinib mesylate</b> 400-800 mg PO, daily', 'Low', 'Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033. $J Clin Oncol. 2008;26(4):626-632$', '<b>Hepatic Impairment</b><ul><li>Imatinib:<br>If bilirubin < 3 upper normal limit, no dose reduction <br>                            If bilirubin > 3 upper normal limit, use with caution </li></ul><b>Renal Impairment</b><ul><li>Imatinib:<br>No dose reduction </li></ul>', 'Imatinib : Gleevec');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (78, 8, 'Nilotinib', '<b>Nilotinib</b>', '<b>Nilotinib</b> 400 mg PO bid', 'Low', 'Montemurro M, Schoffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. $Eur J Cancer. 2009;45:2293-2297.$', '<b>Hepatic Impairment</b><ul><li>Nilotinib:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Nilotinib:<br>Not tested. Not renally excreted </li></ul>', 'Nilotinib : Tasigna');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (79, 8, 'Sunitinib', '<b>Sunitinib</b>', '<b>Sunitinib malate</b> 50 mg/d for 28 days, 14 days rest then repeat cycle', 'Low', 'Demetri GD, van Oossterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour afer failure of imatinib: a randomised controlled trial. $Lancet. 2006;368(9544):1329-1338.$', '<b>Hepatic Impairment</b><ul><li>Sunitinib:<br>If Child-Pugh A or B, no dose reduction  <br>                                                    If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sunitinib:<br>If CrCl > 42 mL/min, no dose reduction </li></ul>', 'Sunitinib : Sutent');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (80, 12, 'Carbo-Tax', '<b>Carbo-Tax</b>', '<b>Paclitaxel</b> 225mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Carboplatin</b> dose targeted by AUC of 6 mg/mL/min, day 1<br> Repeat every 21 days', 'Moderate', 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. $N Engl J Med. 2002;346(2):92-98.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (81, 12, 'Cisplatin/Pemetrexed', '<b>Cisplatin/Pemetrexed</b>', '<b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Pemetrexed</b> 500 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for up to 6 cycles', 'High', 'Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. $J Clin Oncol. 2008;26(21):3543-3551.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Pemetrexed:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Pemetrexed:<br>If CrCl > 45 mL/min, no dose reduction    <br>                                                                        If CrCl < 45 mL/min, do not use </li></ul>', 'Cisplatin : CDDP<br>Pemetrexed : Alimta');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (82, 12, 'Cisplatin/Vinorelbine/Cetuximab', '<b>Cisplatin/Vinorelbine/Cetuximab</b>', '<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose, <b>THEN</b><br> 250 mg/m<sup>2</sup>/wk<br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1<br> <b>Vinorelbine</b> 25 mg/m<sup>2</sup> IV, days 1, 8<br> Repeat every 21 days', 'High', 'Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. $Lancet. 2009;373(9674):1525-1531.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Vinorelbine:<br>No dose reduction</li></ul>', 'Cetuximab : Erbitux<br>Cisplatin : CDDP<br>Vinorelbine : Navelbine');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (83, 12, 'Docetaxel/Cisplatin', '<b>Docetaxel/Cisplatin</b>', '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days', 'High', 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. $N Engl J Med. 2002;346(2):92-98.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (84, 12, 'Gemcitabine/Cisplatin', '<b>Gemcitabine/Cisplatin</b>', '<b>Gemcitabine</b> 1,000mg/m<sup>2</sup> /d IV,days 1,8,15<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> Repeat every 28 days<br> <b>OR</b><br> <b>Gemcitabine</b> 1,250 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IV over 60 minutes, day 1<br> Repeat every 21 days                                         ', 'High', 'Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. $N Engl J Med. 2002;346(2):92-98.$<b> Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. $J Clin Oncol. 1999;17(1):12-18.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (85, 12, 'Gemcitabine/Docetaxel', '<b>Gemcitabine/Docetaxel</b>', '<b>Gemcitabine</b> 1,100 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8<br> <b>Docetaxel</b> 100 mg/m<sup>2</sup> IV over 1 hour, day 8<br>  Repeat every 21 days.', 'Low', 'Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial. $Lancet. 2001;357(9267):1478-1484.$', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Docetaxel : Taxotere<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (86, 12, 'Gemcitabine/Paclitaxel', '<b>Gemcitabine/Paclitaxel</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8<br> <b>Paclitaxel</b> 200 mg/m<sup>2</sup> IV over 3 hours, day 1<br> Repeat every 21 days', 'Low', 'Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. $J Clin Oncol. 2002;20(17):3578-3585.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Gemcitabine : Gemzar, various<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (87, 12, 'Gemcitabine/Vinorelbine', '<b>Gemcitabine/Vinorelbine</b>', '<b>Gemcitabine</b> 1,200 mg/m<sup>2</sup>/d IV, days 1, 8<br> <b>Vinorelbine</b> 30 mg/m<sup>2</sup>/d IV, days 1, 8<br> Repeat every 21 days<br> <b>OR</b><br> <b>Gemcitabine</b> 800-1,000 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8, 15<br> <b>Vinorelbine</b> 20 mg/m<sup>2</sup>/d IV over 10-30 minutes, days 1, 8, 15<br> Repeat every 28 days', 'Low', 'Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. $J Clin Oncol. 2000;18(13):2529-2536.$<br> Chen YM, Perng, RP, Yang KY, et al. A multi-gemcitabine in previously untreated inoperable (stageIIIB/IV) non-small-cell lung cancer. $Chest. 2000;117(6):1583-1589.$<br> Hainsworth JD, Burris HA 3rd, Litchy S, et al. Gemcitabine and vinorelbine in the second-line treatment of non-small-celll lung carcinoma patients: a Minnie Pearl Cancer Research Network phase II trial. $Cancer. 2000;88(6):1353-1358.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Vinorelbine:<br>No dose reduction</li></ul>', 'Gemcitabine : Gemzar, various<br>Vinorelbine : Navelbine');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (88, 12, 'PC', '<b>PC</b>', '<b>Paclitaxel</b> 135mg/m<sup>2</sup> over 24hours, day 1<br> <b>Cisplatin</b> 75mg/m<sup>2</sup> IV, day 2<br> Repeat every 21 days<br> <b>OR</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> over 3 hours,day 1<br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days   ', 'High', 'Schiller JH, Hamington D, Belani CP, et al. Comparison of four chemotherapy regiments for advanced non-small-cell lung cancer. $N Eng/J Med.2002;346(2);92-98.$<br> Smit EF., van Meerbeeck JP,lianes P,et al.Three-arm randomaized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advance m=non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of cancer Lung Group-EORTC 08975. $J Clin Oncol.2003;21(21):3909-3917.$                                                                                                                                                ', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cisplatin : CDDP<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (89, 12, 'PCB', '<b>PCB</b>', '<b>Paclitaxel</b> 200 mg/m<sup>2</sup> IV, day 1<br> <b>Carboplatin</b> AUC of IV ,day 1<br> <b>Bevacizumab</b> 15 mg/kg IV, day 1<br> Repeat every 21 days', 'Moderate', 'Sandler A, Gray R, Perry MC,et al. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer. $N Engl J Med. 2006;355(24):2542-2550.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Bevacizumab : Avastin<br>Carboplatin : Paraplatin<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (90, 12, 'Vinorelbine/Cisplatin', '<b>Vinorelbine/Cisplatin</b>', '<b>Vinorelbine</b> 30 mg/m<sup>2</sup> IV over 20 minutes, day 1,8,15,22.<br> <b>Cisplatin</b> 100mg/m<sup>2</sup> IV over 1 hour day 1.<br>Repeat cycle every 28 days.', 'High', 'Douillard JY, Rosell R, De Lena M,et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-III A non small-cell lung cancer  (Adjuvant Naverlbine International Trialist Association [ANITA): a randomised controlled trial. $Lancet Oncol.2006:7(9):719-727.$ ', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Vinorelbine:<br>No dose reduction</li></ul>', 'Cisplatin : CDDP<br>Vinorelbine : Navelbine');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (91, 12, 'Crizotinib', '<b>Crizotinib</b>', '<b>Crizotinib</b> 250 mg PO bid in 28-day cycles', 'Moderate-High', 'Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic Lymphoma Kinase inhabitation in non-small-cell lung cancer. $N engl J Med.2010;363(18):1693-1703.$<br> Xalkori [packages insert]. $New York, NY: Pfizer labs;2011.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Crizotinib : Xalkori');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (92, 12, 'Docetaxel', '<b>Docetaxel</b>', '<b>Docetaxel</b> 75mg/m<sup>2</sup> IV over 1hour.<br> Repeat every 21 days', 'Low', 'Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. $J Clin Oncol. 2000;18(10):2095-2103.$<br> Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-lung cancer previously treated with platinum-containing chemotherapy regimens. $J Clin Oncol. 2000;18(12):2354-2362.$', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (93, 12, 'Erlotinib', '<b>Erlotinib</b>', '<b>Erlotinib</b> 150mg PO daily at least 1hour before <b>OR</b> 2 Hours after eating', 'Low', 'Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non small cell  lung cancer Institute of Canada Clinical trials group study BR 21. $J Clin Oncol. 2008;26(14):2350-2357.$<br> Tarceva [packaga insert]. $Melville, NY south San Fransisco, CA:OSI Pharmaceuticals Inc & Genentich Inc;2010.$', '<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li></ul>', 'Erlotinib : Tarceva');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (94, 12, 'Gemcitabine', '<b>Gemcitabine</b>', '<b>Gemcitabine</b> 1000 mg/m<sup>2</sup>/d IV over 30 minutes, day 1,8,15<br> <br>  Repeat every 28 days.', 'Low', 'Crino L, Mosconi AM, Scaglotti G, et al.              Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. $J Clin Oncol. 1999;17(7):2081-2085.$<br> Ricci S, Anonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly paients with advanced non-smell-cell lung cancer: a multicenter phase II study. $Lung Cancer.2000;27(2):75-80.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (95, 12, 'Pemetrexed', '<b>Pemetrexed</b>', '<b>Pemetrexed</b> 500mg/m<sup>2</sup> IV over 10 minutes<br> Repeat every 21 days ', 'Low', 'Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III study of premtrexed versus docetaxel in patients with non-smell-cell lung cancer previously treated with chemotherapy. $J Clin Oncol. 2004;22(9):1589-1597.$', '<b>Hepatic Impairment</b><ul><li>Pemetrexed:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Pemetrexed:<br>If CrCl > 45 mL/min, no dose reduction    <br>                                                                        If CrCl < 45 mL/min, do not use </li></ul>', 'Pemetrexed : Alimta');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (96, 12, 'Vinorelbine', '<b>Vinorelbine</b>', '<b>Vinorelbine</b> 30 mg/m<sup>2</sup> IV over 20 minutes, day 1,8,15,22.<br> Repeat every 7 days .', 'Low', 'Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesin and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. $J Clin Oncol.1994;12(2):360-367.$', '<b>Hepatic Impairment</b><ul><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Vinorelbine:<br>No dose reduction</li></ul>', 'Vinorelbine : Navelbine');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (97, 13, 'Carboplatin/Irinotecan', '<b>Carboplatin/Irinotecan</b>', '<b>Carboplatin</b> AUC of 5 IV, day 1<br> <b>Irinotecan</b> 175mg/m<sup>2</sup> IV, day 1<br> Repeat every 21days', 'Moderate', 'Hermes A, Bergman B, Bremnes R, et al           Irinotecan plus carboplatin in extensive versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. $J Clin Oncol. 2008:26(26):4261-4267.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Carboplatin : Paraplatin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (98, 13, 'Cisplatin + CPT-11', '<b>Cisplatin + CPT-11</b>', '<b>Cisplatin</b> 60mg/m<sup>2</sup>, day 1<br> <b>Irinotecan</b> 60mg/m<sup>2</sup>/d, days 1, 8, 15<br> Repeat every 28days', 'High', 'Noda K, Nishiwaki Y, Kawahara M, et al.                     Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. $N Engl J Med. 2002;346(2):85-91.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (99, 13, 'CAV', '<b>CAV</b>', '<b>Cyclophosphamide</b>  1,000 mg/m<sup>2</sup>IV on day 1.  <br>                                              <b>Doxorubicin</b> 40 mg/m<sup>2</sup>IV on day 1.<br>                                                                <b>Vincristine</b> 1 mg/m<sup>2</sup>IV on day 1. (maximum, 2 mg) <br>Repeat cycle every 21 days.', 'High', '$Roth  BJ, et al. J Clin Oncol 1992;10:282-291.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (100, 13, 'Carboplatin + Paclitaxel', '<b>Carboplatin + Paclitaxel</b>', '<b>Carboplatin</b>AUC of 2, IV on days1,8, and 15.<br><b>Paclitaxel</b> 80 mg/m<sup>2</sup> IV on days 1,8, and 15. Repeat cycle every 28 days.', 'Moderate', '$Neubauer M, et al. J Clin Oncol2004;22:1872-1877$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (101, 13, 'EC', '<b>EC</b>', '<b>Etoposide</b> 100mg/m<sup>2</sup>/d IV, days 1-3<br><b>Carboplatin</b> 450mg/m<sup>2</sup> IV, day 1<br> Repeat every 28 days for 6 cycles', 'Moderate', 'Viren M, Liippo K, Ojala a, et al. Carboplatin and etoposide in extensive small-cell lung cancer. $Acta Oncal. 1994;33(8):921-924.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Carboplatin : Paraplatin<br>Etoposide : VP-16');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (102, 13, 'EP', '<b>EP</b>', '<b>Etoposide</b> 80mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cisplatin</b> 80mg/m<sup>2</sup> IV, day 1 (Standard dose)<br> Repeat every 21 days <b>OR</b><br> <b>Etoposide</b> 80mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 27mg/m<sup>2</sup> IV, days 1-5(high dose)<br> Repeat every 21 days', 'High', 'Ihde DC, Mulshine JL, Kramer BS, et al.  Prospective randomized comparision of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. $J Clin Oncol.1994; 12(10):2022-2034.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cisplatin : CDDP<br>Etoposide : VP-16');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (103, 13, 'Etoposide', '<b>Etoposide</b>', '<b>Etoposide</b> 160 mg/m<sup>2</sup>/d PO, days 1-5<br> Repeat every 28 days<br> <b>OR</b><br> <b>Etoposide</b> 50 mg PO bid for 14 days<br> Repeat every 21 days', 'Low', 'Johnson DH. Recent developments in chemotherapy treatment of small-cell lung cancer. $Semin Oncol. 1993;20(4):315-325.$', '<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Etoposide : VP-16');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (104, 13, 'Paclitaxel', '<b>Paclitaxel</b>', '<b>Paclitaxel</b> 250 mg/m<sup>2</sup> IV over 24 hours<br> Repeat every 21 days', 'Low', 'Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. $J Clin Oncol. 1995;13(6):1430-1435.$<br> Kirschling RJ, Grill JP, Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive-stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. $Am J Clin Oncol. 1999;22(5):517-522$<br>', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (105, 13, 'Topotecan IV', '<b>Topotecan IV</b>', '<b>Topotecan</b> 1.5 mg/m<sup>2</sup>/d IV over 30 minutes, days 1-5<br> Repeat every 21 days', 'Low', 'Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. $J Clin Oncol.1997;15(5):2090-2096.$<br> von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. $J Clin Oncol. 1999;17(2):658-667.$', '<b>Hepatic Impairment</b><ul><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Topotecan : Hycamtin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (106, 13, 'Topotecan PO', '<b>Topotecan PO</b>', '<b>Topotecan</b> 2.3 mg/m<sup>2</sup>/d PO, days 1-5<br> Repeat every 21 days', 'Low', 'Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. $J Clin Oncol. 2007;25(15):2086-2092.$ $Erratum in: J Clin Oncol. 2007;25(22):3387.$', '<b>Hepatic Impairment</b><ul><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Topotecan : Hycamtin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (107, 14, 'CAP', '<b>CAP</b>', '<b>Cyclophosphamide</b> 500 mg/m<sub>2</sub> IV on day 1<br><b>Doxorubicin</b> 500 mg/m<sub>2</sub> IV on day 1<br><b>Cisplatin</b> 500 mg/m<sub>2</sub> IV on day 1<br>Repeat cycle every 21 days.', 'High', 'Loehrer PJ, et al.$J Clin Oncol 1994;12:1164-1168.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (108, 14, 'Cisplatin + Etoposide', '<b>Cisplatin + Etoposide</b>', '<b>Cisplatin</b> 60 mg/m<sub>2</sub> IV on day 1<br><b>Etoposide</b> 120 mg/m<sub>2</sub> IV on day 1 - 3<br>Repeat cycle every 21 days.', 'High', 'Giaccone G, et al.$J Clin Oncol 1996;14:814-820.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cisplatin : CDDP<br>Etoposide : VP-16');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (109, 14, 'ADOC', '<b>ADOC</b>', '<b>Cisplatin</b> 50 mg/m<sub>2</sub> IV on day 1<br><b>Doxorubicin</b> 40 mg/m<sub>2</sub> IV on day 1<br><b>Vincristine</b> 0.6 mg/m<sub>2</sub> IV on day 3<br><b>Cyclophosphamide</b> 700 mg/m<sub>2</sub> IV on day 4<br>Repeat cycle every 28 days.', 'High', 'Fornasiero A, et al.$Cancer 1991;68:30-33.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (110, 14, 'VIP', '<b>VIP</b>', '<b>Etoposide(VP-I6)</b> 75 mg/m<sub>2</sub> IV on days 1-4<br><b>Ifosfamide</b> 1200 mg/m<sub>2</sub> IV on days 1-4<br><b>Cisplatin</b> 20 mg/m<sub>2</sub> IV on days 1-4<br><b>Mesna</b> 240 mg/m<sub>2</sub> IV before first ifosfamide dose, then 4 and 8 hours later on days 1-4<br>Repeat cycle every 21 days for a total of 4 cycles.G-CSF support at 5 micro grams/kg/day on days 5-15', 'High', 'Loehrer PJ, et al.$Cancer 2001;91:2010-2015.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cisplatin : CDDP<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (111, 14, 'Gemcitabine + Topotecan', '<b>Gemcitabine + Topotecan</b>', '<b>Gemcitabine</b>1000 mg/m<sub>2</sub> IV on days 1,8, and 15.<br><b>Topotecan</b>0.75-1.5 mg/m<sub>2</sub> IV on days 1,8, and 15.<br> Repeat cycle every 21 days', 'Moderate', 'William WN, et al.$Am J Clin Oncol 2009;32:15-19.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Gemcitabine : Gemzar, various<br>Topotecan : Hycamtin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (112, 14, 'Carboplatin + Paclitaxel', '<b>Carboplatin + Paclitaxel</b>', '<b>Carboplatin</b> AUC of 6, IV on day 1 <br><b>Paclitaxel</b>225 mg/m<sub>2</sub> IV on day 1<br> Repeat cycle every 21 days', 'Moderate', 'Lemma GL, et al.$ J Clin Oncol 2011;29:2060-2065.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (113, 15, 'AC', '<b>AC</b>', '<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles', 'High', 'Fisher B,Brown AM,Dimitor NV,et al.Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide,methotrexade,and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors:results from the National Surgical Adjuvant Breast and Bowel Project B-15. $J Clin Oncol. 1990;8(9):1483-1496$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (114, 15, 'AC/Docetaxel', '<b>AC/Docetaxel</b>', '<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles<br> <b>FOLLOWED BY</b><b>Docetaxel</b> 100 mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles   ', 'High for AC, low for docetaxel', 'Swain SM,Jeong JH ,Geyer CE,et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. $N Engl J Med.2010;362(22):2053-2065$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Docetaxel:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Docetaxel : Taxotere<br>Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (115, 16, 'AC  Paclitaxel/Trastuzumab', '<b>AC  Paclitaxel/Trastuzumab</b>', '<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles<br> <b>FOLLOWED BY</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours, day 1<br> Repeat every 21 days for 4 cycles<br> <b>OR</b><br> <b>Paclitaxel</b> 80 mg/m<sup>2</sup> IV over 1 hour, weekly X 12 <br> <b>Trastuzumab</b> (concurrently with paclitaxel) 4 mg/kg IV over 90 minutes, day 1<br> <b>FOLLOWED BY</b><br> 2 mg/kg IV weekly for 51 additional weeks     ', 'High for AC,low for paclitaxel and/or tratuzumab', 'Romond EH,perez EA,Bryant J.et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. $N Engl J Med. 2005;353(16):1673-1684.$ ', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol<br>Trastuzumab : Herceptin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (116, 15, 'AC  T (dose-dense)               ', '<b>AC  T (dose-dense)</b>               ', '<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles<br> <b>Filgrastim</b> (prophylactic) given on days 3-10 of   each cycle<br><b>OR</b> <b>PEG-Filgastrim</b> 6 mg SQ on day 2<b>FOLLOWED BY</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours every 14 days for 4 cycles<br> <b>Filgrastim</b> (prophylactic) given on days 3-10 of each cycle<b>OR</b> <b>PEG-Filgastrim</b> 6 mg SQ on day 2.                                                                               ', 'High for AC, low for paclitaxel  ', 'Citron ML, berry DA, Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combinational chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial C9741/cancer and leukemia Group B trial 9741. $J Clin Oncol. 2003;21(8): 1431-1439$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (117, 16, 'AC  TH                                                  ', '<b>AC  TH</b>                                                  ', '<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles<br> <b>FOLLOWED BY</b><br> <b>Docetaxel</b> 100 mg/m<sup>2</sup> IV, day1<br> Repeat every 21 days for 4 cycles<br> <b>Trastuzumab</b> 4 mg/kg IV, day 1,<br> <b>FOLLOWED BY</b><br> 2 mg/kg IV weekly during docetaxel,<br> <b>FOLLOWED BY</b><br> 6 mg/kg IV every 21 days for 1 year                                                      ', 'High for AC, low for docetaxel and/or trastuzumab', 'Neyt M, Albrecht J, Cocquyt V.An economic evaluation of herceptinR  in adjuvant setting: the Breast Cancer International Research Group 006 trial. $Ann Oncol. 2006; 17(3):381-390$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Docetaxel:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Docetaxel : Taxotere<br>Doxorubicin : Adriamycin, various<br>Trastuzumab : Herceptin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (118, 15, 'AT - Docetaxel', '<b>AT - Docetaxel</b>', '<b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV over 15 minutes, day 1<br> <b>FOLLOWED 1 HOUR LATER BY</b><br> <b>Docetaxel</b> 75 mg/m<sup>2</sup> day 1<br> Repeat every 21 days.', 'Moderate', 'Nabholz,JM,Falkson C,Campos D, et al. Docetaxel and doxorubicin comparewd with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer:results of a randomized , multicenter, phase III trial. $J Clin Oncol. 2003;21(6):968-975.$', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Docetaxel : Taxotere<br>Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (119, 15, 'AT - Paclitaxel', '<b>AT - Paclitaxel</b>', '<b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV over, day 1<br> <b>FOLLOWED 24 HOUR LATER BY</b><br> <b>Paclitaxel</b>  220 mg/m<sup>2</sup>,IV over 3 hours ,day 2<br> Repeat every 21 days for up to 8 cycles', 'Moderate', 'Jassem J, Pienkowski T, Pluzanska A.et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. $J Clin Oncol. 2001;19(6):1707-1715$', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (120, 15, 'A - T - C (dose-dense)', '<b>A - T - C (dose-dense)</b>', '<b>Doxorubicin</b> 60 mg/m<sup>2</sup> IV ,every 14 days for 4 cycles, <b>FOLLOWED BY</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV, every 14 days for 4 cycles, <b>FOLLOWED BY</b><br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV, every 14 days for 4 cycles<br> <b>Filgrastim</b> (prophylactic) given on days 3-10 of each cycle<b>OR</b> <b>PEG-Filgastrim</b> 6 mg SQ on day 2.                                                  ', 'Moderate, low for paclitaxel', 'Citron ML, Berry DA, Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial C9741/cancer and leukemia Groüp B Trial 9741. $J Clin Oncol. 2003;21(8):1431-1439$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (121, 15, 'Bevacizumab/Paclitaxel', '<b>Bevacizumab/Paclitaxel</b>', '<b>Bevacizumab</b> 10 mg/kg IV, days 1, 15<br> <b>Paclitaxel</b> 90 mg/m<sup>2</sup> IV over 1 hour, days 1, 8, 15<br> Repeat every 28 days', 'Low', 'Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. $J Clin Oncol. 2003;3(6):421-422$', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Bevacizumab : Avastin<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (122, 15, 'CAF(oral)', '<b>CAF(oral)</b>', '<b>Cyclophosphamide</b> 100mg/m<sup>2</sup> PO, days 1-14<br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV ,days 1,8<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup> IV, days 1,8<br> Repeat every 28 days for 6 cycles      ', 'Moderate-High', 'Hutchins LF, Green SJ, Favolin PM, et al. Randomized controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high risk, node-negative breast cancer:treatment results of Intergroup Protocol INT-0102. $J Clin Oncol. 2005;23(33):8313-8321.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (123, 15, 'FEC', '<b>FEC</b>', '<b>Cyclophosphamide</b> 75 mg/m<sup>2</sup>/d PO, days 1-14<br> <b> Epirubicin</b> 60 mg/m<sup>2</sup>/d IV, days 1,8<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup>/d IV, days 1,8<br> Repeat every 28 days for 6 cycles<br> <b>OR</b><br> <b>Cyclophosphamide</b> 500 mg/m<sup>2</sup> IV, day 1<br> <b>Epirubicin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for 4 cycles', 'High', 'Levine MN, Bramwell VH, Pritchard KI, et al. Randomized tiral of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. $J Clin Oncol. 1998;16(8):2651:2658.$<br> French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose intensity and duration of treatment. $J Clin Oncol. 2000;18(7):3115-3124.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Epirubicin : Ellence, various<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (124, 15, 'CMF', '<b>CMF</b>', '<b>Cyclophosphamide </b>100 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Methotrexate</b> 40 mg/m<sup>2</sup>/d IV, days 1,8<br> <b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV, days 1, 8<br> Repeat every 28 days for up to 6 cycles<br> <b>OR</b><br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV, day 1<br> <b>Methotrexate</b> 40 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 600 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for up to 12 courses', 'Moderate for IV, Moderate-High for PO', 'Amadori D, Nanni O, Marangolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapdly proliferating breast cancer: a randomized multicenter study. $J Clin Oncol. 2000:18(17):3125-3134.$<br> Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results.$ JAMA. 1995:273(7):542-547.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (125, 15, 'Gemcitabine/Paclitaxel', '<b>Gemcitabine/Paclitaxel</b>', '<b>Gemcitabine 1,250 mg/m<sup>2</sup> IV over 30-60 minutes, days 1, 8<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours before gemcitabine, day 1<br> Repeat every 21 days', 'Low', 'Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. $J Clin Oncol. 2008;26(24):3950-3957.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Gemcitabine : Gemzar, various<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (126, 15, 'EC', '<b>EC</b>', '<b>Epirubicin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 830 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for up to 8 cycles', 'High', 'Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. $J Clin Oncol. 2001;19(12):3103-3110.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cyclophosphamide : Cytoxan<br>Epirubicin : Ellence, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (127, 15, 'Ixabepilone/Capecitabine', '<b>Ixabepilone/Capecitabine</b>', '<b>Ixabepilone</b> 40 mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat every 21 days for up to 8 cycles', 'Low', 'Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. $J Clin Oncol. 2007;25(33):5210-5217.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Ixabepilone:<br>Monotherapy:  <br>                                                                                                 If AST and ALT < 2.5 upper normal limit, and bilirubin < 1 upper normal limit, use 40 mg/m2<br>                                                                         If AST or ALT < 10 upper normal limit, and bilirubin < 1 upper normal limit, use 32 mg/m2  <br>                                                                                     If AST and ALT < 10 upper normal limit, and bilirubin 1.5-3 upper normal limit, use 20-30 mg/m2 <br>                                                                  If AST or ALT > 10 upper normal limit, or bilirubin > 3 upper normal limit, do not use <br>                                                                                                                                                                                   In combination with capecitabine:  <br>                                                             If AST and ALT < 2.5 upper normal limit, and bilirubin < 1 upper normal limit, use 40 mg/m2 <br>                                                                        If AST or ALT > 2.5 upper normal limit, or bilirubin > 1 upper normal limit, do not use </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Ixabepilone:<br>If CrCl > 30 mL/min, no dose reduction</li></ul>', 'Capecitabine : Xeloda<br>Ixabepilone : Ixempra');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (128, 16, 'Lapatinib/Capecitabine', '<b>Lapatinib/Capecitabine</b>', '<b>Lapatinib</b> 1,250 mg PO 1 hour before breakfast, daily<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat every 21 days', 'Low', 'Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. $N Engl J Med. 2006;355(26):2733-2743.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Lapatinib:<br>If Child-Pugh C, reduce dose to 750 mg/d </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Lapatinib:<br>Not studied. Only 2% eliminated by kidneys </li></ul>', 'Capecitabine : Xeloda<br>Lapatinib : Tykerb');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (129, 16, 'Lapatinib/Letrozole', '<b>Lapatinib/Letrozole</b>', '<b>Lapatinib</b> 1,500 mg PO, daily<br> <b>Letrozole</b> 2.5 mg PO, daily', 'Low', 'Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. $J Clin Oncol. 200927(33):5538-5546.$', '<b>Hepatic Impairment</b><ul><li>Lapatinib:<br>If Child-Pugh C, reduce dose to 750 mg/d </li><li>Letrozole:<br>If Child-Pugh A or B, no dose reduction <br>                                                     If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Lapatinib:<br>Not studied. Only 2% eliminated by kidneys </li><li>Letrozole:<br>If CrCl > 10 mL/min, no dose reduction </li></ul>', 'Lapatinib : Tykerb<br>Letrozole : Femara');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (130, 15, 'Sequential AC --> T', '<b>Sequential AC --> T</b>', '<b>Doxorubicin</b> 60 mg/m<sup>2</sup> over 5-15 minutes, day 1<br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV 30-60 minutes, day 1<br> Repeat every 21 days for 4 cycles<br> <b>FOLLOWED BY</b><br> <b>Paclitaxel</b> 80 mg/m<sup>2</sup> IV over 1 hour<br> Repeat every 7 days for 12 cycles', 'High for AC, low for paclitaxel  ', 'Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. $N Engl J Med. 2008;238(16):1663-1671.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (131, 15, 'TAC', '<b>TAC</b>', '<b>Doxorubicin</b> 50 mg/m<sup>2</sup> as a 15-minute IV bolus, <b>FOLLOWED BY</b><br> <b>Cyclophosphamide</b> 500 mg/m<sup>2</sup> as a 1- to 5-minute IV bolus,<br> <b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 1 hour', 'High', 'Martin M, Pienkowshi T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. $N Engl J Med. 2005;352(22):2303-2313.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Docetaxel:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Docetaxel : Taxotere<br>Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (132, 15, 'TC', '<b>TC</b>', '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 30-60 minutes, day 1<br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV over 30-60 minutes, day 1<br> Repeat every 21 days for 4 cycles', 'Moderate', 'Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. $J Clin Oncol. 2006:24(34):5381-5387.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (133, 15, 'X+T', '<b>X+T</b>', '<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> PO bid, days 1-14<br> <b>Docetaxel</b> 75 mg/m<sup>2</sup> as a 1-hour IV infusion, day 1<br> Repeat every 21 days', 'Low', 'O''Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthraccline-pretreated patients with advanced breast cancer: phase III trial results. $J Clin Oncol. 2002;20(12):2812-2823.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Capecitabine : Xeloda<br>Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (134, 16, 'TCH', '<b>TCH</b>', '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Carboplatin</b> AUC of 6 day 1 <br> Repeat every 21 days for 8 cycles<br> <b>Trastuzumab</b> 4 mg/kg IV,<br> <b>FOLLOWED BY</b><br> <b>Trastuzumab</b> 2 mg/kg IV weekly during chemotherapy, <b>THEN</b> 6 mg/kg IV<br> Repeat every 21 days for 1 year', 'Moderate for combination therapy, low for trastuzumab monotherapy', 'Pegram M, Forbes J, Pienkowski T, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). $J Clin Oncol. 2007;25:LBA 1008 (abstract).$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Carboplatin : Paraplatin<br>Docetaxel : Taxotere<br>Trastuzumab : Herceptin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (135, 15, 'TP', '<b>TP</b>', '<b>Trastuzumab</b> 4 mg/kg IV loading dose, day 1 <b>THEN</b> 2 mg/kg IV weekly, days 8, 15<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV, day 2<br> Repeat every 21 days', 'Low', 'Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. $J Clin Oncol. 2006;24(18):2786-2792.$', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Paclitaxel : Taxol<br>Trastuzumab : Herceptin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (136, 16, 'Trastuzumab/Paclitaxel/Carboplatin', '<b>Trastuzumab/Paclitaxel/Carboplatin</b>', '<b>Trastuzumab</b> 4 mg/kg loading dose, day 1 of cycle 1, <b>THEN</b> 2 mg/kg weekly thereafter<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV, day 2<br> <b>Carboplatin</b> AUC of 6, day 2<br> Repeat every 21 days for at least 6 cycles<br> <b>FOLLOWED BY Trastuzumab</b> 2 mg/kg weekly until disease progression.', 'Moderate (low for single-agent trastuzumab)', 'Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. $J Clin Oncol. 2006;24(18):2786-2792.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol<br>Trastuzumab : Herceptin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (137, 15, 'Abraxane', '<b>Abraxane</b>', '260 mg/m<sup>2</sup> IV over 30 minutes<br> Repeat every 21 days', 'Low', 'Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. $J Clin Oncol. 2005;23(31):7794-7803.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (138, 17, 'Anastrozole', '<b>Anastrozole</b>', '<b>Anastrozole</b> 1 mg PO  once daily', 'N/A', 'Arimidex [package insert]. $Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2011.$', '<b>Hepatic Impairment</b><ul><li>Anastrozole:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Anastrozole:<br>No dose reduction </li></ul>', 'Anastrozole : Arimidex');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (139, 15, 'Capecitabine', '<b>Capecitabine</b>', '<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> PO bid, days 1-14, <br>Repeat every 21 days ', 'Low', 'Xeloda [package insert]. $San Francisco, CA: Genentech; 2011.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Capecitabine : Xeloda');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (140, 15, 'Docetaxel', '<b>Docetaxel</b>', '<b>Docetaxel</b> 100 mg/m<sup>2</sup> IV over 1 hour<br> Repeat every 21 days <b>OR</b><br><b>Docetaxel</b>40 mg/m <sup>2</sup>', 'Low', 'Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. $J Clin Oncol. 1999;17(8):2341-2354.$<br> Nabholtz JM, Senn Hj, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. $J Clin Oncol. 1999;17(5):1413-1424.$<br> Taxotere [package insert]. $New York, NY: Sanofi-Aventis; 2010.$', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (141, 15, 'Eribulin', '<b>Eribulin</b>', '<b>Eribulin</b> 1.4 mg/m<sup>2</sup> IV over 2-5 minutes, days 1 and 8<br> Repeat cycle every 21 days', 'Low', 'Cortes J, O''Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician''s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. $Lancet. 2011;377(9769):914-923.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Eribulin : Halaven');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (142, 17, 'Exemestane', '<b>Exemestane</b>', '<b>Exemestane</b> 25 mg PO once daily', 'NA', 'Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase in hibitors: a phase II trial. $J Clin Oncol. 2000;18(11):2234-2244.$<br> Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. $J Clin Oncol. 2000;18(7):1399-1411.$<br> Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. $N Engl J Med. 2004;350(11):1081-1092.$', '<b>Hepatic Impairment</b><ul><li>Exemestane:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Exemestane:<br>No dose reduction </li></ul>', 'Exemestane : Aromasin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (143, 17, 'Fulvestrant', '<b>Fulvestrant</b>', '<b>Fulvestrant</b> 500 mg IM loading dose on day 1,15, and 29 and then every 28 days. ', 'N/A', 'Di Leo A, et al.Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.$J Clin Oncol. 2010 Oct 20;28(30):4594-600$', '<b>Hepatic Impairment</b><ul><li>Fulvestrant:<br>If SGOT, SGPT, bilirubin and alkaline phosphatase < 2 upper normal limit, no dose reduction<br>                                                                                If SGOT, SGPT, bilirubin and alkaline phosphatase > 2 upper normal limit, unknown </li></ul><b>Renal Impairment</b><ul><li>Fulvestrant:<br>No dose reduction </li></ul>', 'Fulvestrant : Faslodex');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (144, 15, 'Gemcitabine', '<b>Gemcitabine</b>', '<b>Gemcitabine</b> 800 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8, 15<br> Repeat every 28 days', 'Low', 'Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. $J Clin Oncol. 1995;13(11):2731-2736.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (145, 17, 'Letrozole', '<b>Letrozole</b>', '<b>Letrozole</b> 2.5 mg PO once daily', 'NA', 'Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol aectate. $J Clin Oncol. 1998;16(2):453-461.$<br> Ingle JN, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. $Cancer. 1997;80(2):218-224.$<br> Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. $N Engl J Med. 2003;349(19): 1793-1802.$', '<b>Hepatic Impairment</b><ul><li>Letrozole:<br>If Child-Pugh A or B, no dose reduction <br>                                                     If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Letrozole:<br>If CrCl > 10 mL/min, no dose reduction </li></ul>', 'Letrozole : Femara');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (146, 17, 'Megestrol', '<b>Megestrol</b>', '<b>Megestrol</b> 40 mg PO, every 6 hours', 'N/A', 'Buzdar A, Douma J, et al. Phase III, multicenter, double-blind, randomized study of letrozole, and aromatiase inhibitor, for advanced breast cancer versus megestrol acetate. $J Clin Oncol. 2001;19(14):3357-3366.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (147, 15, 'Paclitaxel', '<b>Paclitaxel</b>', '<b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours<br> Repeat every 21 days', 'Low', 'Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. $J Clin Oncol. 1995;13(10):2575-2581.$<br> Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. $J Clin Oncol. 1999;17(11):3403-3411.$', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (148, 17, 'Tamoxifen', '<b>Tamoxifen</b>', '<b>Tamoxifen</b> 20-40 mg PO once daily', 'N/A', 'Hackshaw A, Roughton M, et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. $J Clin Oncol. 2011;29(13):1657-1663.$', '<b>Hepatic Impairment</b><ul><li>Tamoxifen:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Tamoxifen:<br>No dose reduction</li></ul>', 'Tamoxifen : Nolvadex');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (149, 17, 'Toremifene', '<b>Toremifene</b>', '<b>Toremefene</b> 60 mg/d PO', 'N/A', 'Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. $J Clin Oncol. 1995;13(10):2556-2566.$<br> Fareston [package insert]. $Memphis, TN: GTx, Inc,:2011.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (150, 16, 'Trastuzumab qwk', '<b>Trastuzumab qwk</b>', '<b> Trastuzumab 4 mg/kg IV loading dose over 90 minutes, <b>FOLLOWED BY</b> 2 mg/kg IV over 30 minutes, weekly', 'Low', 'Herception [package insert]. $South San Francisco, CA: Genentech, Inc: 2010.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Trastuzumab : Herceptin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (151, 15, 'Trastuzumab q3wk', '<b>Trastuzumab q3wk</b>', '<b>Trastuzumab</b> 8 mg/kg IV over 90 minutes, day 1, then 6 mg/kg IV over 90 minutes<br> Repeat every 21 days for 1 year(adjuvant).', 'Low', 'Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. $N Engl J Med. 2005;353(16):1659-1672.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Trastuzumab : Herceptin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (152, 15, 'Vinorelbine', '<b>Vinorelbine</b>', '<b>Vinorelbine</b> 30 mg/m<sup>2</sup> IV<br> Repeat every 7 days', 'Low', 'Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast  cancer. $J Clin Oncol. 1995;13(11):2722-2730.$', '<b>Hepatic Impairment</b><ul><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Vinorelbine:<br>No dose reduction</li></ul>', 'Vinorelbine : Navelbine');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (153, 20, 'Carbo-Docetaxel', '<b>Carbo-Docetaxel</b>', '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1,<br> <b>FOLLOWED BY</b><br> <b>Carboplatin</b> dose AUC of 5 IV over 1 hour day 1<br> Repeat every 21 days for 6 cycles', 'Moderate', 'Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. $J Natl Cancer Inst. 2004;96(22):1682-1691.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Carboplatin : Paraplatin<br>Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (154, 20, 'Carbo-Tax', '<b>Carbo-Tax</b>', '<b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Carboplatin</b> dose AUC of 5 IV  day 1<br> Repeat every 21 days', 'Moderate', 'Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. $J Clin Oncol. 2000;18(17):3084-3092.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Carboplatin : Paraplatin<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (155, 20, 'CD (Doxil/Carboplatin)', '<b>CD (Doxil/Carboplatin)</b>', '<b>Liposomal doxorubicin</b> 30 mg/m<sup>2</sup> IV, day 1 <b>Carboplatin</b>AUC of 5 IV day 1<br> Repeat every 28 days', 'Moderate', 'Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relppase. $J Clin Oncol. 2010;28:3323-3329.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li></ul>', 'Carboplatin : Paraplatin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (156, 20, 'CT', '<b>CT</b>', '<b>Paclitaxel</b> 135 mg/m<sup>2</sup> CIVI over 24 hours, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for 6 cycles<br> <b>OR</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days', 'High', 'McGuire WP, Hoskins WJ, Brady MF, et al. Cyclo-phosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. $N Engl J Med. 1996;334(1):1-6.$<br> Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. $J Clin Oncol. 2000;18(17):3084-3092.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cisplatin : CDDP<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (157, 20, 'GC', '<b>GC</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV, days 1, 8<br> <b>Carboplatin</b> AUC of 4, IV, day 1<br> Repeat every 21 days for 6 cycles', 'Moderate', 'Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. $J Clin Oncol. 2006;24(29):4699-4707.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Carboplatin : Paraplatin<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (158, 20, 'Intraperitoneal CT', '<b>Intraperitoneal CT</b>', '<b>Paclitaxel</b> 135 mg/m<sup>2</sup> CIVI over 24 hours, day 1<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IP, day 2<br> <b>Paclitaxel</b> 60 mg/m<sup>2</sup> IP, day 8<br> Repeat every 21 days for 6 cycles', 'High', 'Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. $N Engl J Med. 2006;354(1):34-43.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cisplatin : CDDP<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (159, 20, 'Altretamine', '<b>Altretamine</b>', '<b>Altretamine</b> 260 mg/m<sup>2</sup>/d PO in 4 divided doses for 14 days<br> Repeat every 28 days', 'Moderate-High', 'Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. $Gynecol Oncol. 1998;69(3):226-229.$', '<b>Hepatic Impairment</b><ul><li>Altretamine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul></ul>', 'Altretamine : Hexalen');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (160, 20, 'Bevacizumab', '<b>Bevacizumab</b>', '<b>Bevacizumab</b> 15 mg/kg IV, day 1<br> Repeat every 21 days until disease progression ', 'Low', 'Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistant or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. $J Clin Oncol. 2007;25(33):5165-5171.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Bevacizumab : Avastin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (161, 20, 'Gemcitabine', '<b>Gemcitabine</b>', '<b>Gemcitabine</b> 800 mg/m<sup>2</sup>/d, days 1, 8, 15<br> Repeat every 28 days', 'Low', 'Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2'', 2'' difluorodeoxycytidine) in previously treated ovarian cancer patients. $J Natl Cancer Inst. 1994;86(20):1530-1533.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (162, 20, 'Paclitaxel', '<b>Paclitaxel</b>', '<b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours<br> Repeat every 21 days', 'Low', 'ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. $J Clin Oncol. 1997;15(6):2183-2193.$', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (163, 20, 'Pegylated liposomal doxorubicin', '<b>Pegylated liposomal doxorubicin</b>', '<b>Pegylated liposomal doxorubicin</b> 50 mg/m<sup>2</sup> IV every 28 days', 'Low', 'Gordon AN, Granai CO, Rose CG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. $J Clin Oncol. 2000;18(17):3093-3100.$<br> Doxil [package insert]. $Raritan, NJ: Centocor Ortho Biotech Products, LP;2010.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (164, 20, 'Topotecan', '<b>Topotecan</b>', '<b>Topotecan</b> 1.5 mg/m<sup>2</sup>/d IV over 30 minutes, days 1-5<br> Repeat every 21 days', 'Low', 'ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. $J Clin Oncol. 1997;15(6):2183-2193.$', '<b>Hepatic Impairment</b><ul><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Topotecan : Hycamtin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (165, 19, 'Cisplatin/Doxorubicin', '<b>Cisplatin/Doxorubicin</b>', '<b>Doxorubicin</b> 60 mg/m<sup>2</sup> IV day 1<br> <b>Cisplatin</b> 50 mg/m<sup>2</sup> IV, day 1, cycles 1-7<br> Repeat every 21 days upto 8 cycles', 'High', 'Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. $J Clin Oncol. 2006;24(1):36-44.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (166, 19, 'TAP', '<b>TAP</b>', '<b>Doxorubicin</b> 45 mg/m<sup>2</sup>, day 1<br> <b>FOLLOWED BY</b><br> <b>Cisplatin</b> 50 mg/m<sup>2</sup>, day 1<br> <b>Paclitaxel</b> 160 mg/m<sup>2</sup> over 3 hours, day 2<br> <b>Filgrastim</b> 5 mcg/kg d SQ, days 3-12<br> <b>OR</b><br>Repeat every 21 days for a maximum of 7 cycles<br><b>PEG-Filgastrim</b>6 mg SQ on day 3.', 'High', 'Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastimin advanced endometrial carcinoma: a Gynecologic Oncology Group Study. $J Clin Oncol. 2004;22(11):2159-2166.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (167, 19, 'Doxorubicin', '<b>Doxorubicin</b>', '<b>Doxorubicin</b> 60 mg/m<sup>2</sup> IV every 21 days (maximum cumulative dose, 500 mg/m<sup>2</sup>)<br> Repeat every 21 days', 'Moderate', 'Thigpen JT, Brady MF, Homesly HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. $J Clin Oncol. 2004;22(19):3902-3908.$', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (168, 19, 'Medroxy-progesterone', '<b>Medroxy-progesterone</b>', '<b>Medroxyprogesterone acetate</b> 200 mg/d PO', 'N/A', 'Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecological Oncology Group. $J Clin Oncol. 1999;17(6):1736-1744.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (169, 18, 'Cisplatin/Fluorouracil', '<b>Cisplatin/Fluorouracil</b>', '<b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 4 hours, day 1, given within 16 hours of the first dose of RT<br> <b>Fluorouracil</b> 4,000 mg/m<sup>2</sup> CIVI over 96 hours, days 2-5<br> Repeat every 21 days for 3 cycles<br> <b>OR</b><br> <b>Cisplatin</b> 50 mg/m<sup>2</sup>/d IV, days 1, 29, given 4 hours before the first dose of RT<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d IV, days 2-5, 30-33', 'High', 'Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemoterapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. $N Engl J Med. 1999;340(15):1137-1143.$<br> Whitney CW, Sausse W, Bundy BN, et al. Randomized commparison of fluorouuracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. $J Clin Oncol. 1999;17(5):1339-1348.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (170, 18, 'C-P', '<b>C-P</b>', '<b>Cisplatin</b> 50 mg/m2 IV, day 1<br> <b>Paclitaxel</b> 135 mg/m<sup>2</sup> CIVI over 24 hours<br> Repeat every 21 days for 6 cycles', 'High', 'Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet commbinations in stage IVB recurrent or persistent cervical carcinoma: A Gynecologic Group Study. $J Clin Oncol. 2009;27(28):4649-4655.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cisplatin : CDDP<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (171, 18, 'Cisplatin/Topotecan', '<b>Cisplatin/Topotecan</b>', '<b>Cisplatin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Topotecan</b> 0.75 mg/m<sup>2</sup>/d IV, days 1-3<br> Repeat every 21 days', 'High', 'Long HJ, Bundy BN, Grendys EC, et al. Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. $J Clin Oncol. 2005;23(21):4626-4633.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Cisplatin : CDDP<br>Topotecan : Hycamtin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (172, 18, 'Cisplatin', '<b>Cisplatin</b>', '<b>Cisplatin</b> 40 mg/m<sup>2</sup> IV once per week during RT for up to 6', 'High', 'Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. $N Engl J Med. 1999;340(15):1154-1161.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (173, 22, 'Bevacizumab/Interferon alfa', '<b>Bevacizumab/Interferon alfa</b>', '<b>Bevacizumab</b> 10 mg/kg IV<br> Repeat every 14 days until disease progression<br> <b>Interferon alfa-2a</b> 9 million IU SQ 3 times per week<br> Repeat every 14 days for a maximum of 52 weeks', 'Low', 'Escudier B, Pluzanska A, Koralweski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. $Lancet. 2007;370(9605):2103-2111.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Bevacizumab : Avastin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (174, 22, 'Everolimus', '<b>Everolimus</b>', '<b>Everolimus</b> 10 mg PO daily', 'Low', 'Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, plaebo-controlled phase III trial. $Lancet. 2008;372(9637);449-456.$', '<b>Hepatic Impairment</b><ul><li>Everolimus:<br><b>Mild hepatic impairment (Child-Pugh class A)</b> – The recommended dose is 7.5 mg daily; the dose may be decreased ;
to 5 mg if not well tolerated. <br>;
<b>Moderate hepatic impairment (Child-Pugh class B) </b>– The recommended dose is 5 mg daily; the dose may be ;
decreased to 2.5 mg if not well tolerated.<br> ;
<b>Severe hepatic impairment (Child-Pugh class C)</b> – If the desired benefit outweighs the risk, a dose of 2.5 mg daily ;
may be used but must not be exceeded.;
</li></ul><b>Renal Impairment</b><ul><li>Everolimus:<br>No dose adjustment is recommended.</li></ul>', 'Everolimus : Afinitor, Zortress');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (175, 22, 'Interleukin-2', '<b>Interleukin-2</b>', '<b>Interleukin-2</b><br> <b>High Dose:</b> 600,000-720,000 units/kg IV over 15 minutes, every 8 hours until toxicity or 14 doses; administer 2 courses separated by 5-9 days<br> Repeat 2-course cycle every 6-12 weeks<br> <b>Low Dose:</b> 72,000 units/kg IV bolus every 8 hours up to 14 doses in 5 days. Repeat treatment following 7-10 days of rest<br> Repeat every 8 weeks<br> <b>OR</b><br> 18 million units/m2/d CIVI, days 1-5 and 12-17; repeat cycle on day 35 <b>followed by</b>  9 million units/m2/d CIVI, days 1-5<br> Repeat second cycle every 28 days for 4 cycles', 'Moderate', 'Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. $J Clin Oncol. 1995;13(3):688-696.$<br> Sleijfer DT, Janssen RAJ, Buter J, et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. $J Clin Oncol. 1992;10(7):1119-1123.$<br> Yang JC, Sherry R, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. $J Clin Oncol. 2003;21(16):3127-3132.$', '<b>Hepatic Impairment</b><ul><li>Interleukin-2:<br>Do not use in liver failure</li></ul><b>Renal Impairment</b><ul><li>Interleukin-2:<br>If Cr > 4-4.5 mg/dL, do not use</li></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (176, 22, 'Pazopanib', '<b>Pazopanib</b>', '<b>Pazopanib</b> 800 mg PO daily<br> Repeat every 6 weeks for 4 cycles <b>THEN</b> every 8 weeks', 'Low', 'Sternberg CN, Szcylic C, Lee E, et al. A randomized double blind Phase III study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). $J Clin Oncol. 2009;27 (Suppl 15):5021.$', '<b>Hepatic Impairment</b><ul><li>Pazopanib:<br>The maximum tolerated dose in patients with moderate hepatic impairment (total bilirubin >1.5 X to 3 X ULN regardless of the ;
ALT value) was 200 mg per day (N = 11). <br> The median steady-state Cmax and AUC(0-24) achieved at this dose was approximately 40% and 29%, respectively, of that seen in patients with normal ;
hepatic function at the recommended daily dose of 800 mg. <br>The maximum dose explored in patients with severe hepatic impairment (total bilirubin >3 X ULN regardless of the ALT value) ;
was 200 mg per day (N = 14). <br>This dose was not well tolerated. Median exposures achieved at this dose were approximately 18% and 15% of those seen in patients with normal liver function ;
at the recommended daily dose of 800 mg. Therefore, VOTRIENT is not recommended in these patients.</li></ul><b>Renal Impairment</b><ul><li>Pazopanib:<br>No dose adjustment is recommended.</li></ul>', 'Pazopanib : Votrient');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (177, 22, 'Sorafenib', '<b>Sorafenib</b>', '<b>Sorafenib</b> 400 mg PO bid', 'Low', 'Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. $N Engl J Med. 2007;356(2):125-134.$', '<b>Hepatic Impairment</b><ul><li>Sorafenib:<br>If Child-Pugh A or B, no dose reduction     <br>                                                 If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sorafenib:<br>No dose reduction </li></ul>', 'Sorafenib : Nexavar');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (178, 22, 'Sunitinib', '<b>Sunitinib</b>', '<b>Sunitinib malate</b> 50 mg PO daily for 28 days on<br> <b>FOLLOWED BY</b> 14 days off', 'Low', 'Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. $N Engl J Med. 2007;356(2):115-124$', '<b>Hepatic Impairment</b><ul><li>Sunitinib:<br>If Child-Pugh A or B, no dose reduction  <br>                                                    If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sunitinib:<br>If CrCl > 42 mL/min, no dose reduction </li></ul>', 'Sunitinib : Sutent');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (179, 22, 'Temsirolimus', '<b>Temsirolimus</b>', '<b>Temsirolimus</b> 25 mg IV over 30 minutes weekly', 'Low', 'Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. $N Engl J Med. 2007;356(22):2271-2281.$', '<b>Hepatic Impairment</b><ul><li>Temsirolimus:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Temsirolimus:<br>No dose reduction </li></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (180, 21, 'Gemcitabine/Carboplatin', '<b>Gemcitabine/Carboplatin</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes, days 1 and 8<br> <b>Carboplatin</b> AUC of 5 IV over 1 hour, day 1<br> Repeat cycle every 21 days upto 6 cycles', 'Moderate', 'Bamias A, Moulopoulos LA, Koutras A, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. $Cancer. 2006;106(2):297-303.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Carboplatin : Paraplatin<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (181, 21, 'Gemcitabine/Cisplatin', '<b>Gemcitabine/Cisplatin</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>/d IV over 30-60 minutes, days 1,8,15<br> <b>Cisplatin</b> 70mg/m<sup>2</sup> IV, day 2<br> Repeat every 28 days', 'High', 'von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and ciplatin in advanced or metastatic bladder cancer: results of a large, randomized, mulinational, multicenter, phase III study. $J Clin Oncol. 2000;18(17):3068-3077.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (182, 21, 'MVAC', '<b>MVAC</b>', '<b>Methotrexate</b> 30 mg/m<sup>2</sup>/d IV, days 1, 15, 22<br> <b>Vinblastine</b> 3 mg/m<sup>2</sup>/d IV, days 2, 15,22<br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV, day 2<br> <b>Cisplatin</b> 70 mg/m<sup>2</sup> IV, day 2<br> Repeat every 28 days', 'High', 'von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and ciplatin in advanced or metastatic bladder cancer: results of a large, randomized, mulinational, multicenter, phase III study. $J Clin Oncol. 2000;18(17):3068-3077.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Vinblastine:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various<br>Vinblastine : Velban');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (183, 25, 'BEP', '<b>BEP</b>', '<b>Bleomycin</b> 30 units IV bolus, weekly for 12 weeks<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV over 30-60 minutes,days 1-5<br> <b>Cisplatin</b> 20 mg/m<sup>2</sup>/d IV over 30-60 minutes, days 1-5<br> Repeat every 21 days for 4 courses', 'High', 'Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, jSouthwest Oncology Group, and Cancer and Leukemia Group B Study. $J Clin Oncol. 1998;16(4):1287-1293.$', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Bleomycin : Blenoxane<br>Cisplatin : CDDP<br>Etoposide : VP-16');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (184, 25, 'EP', '<b>EP</b>', '<b>Etoposide</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-5<br> <b>Cisplatin</b> 20 mg/m<sup>2</sup>/d IV, days 1-5<br> Repeat after 21 days', 'High', 'Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. $J Clin Oncol. 1995;13(11):2700-2704.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cisplatin : CDDP<br>Etoposide : VP-16');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (185, 25, 'TIP', '<b>TIP</b>', '<b>Paclitaxel</b> 250 mg/m<sup>2</sup>/d CIVI over 24 hours, day 1<br> <b>Ifosfamide</b> 1,500 mg/m<sup>2</sup>/d IV over 1 hour, days 2-5<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d IV over 30 minutes, days 2-5<br> <b>Mesna</b> 500 mg/m<sup>2</sup> IV before ifosfamide, and at 4 and 8 hours after ifosfamide daily, days 2-5<br> <b>Peg-Filgrastim</b> 6 mcg SQ, days 6<br> Repeat every 21 days for 4 cycles', 'High', 'Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. $J Oncol. 2005;23(27):6549-6555.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cisplatin : CDDP<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (186, 25, 'VIP', '<b>VIP</b>', '<b>Vinblastine</b> 0.11 mg/kg/d IV, days 1, 2<br> <b>OR</b><br> <b>Etoposide</b> 75 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>AND</b><br> <b>Infosfamide</b> 1,2000 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 20mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Mesna</b> 400 mg IV 15 minutes prior to ifosfamide, <b>THEN</b> 1,200 mg/d CIVI, days 1-5<br> Repeat every 21 days for 4 cycles', 'High', 'Loehrer PJ, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ-cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. $Ann Intern Med. 1988;109(7):540-546.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Mesna:<br>No dose reduction</li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vinblastine:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Etoposide : VP-16<br>Mesna : Mesnex, various<br>Vinblastine : Velban');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (187, 23, 'Cabazitaxel', '<b>Cabazitaxel</b>', '<b>Cabazitaxel</b> 25 mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Prednisone</b> 10 mg PO daily<br> Repeat every 21 days', 'Low', 'de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. $Lancet. 2010;376(9747):1147-1154.$', '<b>Hepatic Impairment</b><ul><li>Cabazitaxel:<br></li></ul><b>Renal Impairment</b><ul><li>Cabazitaxel:<br>Caution should be used in patients with severe renal impairment (creatinine clearence of <30 ml/hr)</li></ul>', 'Cabazitaxel : Jevtana<br>Prednisone : various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (188, 23, 'Docetaxel/Estramustine', '<b>Docetaxel/Estramustine</b>', '<b>Docetaxel</b> 60 mg/m<sup>2</sup> IV, day 2<br><b>Estramustine</b> 280 mg PO tid, days 1-5<br> Repeat every 21 days until progression or to a maximum of 12 cycles ', 'Moderate-High', 'Petrylak DP, Tangen CM, Hussain MA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. $N Engl J Med. 2004;351(15):1513-1520.$', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Estramustine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Docetaxel : Taxotere<br>Estramustine : Estracyte');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (189, 23, 'Docetaxel/Prednisone', '<b>Docetaxel/Prednisone</b>', '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Prednisone</b> 5 mg PO bid, days 1-21<br> Repeat every 21 days', 'Low', 'Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. $N Engl J Med. 2004;351(15):1502-1512.$', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Docetaxel : Taxotere<br>Prednisone : various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (190, 23, 'FL', '<b>FL</b>', '<b>Flutamide</b> 250 mg PO tid <b>WITH</b><br> <b>Leuprolide acetate depot</b> 7.5 mg IM<br> Repeat every 28 days', 'N/A', 'Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJCM. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? $Urology. 2000;55(3):391-396.$', '<b>Hepatic Impairment</b><ul><li>Leuprolide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Flutamide : various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (191, 23, 'FZ', '<b>FZ</b>', '<b>Flutamide</b> 250 mg PO tid <b>WITH</b><br> <b>Goserelin acetate implant</b> 3.6 mg SQ<br> Repeat every 28 days, beginning 8 weeks prior to Radiation theraupy for 4 cycles<br> <b>OR</b><br> <b>Goserelin acetate implant</b> 3.6 mg SQ 8 weeks prior to Radiation theraupy <b>AND</b><br> <b>Goserelin acetate implant</b> 10.8 mg SQ 4 weeks prior to Radiation theraupy', 'N/A', 'Zoladex 3.6 mg, Zoladex 10.8 mg [package inserts]. Wilmington, DE: AstraZeneca; 2010. Roach M, Bae K, Speight J, et al. Short-term androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: Long-term results of RJOG 8610. $J Clin Oncol. 2009;26(4):585-591.$', '<b>Hepatic Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul>', 'Flutamide : various<br>Goserelin : Zoladex');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (192, 23, 'Mitoxantrone/Prednisone', '<b>Mitoxantrone/Prednisone</b>', '<b>Mitoxantrone</b> 12 mg/m<sup>2</sup> IV, day 1<br> <b>Prednisone</b> 5 mg PO bid<br> Repeat every 21 days', 'Low', 'Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. $J Clin Oncol. 1996;14(6)1756-1764.$', '<b>Hepatic Impairment</b><ul><li>Mitoxantrone:<br>If bilirubin > 3 mg/dL, reduce dose by 25%</li></ul><b>Renal Impairment</b><ul><li>Mitoxantrone:<br>No dose reduction</li></ul>', 'Mitoxantrone : Novantrone<br>Prednisone : various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (193, 23, 'Bicalutamide/Leuprolide.  ', 'Bicalutamide/Leuprolide.  ', '<b>Bicalutamide</b> 50 mg/d PO <b>WITH</b><br> <b>Leuprolide acetate depot</b> 7.5 mg IM<br> Repeat every 28 days', 'N/A', 'Schellhammer P, Sharifi R, Block N, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. $Urology. 1995;45(5):745:752.$', '<b>Hepatic Impairment</b><ul><li>Bicalutamide:<br>No dose reduction</li><li>Goserelin:<br>No dose reduction </li><li>Leuprolide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bicalutamide:<br>No dose reduction </li><li>Goserelin:<br>No dose reduction </li></ul>', 'Bicalutamide : Casodex<br>Goserelin : Zoladex');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (194, 24, 'Degarelix', '<b>Degarelix</b>', '<b>Degarelix</b> 240 mg SQ <br> <b>FOLLOWED BY</b><br> 80 mg SQ<br> Repeat every 28 days for 13 courses', 'N/A', 'Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. $BJU Int. 2008;102(11):1531-1538.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Degarelix : Firmagon');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (195, 23, 'Abaraterone', '<b>Abaraterone</b>', '<b>Abaraterone</b>1000 mg PO once daily on empty stomach<br> <b>Prednisone</b> 5 mg PO twice daily', 'Low', 'Ryan CJ, et al. "Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy". $N. Engl. J. Med. 368 (2): 138–48.$', '<b>Hepatic Impairment</b><ul><li>Abaraterone:<br>No dosage adjustment is necessary for patients with baseline mild hepatic impairment. <br>In patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the recommended dose of ZYTIGA to 250 mg once daily. If elevations in ALT or AST >5X ULN or total bilirubin >3X ULN occur in patients with baseline moderate hepatic impairment, discontinue ZYTIGA treatment. <br> The safety of ZYTIGA in patients with baseline severe hepatic impairment has not been studied. These patients should not receive ZYTIGA. For patients who develop hepatotoxicity during treatment, interruption of treatment</li></ul><b>Renal Impairment</b><ul><li>Abaraterone:<br>No dose adjustment needed</li></ul>', 'Abaraterone : Zytiga');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (196, 23, 'Estramustine', '<b>Estramustine</b>', '<b>Estramustine</b> 14 mg/kg/d PO in 3 or 4 divided doses', 'Moderate-High', 'Emcyt [package insert]. $New York, NY: Pfizer; 2007.$', '<b>Hepatic Impairment</b><ul><li>Estramustine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Estramustine : Estracyte');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (197, 23, 'Enzalutamide', '<b>Enzalutamide</b>', '<b>Enzalutamide</b>160 mg po daily with or without food', 'Low', 'Howard I, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
$N Engl J Med 2012; 367:1187-1197September 27, 2012DOI: 10.1056/NEJMoa1207506$', '<b>Hepatic Impairment</b><ul><li>Enzalutamide:<br>No initial dosage adjustment is necessary for patients with baseline mild or moderate hepatic impairment.<br> Baseline severe hepatic impairment (Child-Pugh Class C) has not been assessed</li></ul><b>Renal Impairment</b><ul><li>Enzalutamide:<br>No initial dosage adjustment is necessary for patients with mild ;
to moderate renal impairment. <br>Severe renal impairment (CrCL < 30 mL/min) and end-stage renal disease have not been ;
assessed</li></ul>', 'Enzalutamide : Xtandi');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (198, 24, 'Goserelin', '<b>Goserelin</b>', '<b>Goserelin acetae implant</b> 3.6 mg SQ every 28 days or 10.8 mg SQ every 12 weeks.', 'N/A', 'Zoladex 3.6 mg, Zoladex 10.8 mg [package inserts]. $Wilmington, DE: AstraZeneca; 2010.$  ', '<b>Hepatic Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul>', 'Goserelin : Zoladex');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (199, 24, 'Leuprolide', '<b>Leuprolide</b>', '<b>Leuprolide acetate depot</b> 7.5 mg IM every 28 days <br>22.5 mg IM every 3 months, <br><b>OR</b> <br>30 mg IM every 4 months', 'N/A', 'Lupron Depot 7.5 mg, 22.5 mg, 30 mg [package insers]. $North Chicago, IL: Abbot Laboratories; 2011.$', '<b>Hepatic Impairment</b><ul><li>Leuprolide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (200, 24, 'Nilutamide', '<b>Nilutamide</b>', '<b>Nilutamide</b> 300 mg/d PO, days 1-30, <b>THEN</b> 150 mg/d PO, in combination with surgical castration; begin on same day or day after castration', 'N/A', 'Dijkman GA, Janknegt RA, et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate speific antigen normalization. International Anadron Study Group. $J Urol. 1997;158(1):160-163.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Nilutamide:<br>No dose reduction</li></ul>', 'Nilutamide : Nilandron');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (201, 23, 'Prednisone', '<b>Prednisone</b>', '<b>Prednisone</b> 5 mg PO bid', 'N/A', 'Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. $J Clin Oncol. 1996;14(6)1756-1764.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Prednisone : various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (202, 23, 'Sipuleucel-T', '<b>Sipuleucel-T</b>', '<b>Sipuleucel-T</b> Administer 3 doses at 14-day intervals', 'N/A', 'Provenge [package insert]. $Parsippany, NJ: Watson Pharma, Inc.; 2011.$', '<b>Hepatic Impairment</b><ul><li>Sipuleucel-T:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Sipuleucel-T:<br>Unknown</li></ul>', 'Sipuleucel-T : Provenge');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (203, 24, 'Triptorelin', '<b>Triptorelin</b>', '<b>Triptorelin pamoate depot</b> 3.75 mg IM<br> Repeat every 28 days', 'N/A', 'Trelstar [package insert]. $Parsippany, NJ: Watson Pharma, Inc.; 2011.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (204, 26, 'AD', '<b>AD</b>', '<b>Doxorubicin</b> 15 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Dacarbazine 250 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days', 'High', 'Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. $J Clin Oncol. 1993;11(7):1276-1285.$', '<b>Hepatic Impairment</b><ul><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Dacarbazine : DTIC<br>Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (205, 26, 'DI', '<b>DI</b>', '<b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV bolus, day 1,<br> <b>FOLLOWED BY</b><br> <b>Ifosfamide</b> 5,000 mg/m<sup>2</sup> CIVI, day 1<br> <b>Mesna</b> 600 mg/m<sup>2</sup> IV bolus, before ifosfamide, FOLLOWED BY 2,500 mg/m<sup>2</sup> CIVI with ifosfamide, and 1,250 mg/m<sup>2</sup> IV over 12 hours following ifosfamide<br> Repeat every 21 days ', 'Moderate', 'Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. $J Clin Oncol. 1995;13(7):1537-1545.$', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Doxorubicin : Adriamycin, various<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (206, 26, 'VAC-IE', '<b>VAC-IE</b>', '<b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 1<br> <b>FOLLOWED BY</b>  mesna<br> <b>Vincristine<sup></b> 2 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 75 mg/m<sup>2</sup> IV bolus, day 1<br> <b>Dactinomycin</b> 1.25 mg/m<sup>2</sup> IV, day 1 substitued for doxorubicin when cumulative doxorubicin dose reaches 375 mg/m<sup>2</sup><br> Alternating with each cycle<br> <b>Ifosfamide</b> 1,800 mg/m<sup>2</sup>/d IV, days 1-6 (given with mesna)<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5<br> Repeat cycle every 21 days for 17 total cycles', 'VAC-High<br> IE-Moderate', 'Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing''s sarcoma and primitive neuroectodermal tumor of bone. $N Engl J Med. 2003;348(8):694-701.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Dactinomycin:<br>If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Dactinomycin : Actinomycin<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (207, 26, 'MAID', '<b>MAID</b>', '<b>Mesna</b> 2,500 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Doxorubicin</b> 15 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Ifosfamide</b> 2,500 mg/m<sup>2</sup>/d CIVI, days 1-3<br> <b>Dacarbazine</b> 250 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days', 'High', 'Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. $J Clin Oncol. 1993;11(7):1276-1285.$', '<b>Hepatic Impairment</b><ul><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Dacarbazine : DTIC<br>Doxorubicin : Adriamycin, various<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (208, 26, 'Methotrexate/Cisplatin/Doxorubicin Ifosfamide', '<b>Methotrexate/Cisplatin/Doxorubicin Ifosfamide</b>', '<b>Methotrexate</b> 12,000 mg/m<sup>2</sup> IV over 4 hours day 1<br> <b>WITH Leucovorin calcium</b> 8 mg/m<sup>2</sup> IV every 6 hours for 11 doses beginning 24 hours from the start of the Methotrexate infusion, days 1, 42 (preoperatively); days 133, 196, 238 (postoperatively)<br> <b>Cisplatin</b> 120 mg/m<sup>2</sup> CIVI over 48 hours, days 7-8, 49-50 (preoperatively); days 140-141, 203-204, 245-246 (postoperatively). <br> <b>Doxorubicin</b> 75 mg/m<sup>2</sup> CIVI over 24 hours, days 7, 49 (preoperatively); days 98, 161 (postoperatively). Doxorubicin was increased to 90 mg/m<sup>2</sup> IV over 24 hours for postoperative treatment courses<br> <b>Ifosfamide</b> 3,000 mg/m<sup>2</sup>/d CIVI for 5 days with equimolar doses of mesna, days 28-32, 70-74 (preooperatively); days 119-123, 182-186, 224-228 (postoperatively)', 'High', 'Ferrrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. $J Clin Oncol. 2005;23(34):8845-8852.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Leucovorin:<br>No dose reduction</li><li>Methotrexate:<br>If bilirubin 3.1-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25% <br>  If bilirubin > 5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Leucovorin:<br>No dose reduction</li><li>Methotrexate:<br>If CrCl 30-60 mL/min, reduce dose by 50%    <br>                                                                  If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various<br>Ifosfamide : Ifex');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (209, 26, 'Doxorubicin', '<b>Doxorubicin</b>', '<b>Doxorubicin</b> 75 mg/m<sup>2</sup> IV<br> Repeat every 21 days', 'Moderate', 'Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas: a study of the EORTC soft tissue and bone sarcoma group. $Br J Cancer. 1998;78(12):1634-1639.$', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (210, 27, 'Interferon alfa-2b', '<b>Interferon alfa-2b</b>', '<b>Interferon alfa-2b</b>  30 million IU/m<sup>2</sup> IM <b>OR</b> SQ 3 times per week<br>Repeat until disease progression ', 'Moderate', 'Groopman JE, et al. Recombinant alpha-2 interferon therapy for Kaposi''s sarcoma associated with the acquired immunodeficiency syndrome.$Ann Intern Med. 1984 May;100(5):671-6$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (211, 27, 'Liposomal daunorubicin', '<b>Liposomal daunorubicin</b>', '<b>Liposomal daunorubicin</b> 40 mg/m<sup>2</sup> IV over 60 minutes<br>  Repeat every 14 days', 'Moderate', 'Rosenthal E, Poizot-Martin I, Saint Marc T, et al. Phase Ivstudy of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. $AM J Clin Oncol.2002;25(1): 57-59$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (212, 27, 'Paclitaxel', '<b>Paclitaxel</b>', '<b>Paclitaxel</b>  135 mg/m<sup>2</sup> IV over 3 hours<br> Repeat every 21 days<br><b>OR</b><br> <b>Paclitaxel<sup>a</sup></b> 100 mg/m<sup>2</sup> IV over 3 hours<br>Repeat every 14 days   ', 'Low', 'Parkash S. Gill, et al. Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi''s Sarcoma.$http://jco.ascopubs.org/content/17/6/1876.full$', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (213, 27, 'Pegylated liposomal doxorubicin', '<b>Pegylated liposomal doxorubicin</b>', '<b>Pegylated liposomal doxorubicin</b> 20 mg/m<sup>2</sup> IV every 3 weeks as tolerated', 'Low', 'Udhrain A, et al.Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma.$Int J Nanomedicine. 2007 September; 2(3): 345–352.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (214, 28, 'Carbo-Tax', '<b>Carbo-Tax</b>', '<b>Carboplatin</b> AUC of 6 mg/ml/min IV over 30 minutes.<br><b>FOLLOWED  BY</b><br><b>Paclitaxel</b> 200mg/m<sup>2</sup>  IV over 3 hours, day 1<br><b> Filgrastim </b> 300 mcg/d SQ, days 5-12<br><b>OR</b> <br><b>PEG-Filgrastim</b>6 mg SQ on day 2.<br>Repeat every 21 days', 'Moderate', 'Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary Carcinoma: a Phase II Hellenic Cooperative Oncology Group Study. $J Clin Oncol. 2000; 18(17):3101-3107.$                                                      ', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>paclitaxel:<br>No dose reduction</li></ul>', 'Carboplatin : Paraplatin<br>paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (215, 28, 'Docetaxel/Carboplatin', '<b>Docetaxel/Carboplatin</b>', '<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 30 minutes, day1<br><b>Carboplatin</b> AUC of 5 mg/mL/min IV over 30 minutes, day 1<br>Repeat every 21 days', 'Moderate', 'Pentheroudakis G, Briasoulis E, Kalofonos HP, et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group Phase II study. $Acta Oncol. 2008;47(6): 1148-1155.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Carboplatin : Paraplatin<br>Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (216, 28, 'Gemcitabine/Carboplatin/paclitaxel', '<b>Gemcitabine/Carboplatin/paclitaxel</b>', '<b>Gemcitabine</b> 1,000mg/m<sup>2</sup>  1V, days 1,8<br><b>Carboplatin</b> AUC of 5 IV, day 1<br><b>Paclitaxel</b> 200 mg/m2 IV over 1 hour, day 1<br>Repeat cycle every 21 days', 'Moderate', 'Greco FA, Burris HA III, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie pearl cancer center research Network study. J Clin Oncol.2002;20(6):1651-1656.                ', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li><li>paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Gemcitabine:<br>No dose reduction </li><li>paclitaxel:<br>No dose reduction</li></ul>', 'Carboplatin : Paraplatin<br>Gemcitabine : Gemzar, various<br>paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (217, 28, 'Gemcitabine/Cisplatin', '<b>Gemcitabine/Cisplatin</b>', '<b>Gemcitabine</b> 1,250 mg/m<sup>2</sup> IV, days 1 and 8<br><b>Cisplatin</b> 100mg/m<sup>2</sup> IV, day 1<br>Repeat every 21 days', 'High', 'Culine S, Lortholary A, Voigt JJ, et al. Gemcitabine, carboplatin combintion with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study- trial for the French study Group on Carcinomas of Unknown Primary (GEFCAPI 01). $JClin Oncol. 2003;21(18):3479-3482.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (218, 28, 'Gemcitabine/Docetaxel', '<b>Gemcitabine/Docetaxel</b>', '<b>Gemcitabine</b> 1,000mg/m<sup>2</sup> IV over 30 minutes, days 1 and 8<br><b>Docetaxel</b> 75 mg/m<sup>2</sup>  IV over 1 hour, day 8<br>Repeat every 21 days', 'Low', 'Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. $Cancer. 2004; 100(6): 1257-1261.$', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Docetaxel : Taxotere<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (219, 28, 'Oxaliplatin Capecitabine', '<b>Oxaliplatin Capecitabine</b>', '<b>Oxaliplatin</b> 130 mg/m<sup>2</sup>  IV, day 1<br><b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br>Repeat cycle every 21 days upto 6 cycles                                                 ', 'Moderate', 'Hainsworth JD, Spigel DR, Burris HA, et al. Oxaliplatin and capecitabine inn the treatment of patients with recurrent or refractory carcinoma of unknown primary site: A phase 2 trial of the Sarah Cannon Oncology Research Consortium. $Cancer. 2010; 116(10):2448-2454.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Capecitabine : Xeloda<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (220, 28, 'Paclitaxel/Carboplatin/Etoposide', '<b>Paclitaxel/Carboplatin/Etoposide</b>', '<b>Paclitaxel</b>  200mg/m<sup>2</sup> IV over 1 hour, day 1,<br><b>FOLLOWED BY</b><br> <b>Carboplatin</b> dose targeted by Calvert equation to AUC of 6 mg/mL/min IV, day 1<br><b>Etoposide</b> 50 mg/d PO alternated with 100mg/d PO, days 1-10<br> Repeat every 21 days', 'Moderate', 'Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neutroendocrine carcinoma: a Minnie Pearl Cancer Network Study. $J Clin Oncol. 2006;24(22):3548-3554.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Carboplatin : Paraplatin<br>Etoposide : VP-16<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (221, 30, 'ABVD', '<b>ABVD</b>', '<b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Bleomycin</b> 10 units/m<sup>2</sup>/d IV, days 1, 15<br> <b>Vinblastine</b> 6 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Dacarbazine</b> 375 mg/m<sup>2</sup>/d IV, days 1, 15<br> Repeat every 28 days', 'High', 'Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin''s disease after failure of MOPP: ABVD and B-CAVe. $Ann Intern Med. 1984;  101(4):440-446$.<br> Longo DL, Glastein E, Duffey PL,et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgikin''s disease. $J Clin Oncol. 1997; 15(11): 3338-3346$.     ', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vinblastine:<br>No dose reduction </li></ul>', 'Bleomycin : Blenoxane<br>Dacarbazine : DTIC<br>Doxorubicin : Adriamycin, various<br>Vinblastine : Velban');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (222, 30, 'BEACOPP (Escalated)', '<b>BEACOPP (Escalated)</b>', '<b>Bleomycin</b> 10 mg/m<sup>2</sup> IV, day8<br> <b>Etoposide</b> 200 mg/m<sup>2</sup> IV, days 1-3<br> <b>Doxorubicin</b> 35 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, day 8<br> <b>Procarbazine</b> 100 mg/m<sup>2</sup> PO, days 1-7<br> <b>Prednisone</b> 40 mg/m<sup>2</sup> IV, days 1-14<br> Repeat on day 22 for 8 cycles', 'High', 'Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgikin''s disease. $N Engl J Med. 2003;348(24):2386-2395$.', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Procarbazine:<br>If CrCl < 30 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Bleomycin : Blenoxane<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Prednisone : various<br>Procarbazine : Matulane<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (223, 30, 'Stanford V', '<b>Stanford V</b>', '<b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Vinblastine</b> 6 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Mechlorethamine</b> 6 mg/m<sup>2</sup> IV,day1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup>/d IV, days 8, 22<br> <b>Bleomycin</b> 5 units per m<sup>2</sup> per day  IV, days 8,22<br> <b>Etoposide</b> 60mg/m<sup>2</sup>/d IV, days 15,16<br> <b>Prednisone</b> 40 mg/m<sup>2</sup> PO every other day', 'High', 'Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ.Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgikin''s disease: a Preliminary report. $J Clin Oncol. 1995; 13(5):1080-1088$.', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Mechlorethamine:<br>No dose reduction</li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vinblastine:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Bleomycin : Blenoxane<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Prednisone : various<br>Vinblastine : Velban<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (224, 30, 'Brentuximab vedotin', '<b>Brentuximab vedotin</b>', '<b>Brentuximab</b> 1.8 mg/kg IV over 30 minutes, day 1<br> Repeat every 21 days', 'Low', 'Adcetris [package insert]. $Bothell, WA: Seattle Genetics;2011$.', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (225, 31, 'BR', '<b>BR</b>', '<b>Rituximab</b> 375mg/m<sup>2</sup> IV, day 1<br> <b>Bendamustine</b> 90 mg/m<sup>2</sup> IV, days 1, 2<br> Repeat every 28 days for 6 cycles', 'Moderate', 'Rummel MK, Niederle N, Mascmeyere G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared too CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and matle cell lymphomas: Final results of a randomized phase III study of StiL (Study Group of Indolent Lymphomas, Germany). $Presented at :51st American Society of Hematology Annual Meeting; December 5-8, 2009; New Orleans, LA. Abstract 405.$', '<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>', 'Bendamustine : Treanda<br>Rituximab : Rituxan');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (226, 31, 'CHOP', '<b>CHOP</b>', '<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, day 1<br> <b>Prednisolone</b> 50 mg/m<sup>2</sup>/d PO, days 1-5<br> Repeat every 21 days', 'Moderate', 'Bezwoda W, Ristogi RB, Erazo Valla A, et al. Long-term results of a multicentre randomised, comparitive phase III trial of CHOP versus CNOP regimens in patients with intermediate-and high-grade non-Hodgikin''s lymphomas. $ Eur J Cancer. 1995;31A(6):903-911$.', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Prednisolone : Flo-pred, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (227, 31, 'R - CHOP', '<b>R - CHOP</b>', '<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, day 1 upto a maximum dose of 2mg<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO, days 1-5<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days ', 'Moderate', 'Coiffier B, Leapage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. $N Engl J Med. 2002;346(4):235-242.$<br> Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. $J Clin Oncol. 1999; 17(1):268-276$.', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Rituximab:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Prednisone : various<br>Rituximab : Rituxan<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (228, 31, 'CODOX-M/IVAC', '<b>CODOX-M/IVAC</b>', '<u>Cycles 1 AND 3 (CODOX-M)</u><br> <b>Cyclophosphamide</b> 800 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup>/d IV, days 2-5<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV up to a maximum dose of 2 mg, days 1,8 for cycle 1, days 1,8, 15 for cycle 2<br> <b>Methotrexate</b> 1,200 mg/m<sup>2</sup> IV over 1 hour, day 10,          <b>THEN</b> 240 mg/m<sup>2</sup>/h CIVI for the next 23 hours<br> <b>Leucovorin calcium </b>192 mg/m<sup>2</sup> IV, starting at hour 36  <b>THEN</b> 12 mg/m<sup>2</sup> every 6 hours until Methotrexate level is <5*10<sup>-8</sup> M<br> <b>Filgrastim</b>5 mcg/kg/d SQ until ANC >1,000/mm<sup>3</sup><br> <b>Methotrexate</b> 12mg IT, day 15<br> <b>Leucovorin calcium</b> 15 mg PO 24 hours after Methotrexate, day 16<br>                                                              <u>CNS PROPHYLAXIS</u><br> <b>Cytarabine</b> 70 mg IT, days 1,3,5<br> <b>Methotrexate</b> 12 mg IT, day 12 Cycles 2 AND 4 (IVAC)<br> <b>Ifosfamide</b> 1,500mg/m<sup>2</sup> IV over 1 hour, days 1-5<br> <b>Mesna</b> 360 mg/m<sup>2</sup> IV over 1 hour <b>THEN</b> 360 mg/m<sup>2</sup> IV every 3 hours for a maximum of 7 doses  per 24 hour period, days 1-5<br> <b>Cytarabine</b>  2,000 mg/m<sup>2</sup> IV over 3 hours every 12 hours, days 1 and 2<br> <b>Methotrexate</b> 12 mg IT, day 5<br> <b>Leucovorin calcium</b> 15 mg PO 24 hours after Methotrexate, day 6<br> <b>Filgrastim</b> 5 mcg/kg/d SQ until ANC > 1,000/mm<sup>3</sup>                                                  ', 'Moderate', 'Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt''s lymphoma: results of United Kingdom Lymphoma Group LY06 Study. $Ann Oncol. 2002, 13(8): 1254-1274.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Leucovorin:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (229, 31, 'R - CVP', '<b>R - CVP</b>', '<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> up to a maximum dose of 2 mg IV, day 1<br> <b>Prednisone</b> 40 mg PO, days 1-5<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for a maximum off 8 cycles ', 'Moderate', 'Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. $Blood, 105(4): 1417-1423.$<br> Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously utreated advanced follicular lymphoma. $J Clin Oncol. 2008;26(28):4578-4589.$', '<b>Hepatic Impairment</b><ul><li>Rituximab:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>', 'Prednisone : various<br>Rituximab : Rituxan<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (230, 31, 'DHAP', '<b>DHAP</b>', '<b>Dexamethasone</b> 40 mg/d PO or IV over 24 hours, days 1-4<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> CIVI, day 1<br> <b>Cytarabine</b> 2,000 mg/m<sup>2</sup> IV over 3 hours every 12 hours for 2 doses, day 2<br> Repeat every 21-28 days', 'High', 'Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). $Blood. 1988;71(1):117-122.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP<br>Cytarabine : Ara-C<br>Dexamethasone : various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (231, 31, 'ESHAP', '<b>ESHAP</b>', '<b>Etoposide</b> 40 mg/m<sup>2</sup>/d IV, days 1-4<br> <b>Methylprednisolone</b> 500 mg/d IV, days 1-5<br> <b>Cytarabine</b> 2,000 mg/m<sup>2</sup> IV over 2-3 hours,             day 5<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>OR</b><br> <b>Etoposide</b> 60 mg/m<sup>2</sup>/d IV, days 1-4<br> <b>Methylprednisolone</b> 500 mg/d IV, days 1-4<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Cytarabine</b> 2,000 mg/m<sup>2</sup> IV over 2 hours, day 5, immediately following completion of cisplatin<br> Repeat every 21-28 days        ', 'High', 'Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP- an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. $J Clin Oncol. 1994; 12(6): 1169-1176.$<br> Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. $J Clin Oncol. 1995; 13(7): 1734-1741.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cisplatin : CDDP<br>Cytarabine : Ara-C<br>Etoposide : VP-16<br>Methylprednisolone : Depo-Medrol, Solu-Medrol, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (232, 31, 'Hyper-CVAD/MTX-Ara-C', '<b>Hyper-CVAD/MTX-Ara-C</b>', '<u>COURSE 1</u><br> <b>Cyclophosphamide</b> 300 mg/m<sup>2</sup> over 3 hours every 12 hours  for 6 doses , days 1-3<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> over 48 hours after cyclophosphamide, days 4-5<br> <b>Vincristine</b> 2 mg administered 12 hours  after last cyclophosphamide dose, repeated on day 11<br> <b>Dexamethasone</b> 40 mg/d IV or PO,days 1-4,11-14<br> <b>Filgrastim</b> 5 mcg/kg IV or SQ beginning 24 hours after doxorubicin is complete.<br> <u>COURSE 2 <br>(BEGIN AFTER CLINICAL AND HEMATOLOGIC RECOVERY FROM COURSE 1)</u><br> <b>Methotrexate</b> 200 mg/m<sup>2</sup> IV bolus, day 1<br> <b>FOLLOWED BY</b><br> <b>Methotrexate</b> 800mg/m<sup>2</sup>over 24 hours day1 <b>Followed by</b><br><b>Cytarabine</b>3000 mg/m<sup>2</sup> IV every 12 hours for 4 doses, days 2-3 (dose reduced to 1,000 mg/m<sup>2</sup> in patients >60 years or with serum creatinine >1.5 mg/dL)<br> <b>Leucovorin calcium</b> 50 mg PO 24 hours after end of Methotrexate infusion<br> <b>FOLLOWED 6 HOURS LATER BY</b><br> <b>Leucovorin calcium</b> 15 mg PO every 6 hours for 8 doses (dose adjusted for Methotrexate concentration at 24 and 48 hours after completion of Methotrexate infusion)<br> <b>Filgrastim</b> 5mcg/kg IV or SQ begining 24 hours after cytarabine.<br> Repeat courses every 21 days.            ', 'High', 'Khouri IF, Romaguera J, Kantrajian H,et al. Hyper-CVAD and high -dose methotrexate/ cytarabine followed by stem-cell tans-plantation: an active regimen for aggressive mantle-cell lymphoma. $J Clin Oncol. 1998; 16(12): 3803-3809$.', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Dexamethasone : various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (233, 31, 'R-EPOCH', '<b>R-EPOCH</b>', '<b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> <b>Etoposide</b> 65 mg/m<sup>2</sup>/d CIVI, days 2-4<br> <b>Doxorubicin</b> 15 mg/m<sup>2</sup>/d CIVI, days 2-4<br> <b>Vincristine</b> 0.5 mg/m<sup>2</sup>/d CIVI, days 2-4<br> <b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 5<br> <b>Prednisone</b> 60 mg/m<sup>2</sup>/d PO, days 1-14<br> Repeat every 21 days for 4 -6 cycles', 'Moderate', 'Jermann M, jost M, Taverna C, et al. Rituximab EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. $Ann Oncol. 2004; 15(3):511-516$.', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Rituximab:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Prednisone : various<br>Rituximab : Rituxan<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (234, 31, 'RICE', '<b>RICE</b>', '<b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1 every 14 days<br> <b>Ifosfamide</b> 5,000 mg/m<sup>2</sup> with mesna 5,000 mg/m<sup>2</sup> CIVI over 24 hours, day 4<br> <b>Carboplatin</b> AUC of 5 (maximum 800 mg) IV, day 4<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d CIVI, days 3-5<br> Repeat every 14 days', 'Moderate', 'Kewalramani T, Zelenetz AD, Nimer SD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. $Blood. 2004; 103(10):3684-3688.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Carboplatin : Paraplatin<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Rituximab : Rituxan');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (235, 31, 'Bendamustine', '<b>Bendamustine</b>', '<b>Bendamustine</b> 120 mg/m<sup>2</sup> IV days 1 and 2<br> Repeat every 21 days', 'Moderate', 'Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgikin lymphoma: results from a multicenter study. $Cancer. 2010,116(1):106-114 $.', '<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>', 'Bendamustine : Treanda');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (236, 31, 'Bexarotene', '<b>Bexarotene</b>', '<b>Bexarotene</b> 300 mg/m<sup>2</sup>/d PO with a meal', 'Low', 'Targretin [package insert]. $Woodcliff Lake, NJ: Eisai Inc.; 2011.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Bexarotene : Targretin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (237, 31, 'Bortezomib', '<b>Bortezomib</b>', '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup>/d IV bolus, days 1,4, 8, 11<br> Repeat every 21 days for up to 17 cycles.', 'Low', 'Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time to event analyses of the multicenter Phase 2. PINNACLE study. $Ann Oncol. 2009;20(3):520-525.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>', 'Bortezomib : Velcade');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (238, 31, 'Brentuximab vedotin', '<b>Brentuximab vedotin</b>', '<b>Brentuximab</b> 1.8 mg/kg IV over 30 minutes,  day 1<br> Repeat every 21 days for upto 16 cycles', 'Low', 'Advani RH, Shustov AR, Brice P, et al.                                     Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A Phase 2 study update. $Blood (ASH Annula Meeting Abstracts). 2011; 118:443.$<br> Adcetris [package insert]. $Bothell, WA: Seattle Genetics; 2011.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (239, 31, 'Denileukin diftitox', '<b>Denileukin diftitox</b>', '<b>Denileukin diftitox</b> 9 <b>OR</b> 18 mcg/kg/d/IV over 15-60 minutes, days 1-5<br> Repeat every 21 days', 'Low', 'Olsen E, Duvic M Frankel A, et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. $J Clin Oncol. 2001; 19(2):376-388.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (240, 31, 'Fludarabine', '<b>Fludarabine</b>', '<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV over 10 minutes, days 1-5<br> Repeat every 28 days for up to 8 courses', 'Low', 'Klasa RJ,Meyer RM, Shustic C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisione in patients with recurrent low-grade Non-Hodgikin''s lymphoma previously treated with an alkylating agent or alkylatic containing regimen. $J Clin Oncol. 2002;20(24):4649-4654.$', '<b>Hepatic Impairment</b><ul><li>Fludarabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>', 'Fludarabine : Fludara');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (241, 31, 'Ibritumomab tiuxetan', '<b>Ibritumomab tiuxetan</b>', '<b>Ibritumomab tiuxetan</b> is given in 2 steps:<br> Step 1: <b>Rituximab</b> 250 mg/m<sup>2</sup> infusion <b>FOLLOWED WITHIN 4 HOURS BY</b> 5.0 mCi (1.6 mg total antibody dose) of <b>In- 111 ibrituximomab tiuxetan</b> administered as a 10-minute IV push<br> Step 2: (7-9 days after step 1): <b>Rituximab</b> 250 mg/m<sup>2</sup> infusion <b>FOLLOWED WITHIN 4 HOURS BY</b><br> <b>Y-90 ibritumomab tiuxetan</b> 0.4 mCi/kg (maximum, 32 mCi) admistered as a 10-minute IV push               ', 'Low', 'Zevalin [package insert]. $San Deigo, CA: IDEC Pharmaceutical Coorporation; 2010.$<br> Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevali radiommunotherapy for low-grade, follicular, or transofrmed B-cell non-Hodgikin''s lymphoma. $Crit Rev Oncol Hematol. 2001;39(1-2):181-194.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (242, 31, 'Pralatrexate', '<b>Pralatrexate</b>', '<b>Pralatrexate</b> 30 mg/m<sup>2</sup> IV, weekly for 6 weeks<br> Repeat every 7 weeks', 'Low', 'Folotyn [package insert]. $Westminster, CO: Allos Therapeutics Inc.; 2012.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Pralatrexate : Folotyn');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (243, 31, 'Rituximab Maintenance', '<b>Rituximab Maintenance</b>', '<b>Rituximab</b> 375 mg/m<sup>2</sup>/d IV, day 1<br> Repeat every 90 days until relapse or maximum of 2 years', 'Low', 'van Oers NH, Van Glabbeke M, Glurgea L, et al. Rituximab maintenance treatment of relapsed/residual follicular Non Hodgikin''s lymphoma: Long-term outcome or EROTC 20891 phase III randomized intergroup study. $ JClin Oncol. 2010;28(17):2853-2858.$', '<b>Hepatic Impairment</b><ul><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Rituximab : Rituxan');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (244, 31, 'Romidepsin', '<b>Romidepsin</b>', '<b>Romidepsin</b> 14mg\m<sup>2</sup> IV on days 1,8,and 15.<br> Repeat every 28 days           ', 'Low', 'Istodax [package insert]. $Summit , NJ: Celgene Corporation; 2011.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (245, 31, 'Temsirolimus', '<b>Temsirolimus</b>', '<b>Temsirolimus</b> 175 mg IV per week for 3 weeks<br> <b>FOLLOWED BY</b><br> <b>Temsirolimus</b> 75 mg IV weekly  ', 'Low', 'Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evalute temsirolimus compared with investigator''s choice therapy for the treatment or relapsed or refractory mantle cell lymphoma. $J Clin Oncol.2009; 27(23):3822-3829.$', '<b>Hepatic Impairment</b><ul><li>Temsirolimus:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Temsirolimus:<br>No dose reduction </li></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (246, 31, 'Tositumomab', '<b>Tositumomab</b>', 'Dosimetric step: <b>Tositumomab</b> 450 mg IV over 60 minuutes<br> <b>I-131 tositumomab</b> (35 mg tositumomab containing 5.0 mCi I-131) IV over 20 minutes<br> Therapeutic step: <b>Tositumomab</b> 450mg infused over 60minutes<br> <b>I-131 tositumomab</b> (dose individualized for each patient based on results of dosemetric step)', 'Low', 'Bexxar [package insert]. $Seattle, WA, and Philadelphia, PA: Corixa Corp and GlaxoSmithKline;2011.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (247, 31, 'Vorinostat', '<b>Vorinostat</b>', '<b>Vorinstat</b> 400mg PO daily with food', 'Low', 'Zolinza [package insert]. $Whitehouse station, NJ: Merck & Co., Inc.; 2011.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Vorinostat : Zolinza');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (248, 29, 'CDE', '<b>CDE</b>', '<b>Cyclophosphamide</b> 200mg/m<sup>2</sup>/d CIVI for 4 days<br><b>Doxorubicin</b> 12.5 mg/m<sup>2</sup>/d CIVI for 4 days<br> <b>Etoposide</b> 60 mg/m<sup>2</sup>/d CIVI for 4 days<br> Repeat every 28 days for a maximum of 8 cycles', 'Moderate', 'Sparano JA,Lee S, Chen MG, et al. Phase II trial of   infusional, cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkins lymphoma: an Eastern Cooperative Oncology Group Trial (E1491). $J Clin Oncol. 2004; 22(8): 1491-1500.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (249, 29, 'CHOP', '<b>CHOP</b>', '<b>Cyclophosphamide</b> 750mg/m<sup>2</sup> IV, day 1<br> Doxorubicin 50 mg/m<sup>2</sup> IV, day 1<br><b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, day 1<br> <b>Prednisone</b> 100mg/m<sup>2</sup> PO, days 1-5<br> Repeat every 21 days.', 'Moderate', 'Weiss R, Mitrou P, Arasteh K, et.al. Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, Vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial. $Cancer. 2006; 106(7): 1560-1568.$ ', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (250, 29, 'CODOX-M/IVAC', '<b>CODOX-M/IVAC</b>', '<u>CYCLES 1 and 3 (CODOX-M)</u><br>  <b>Cyclophosphamide</b> 800 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 200 mg/m<sup>2</sup>/d IV, days 2-5<br>  <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 1, 8 for cycle 1,days 1, 8, 15 for cycle 2<br> <b>Methotrexate</b> 1,200 mg/m<sup>2</sup> IV over 1 h, day 10, <b>THEN</b> 240 mg/m2/h CIVI for the next 23 hours<br> <b>Leucovorin calcium</b> 50 mg IV q6h, begining 36 hours from the start of Methotrexate until Methotrexate level <0.05 mcM<br> <b>Filgrastim</b> beginning 24 h from the start of leucovorin until ANC>1,000<br> <u>CNS PROPHYLAXIS</u><br> <b>Cytarabine</b> 70 mg IT, days 1, 3<br> <b>Methotrexate<b> 12 mg IT, day 15<br> <u>CYCLES 2 AND 4 (IVAC)</u><br> <b>Ifosofamide</b> 1,500 mg/m<sup>2</sup> IV, days 1-5<br> <b>Mesna</b> 1,500 mg/m<sup>2</sup> IV, days 1-5<br> <b>Etoposide</b> 60 mg/m<sup>2</sup> IV, days 1-5<br> <b>Cytarabine</b> 2,000 mg/m<sup>2</sup> IV q 12h, days 1 and 2<br> <b>Filgrastim</b> beginning 24 h after completion of chemotherapy until ANC >1,000<br> <u>CNS PROPHYLAXIS</u><br> <b>Methotrexate</b> 12 mg IT, day 15<br> Additional IT Treatment for CNS disease- positive patients:<br> Cycle 1: cytarabine 70 mg IT, days 1,3,5, and Methotrexate 12 mg IT, days 15,17<br> Cycle 3: cytarabine 70 mg IT, days 1,3, and Methotrexate 12 mg IT, day 15                                                                                                                                                               ', 'Moderate', 'Wang ES, Strauss DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphosphamide, doxorucibicin, high-dose methotrecate/ ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC)for human immunodeficiency virus-associated Burkitt lymphoma. $Cancer. 2003;98(6): 1196-1205.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Leucovorin:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (251, 29, 'EPOCH Dose-adjusted ', '<b>EPOCH Dose-adjusted </b>', '<b>Etoposide</b> 50 mg/m<sup>2</sup>/d CIVI, days 1-4 (96 hours)<br> <b>Doxorubicin</b> 10 mg/m<sup>2</sup>/d CIVI, days 1-4 (96 hours)<br> <b>Vincristine</b> 0.4 mg/m<sup>2</sup>/d /CIVI, days 1-4 (96 hours)<br> <b>Cyclophosphamide</b> <br>Cycle1: <br>375 mg/m<sup>2</sup> IV, day 5, if CD4+ cells >= 100/mm<sup>3</sup>; 187 mg/m<sup>2</sup> IV, day 5, if CD4+ cells<100/mm<sup>3</sup><br> After cycle 1: increase dose by 187 mg if nadir ANC > 500/mvL or platelets <25,000/mcL<br> <b>Prednisone</b> 60 mg/m<sup>2</sup>/d PO, days 1-5<br> <b>Filgrastim</b> 5 mcg/kg/d SQ, day 6, and until ANC >5,000/mcl<br> Repeat every 21 days', 'Moderate', 'Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. $BLOOD.2003;101(12):4653-4659.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Etoposide : VP-16<br>Prednisone : various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (252, 32, 'CALGB 8811', '<b>CALGB 8811</b>', '<u>INDUCTION (COURSE 1:4 WEEKS)</u><br> <b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day1 (800 mg/m<sup>2</sup> for patients >=60 years)<br> <b>Daunorubicin</b> 45 mg/m<sup>2</sup> IV, days 1-3 (30 mg/m<sup>2</sup> for patients>=60 years)<br> <b>Vincristine</b> 2 mg IV, days 1, 8, 15, 22<br> <b>Prednisone</b> 60 mg/m<sup>2</sup>/d PO, days 1-21 (days 1-7 for patients >=60 years)<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> SQ, days 5, 8, 11, 15, 18, 22<br> <u>EARLY INTENSIFICATION (COURSE 2:4 WEEKS, REPEAT ONCE)</u><br> <b>Methotrexate</b> 15 mg IT, day 1<br> <b>Cyclophosphamide</b> 1,000 mg/m<sup>2</sup> IV, day 1<br> <b>Mercaptopurine</b> 60 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Cytarabine</b> 75 mg/m<sup>2</sup>/d SQ, days 1-4, 8-11<br> <b>Vincristine</b> 2 mg IV, days 15, 22<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> SQ, days 15, 18, 22, 25<br> <u>CNS PROPHYLAXIS AND INTERIM MAINTENANCE (COURSE 3:12 WEEKS)</u><br> <b>Cranial RT</b> 2,400 cGy, days 1-12<br> <b>Methotrexate</b> 15 mg IT, days 1, 8, 15, 22, 29<br> <b>Mercaptopurine</b> 60 mg/m<sup>2</sup>/d PO, days 1-70<br> <b>Methotrexate</b> 20 mg/m<sup>2</sup> PO, days 36, 43, 50, 57, 64<br> <u>LATE INTENSIFICATION (COURSE 4:8 WEEKS)</u><br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV, days 1, 8, 15<br> <b>Vincristine</b> 2 mg IV, days 1, 8, 15<br> <b>Dexamethasone</b> 10 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Cyclophosphamide</b> 1,000 mg/m<sup>2</sup> IV, day 29<br> <b>Thioguanine</b> 60 mg/m<sup>2</sup>/d PO, days 29-42<br> <b>Cytarabine</b> 75 mg/m<sup>2</sup>/d SQ, days 29-32, 36-39<br> <u>MAINTENANCE (COURSE 5:4 WEEKS, FOR 2 YEARS FROM DIAGNOSIS)</u><br> <b>Vincristine</b> 2 mg IV, day 1 of every 4 weeks<br> <b>Prednisone</b> 60 mg/m<sup>2</sup>/d PO, days 1-5 of every 4 weeks<br> <b>Methotrexate</b> 20 mg/m<sup>2</sup> PO, days 1, 8, 15, 22<br> <b>Mercaptopurine</b> 60 mg/m<sup>2</sup>/d PO, days 1-28', 'Moderate', 'Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. $Blood. 1995;85(8):2025-2037.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Thioguanine:<br>If bilirubin > 5 mg/dL, do not use</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Dexamethasone : various<br>Doxorubicin : Adriamycin, various<br>Prednisone : various<br>Thioguanine : 6-TG<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (253, 32, 'Hyper-CVAD', '<b>Hyper-CVAD</b>', '<u>ODD CYCLES (1, 3, 5, 7)</u><br>                            <b>Cyclophosphamide</b> 300 mg/m<sup>2</sup> IV over 3 hours every 12 hours, days 1-3<br> <b>Mesna</b> 600 mg/m<sup>2</sup>/d CIVI, days 1-3, ending 6 hours after cyclophosphamide completion<br> <b>Vincristine</b> 2 mg IV, days 4, 11<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV, day 4<br> <b>Dexamethasone</b> 40 mg/d, days 1-4, 11-14<br> <b>Filgrastim</b> 5 mcg/kg bid SQ beginning 24 hours after doxorubicin completion <br> <b>OR</b><br><b>PEG-Filgrastim</b>6 mg SQ once 24 hours after doxorubicin completion<br> <u>EVEN CYCLES (2, 4, 6, 8)</u><br> <b>Methotrexate</b> 200 mg/m<sup>2</sup> IV over 2 hours, day 1,<br> <b>FOLLOWED BY</b>  800 mg/m<sup>2</sup> IV over 24 hours<br> <b>Leucovorin calcium</b> 15 mg IV every 6 hours for 8 doses, beginning 24 hours after Methotrexate completion; adjust per Methotrexate level<br> <b>Cytarabine</b> 3 g/m<sup>2</sup> IV over 2 hours every 12 hours for 4 doses, days 2, 3<br> <b>Methylprednisolone</b> 50 mg IV bid, days 1-3<br> <b>Filgrastim</b> 6 mg/kg SQ beginning 24 hours after cytarabine completion<br> <b>OR</b><br><b>PEG-Filgrastim</b>6 mg SQ once 24 hours after doxorubicin completion<br> <u>CNS PROPHYLAXIS</u><br> <b>Methotrexate</b> 12 mg IT, day 2 of each cycle<br> <b>Cytarabine</b> 100 mg IT, day 8 of each cycle<br>4-16 cycles based on risk profile', 'High', 'Kantarjian HM, O''Brien S, Smith TL, et al. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. $J Clin Oncol. 2000;18(3):547-561.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Leucovorin:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Dexamethasone : various<br>Doxorubicin : Adriamycin, various<br>Mesna : Mesnex, various<br>Methylprednisolone : Depo-Medrol, Solu-Medrol, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (254, 32, 'Nelarabine', '<b>Nelarabine</b>', '<b>Nelarabine</b> 1,500 mg/m<sup>2</sup>/d IV, days 1, 3 and 5', 'Low', 'Arranon [package insert]. $Research Triangle Park, NC: GlaxoSmithKline;2011.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (255, 33, 'ATRA/Arsenic', '<b>ATRA/Arsenic</b>', '<b>All-trans-retinoic acid (ATRA)</b> 45 mg/m<sup>2</sup> PO in 2 divided doses daily<br> <b>Arsenic trioxide</b> 0.15 mg/kg/d IV over 1 hour, daily beginning day 10 and continued until <5% blasts and absence of promyelocytes', 'Moderate', 'Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans-retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. $Blood. 2006;107(9):3469-3473.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (256, 33, 'ATRA/Idarubicin', '<b>ATRA/Idarubicin</b>', '<b>All-trans-retinoic acid</b> (ATRA) 45 mg/m<sup>2</sup> PO, daily<br> <b>Idarubicin</b> 12 mg/m<sup>2</sup> IV, on days 2, 4, 6, 8', 'Moderate', 'Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcomeon the LPA99 multicenter study by the PETHEMA Group. $Blood. 2008;112(8):3130-3134.$', '<b>Hepatic Impairment</b><ul><li>Idarubicin:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 25%<br> If bilirubin 3.1-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 50% <br> If bilirubin > 5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Idarubicin:<br>If CrCl < 10 mL/min, reduce dose by 25% </li></ul>', 'Idarubicin : Idamycin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (257, 33, 'Idarubicin/Cytarabine/Etoposide', '<b>Idarubicin/Cytarabine/Etoposide</b>', '<b>Cytarabine</b> 25 mg/m<sup>2</sup> IV <b>FOLLOWED BY</b> 100 mg/m<sup>2</sup> CIVI, days 1-10<br> <b>Etoposide</b> 100 mg/m<sup>2</sup> IV, days 1-5<br> <b>Daunorubicin</b> 50 mg/m<sup>2</sup> IV, days 1, 3, 5<br> <b>OR</b><br> <b>Mitoxantrone</b> 12 mg/m<sup>2</sup> IV, days 1, 3, 5<br> <b>OR</b><br> <b>Idarubicin</b> 10 mg/m<sup>2</sup> IV, days 1, 3, 5', 'Moderate', 'Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA group study AML-10. $J Clin Oncol. 2009;32(10):5397-5403.$', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Idarubicin:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 25%<br> If bilirubin 3.1-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 50% <br> If bilirubin > 5 mg/dL, do not use </li><li>Mitoxantrone:<br>If bilirubin > 3 mg/dL, reduce dose by 25%</li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Idarubicin:<br>If CrCl < 10 mL/min, reduce dose by 25% </li><li>Mitoxantrone:<br>No dose reduction</li></ul>', 'Cytarabine : Ara-C<br>Etoposide : VP-16<br>Idarubicin : Idamycin<br>Mitoxantrone : Novantrone');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (258, 33, '7 + 3', '<b>7 + 3</b>', '<b>Cytarabine</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-7<br> <b>WITH</b><br> <b>Daunorubicin</b> 45 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>OR</b><br> <b>Idarubicin</b> 13 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>OR</b><br> <b>Mitoxantrone</b> 12 mg/m<sup>2</sup>/d IV, days 1-3', 'Moderate', 'Presler H, Davis RB, Kirshener J, et al. Comparison of three remission induction regimens and two post-induction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. $Blood. 1987;69(5):1441-1449.$<br> Wiernik PH, BAnks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated patients with acute myeloid leukemia. $Blood. 1992;79(2):313-319.$<br> Wahlin A, Hornsten P, Hedenus M, Malm C. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. $Cancer Chemother Pharmacol. 1991;28(6):480-483.$', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Idarubicin:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 25%<br> If bilirubin 3.1-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 50% <br> If bilirubin > 5 mg/dL, do not use </li><li>Mitoxantrone:<br>If bilirubin > 3 mg/dL, reduce dose by 25%</li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Idarubicin:<br>If CrCl < 10 mL/min, reduce dose by 25% </li><li>Mitoxantrone:<br>No dose reduction</li></ul>', 'Cytarabine : Ara-C<br>Idarubicin : Idamycin<br>Mitoxantrone : Novantrone');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (259, 33, '7 + 3 with hi-dose daunorubicin <br>(<60 years)', '<b>7 + 3 with hi-dose daunorubicin <br>(<60 years)</b>', '<b>Cytarabine</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-7<br> <b>WITH</b><br> <b>Daunorubicin</b> 90 mg/m<sup>2</sup>/d IV, days 1-3', 'Moderate', 'Fernandez HF, Sun Z, Pao X, et al. Anthracycline dose intensification in acute myeloid leukemia. $N Engl J Med. 2009;361(13):1249-1259.$', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li></ul>', 'Cytarabine : Ara-C');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (260, 33, 'Arsenic', '<b>Arsenic</b>', '<b>Arsenic trioxide</b> 0.15 mg/kg IV, daily until remission, not to exceed 60 doses', 'Moderate', 'Trisenox [package insert]. $Frazer, PA: Cephalon; 2010.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (261, 33, 'ATRA', '<b>ATRA</b>', '<b>All-trans-retinoic acid</b> (ATRA, tretinoin) 45 mg/m<sup>2</sup>/d PO', 'N/A', 'Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. $Blood. 1995;85(10):2643-2653.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (262, 33, 'Arsenic', '<b>Arsenic</b>', '<b>Arsenic trioxide</b> 0.15 mg/kg/d IV for 25 doses up to 5 weeks', 'Moderate', 'Trisenox [package insert]. $Frazer, PA: Cephalon; 2010.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (263, 33, 'HiDAC', '<b>HiDAC</b>', 'For patients <60 years of age:<br> <b>Cytarabine</b> 3,000 mg/m<sup>2</sup> CIVI over 3 hours, every 12 hours, days 1, 3, 5<br> Repeat every 28 days', 'Moderate', 'Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid deukemia. Cancer and Leukemia Group B. $N Engl J Med. 1994;331(14):896-903.$', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>', 'Cytarabine : Ara-C');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (264, 33, 'Cytarabine', '<b>Cytarabine</b>', 'For patients >=60 years of age:<br> <b>Cytarabine</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-5<br> Repeat every 28 days for 4 courses', 'Low', 'Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. $Blood. 2001;98(3):548-553.$', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>', 'Cytarabine : Ara-C');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (265, 34, 'BR', '<b>BR</b>', '<b>Bendamustine</b> 90 mg/m<sup>2</sup> IV on days 1 and 2<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV for the first cycle and 500 mg/m<sup>2</sup> for subsequent cycles<br> Repeat every 28 days for up to 6 cycles', 'Moderate', 'Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG). $J Clin Oncol. 2011;29(26)3559-3566.$', '<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>', 'Bendamustine : Treanda<br>Rituximab : Rituxan');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (266, 34, 'FC', '<b>FC</b>', '<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cyclophosphamide</b> 250 mg/m<sup>2</sup>/d IV, days 1-3<br> Repeat every 28 days for 6 cycles', 'Moderate', 'Catovsky D, Richards S, Oscier D, et al. Assesmentof fludarabine plus cyclo-phosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 trial): a randomized ocntrolled trial. $Lancet. 2007; 370(9583):230-239.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fludarabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>', 'Cyclophosphamide : Cytoxan<br>Fludarabine : Fludara');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (267, 34, 'FCR', '<b>FCR</b>', '<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cyclophosphamide</b> 250 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1 cycle 1<br> <b>FOLLOWED BY</b><br> <b>Rituximab</b> 500 mg/m<sup>2</sup> IV, day 1 cycles 2-6<br> Repeat every 28 days for 6 cycles', 'Moderate', 'Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. $J Clin Oncol. 2010;28(10):1756-1765.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fludarabine:<br>No dose reduction</li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>', 'Cyclophosphamide : Cytoxan<br>Fludarabine : Fludara<br>Rituximab : Rituxan');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (268, 34, 'FR', '<b>FR</b>', '<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV over 20-30 minutes, days 1-5<br> Repeat every 28 days for a total of 6 cycles<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV<br> Repeat every 7 days for 4 doses', 'Low', 'Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lympocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). $Blood. 2003;101(1):6-14$', '<b>Hepatic Impairment</b><ul><li>Fludarabine:<br>No dose reduction</li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>', 'Fludarabine : Fludara<br>Rituximab : Rituxan');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (269, 34, 'PCR', '<b>PCR</b>', '<b>Pentostatin</b> 2 mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV, day 1<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for 6 cycles', 'Moderate', 'Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. $Blood. 2007;109(2):405-411.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Pentostatin:<br>No dose reduction</li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cyclophosphamide : Cytoxan<br>Pentostatin : Nipent<br>Rituximab : Rituxan');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (270, 34, 'Alemtuzumab', '<b>Alemtuzumab</b>', '<b>Alemtuzumab</b> 30 mg per day IV, 3 times per week, upto a maximum of 23 weeks', 'Low', 'Campath [package insert]. $Wayne, NJ: Bayer HealthCare Pharmaceuticals: 2009.$', '<b>Hepatic Impairment</b><ul><li>Alemtuzumab:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Alemtuzumab:<br>Unknown</li></ul>', 'Alemtuzumab : Campath');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (271, 34, 'Bendamustine', '<b>Bendamustine</b>', '<b>Bendamustine</b> 100 mg/m<sup>2</sup> IV over 30 min, days 1, 2<br> Repeat every 28 days', 'Moderate', 'Knauf WU, Lissichov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously treated patients with chronic lyphocytic leukemia. $J Clin Oncol. 2009;27(26):4378-4348.$', '<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>', 'Bendamustine : Treanda');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (272, 34, 'Chlorambucil', '<b>Chlorambucil</b>', '<b>Chlorambucil</b> 0.4 mg/kg PO <br> Repeat therapy every 14 days, increase upto  0.8 mg/kg  if  tolerated', 'Low', 'Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. $Blood. 2009;114:3382-3391.$', '<b>Hepatic Impairment</b><ul><li>Chlorambucil:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Chlorambucil:<br>No dose reduction</li></ul>', 'Chlorambucil : Leukeran');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (273, 34, 'Fludarabine', '<b>Fludarabine</b>', '<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV over 30 minutes , days 1-5<br> Repeat every 28 days', 'Low', 'Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. $Blood. 2009;114:3382-3391.$', '<b>Hepatic Impairment</b><ul><li>Fludarabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>', 'Fludarabine : Fludara');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (274, 34, 'Ofatumumab', '<b>Ofatumumab</b>', '<b>Ofatumumab</b> 300 mg IV, initial dose,<br> <b>FOLLOWED 1 week later BY</b><br> <b>Ofatumumab</b> 2,000 mg IV, weekly dose for 7 weeks<br> Repeat every 28 days for 4 doses', 'Low', 'Arzerra [package insert]. $Research Triangle Prk, NC: GlaxoSmithKline; 2011.$<br> Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single agent CD20 immunotherapy in fluda-rabine-refractory chronic lymphocytic leukemia. $J Clin Oncol. 2010;28:1749-1755.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Ofatumumab : Arzerra');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (275, 35, 'Dasatinib', '<b>Dasatinib</b>', '<b>Dasatinib</b> 100 mg PO, daily (chronic phase)<br> <b>OR</b><br> <b>Dasatinib</b> 140 mg PO, daily (accelerated or blast phase)', 'Low', 'Kantarijan H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid deukemia. $N Engl J Med. 2010;362(24):2260-2270.$', '<b>Hepatic Impairment</b><ul><li>Dasatinib:<br>Unknown. Metabolism mainly hepatic </li></ul><b>Renal Impairment</b><ul><li>Dasatinib:<br>Unknown. < 4% excreted by kidney </li></ul>', 'Dasatinib : Sprycel');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (276, 35, 'Imatinib', '<b>Imatinib</b>', '<b>Imatinib mesylate</b> 400 mg PO daily <b>OR</b> 600 mg PO daily(accelarated phase / blast crisis) ', 'Low', 'Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.$N Engl J Med. 2001 Apr 5;344(14):1031-7.$', '<b>Hepatic Impairment</b><ul><li>Imatinib:<br>If bilirubin < 3 upper normal limit, no dose reduction <br>                            If bilirubin > 3 upper normal limit, use with caution </li></ul><b>Renal Impairment</b><ul><li>Imatinib:<br>No dose reduction </li></ul>', 'Imatinib : Gleevec');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (277, 35, 'Nilotinib', '<b>Nilotinib</b>', '<b>Nilotinib</b> 300 mg PO bid  (newly diagnosed)<br> <b>OR</b><br> <b>Nilotinib</b> 400 mg PO bid (resistant or intolerant chronic or accelerated phase)', 'Low', 'Kantarjian HM, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.$Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17$', '<b>Hepatic Impairment</b><ul><li>Nilotinib:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Nilotinib:<br>Not tested. Not renally excreted </li></ul>', 'Nilotinib : Tasigna');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (278, 36, 'Cladribine', '<b>Cladribine</b>', '<b>Cladribine:</b>0.09 mg/kg/day IV continuous infusion on days 1 to 7 <br>Administer one cycle', 'Low', 'Saven A, et al. $Blood 1992;79:1111-1120.$', '<b>Hepatic Impairment</b><ul><li>Cladribine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Cladribine : 2-CdA');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (279, 36, 'Pentostatin', '<b>Pentostatin</b>', '<b>Pentostatin:</b> 4 mg/m<sup>2</sup> IV on day 1 <br>Repeat cycle every 14 days for 6 cycles ', 'Low', 'Cassileth PA, et al.$J Clin Oncol. 1991;9:243-246.$', '<b>Hepatic Impairment</b><ul><li>Pentostatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Pentostatin : Nipent');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (280, 36, 'Interferon alfa-2a', '<b>Interferon alfa-2a</b>', '<b>Interferon alfa-2a:</b> 3 million IU SC or IM, 3 times per week<br>Continue treatment for up to 1 to 1.5 years.', 'Low', 'Ratain MJ, et al. $Blood 1985;65:644-648.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (281, 37, 'Bortezomib/Doxil', '<b>Bortezomib/Doxil</b>', '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11<br> <b>Pegylated liposomal doxorubicin</b> 30 mg/m<sup>2</sup> IV over 1 hour, day 4<br> Repeat every 21 days', 'Low', 'Doxil [package insert]. $Raritan, NJ: Centocor Ortho Biotech Products, LP; 2010.$<br> Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. $J clin Oncol. 2007;25(25):3892.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>', 'Bortezomib : Velcade');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (282, 37, 'Bortezomib/Doxorubicin/Dexamethasone', '<b>Bortezomib/Doxorubicin/Dexamethasone</b>', '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11<br> <b>Doxorubicin</b> 9 mg/m<sup>2</sup> IV, bolus days 1-4<br> <b>Dexamethasone</b> 40 mg PO days 1-4, 9-12, 17-20', 'Moderate', 'Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycin, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). $Blood. 2008;112(11):Abstract 653.$', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Bortezomib : Velcade<br>Dexamethasone : various<br>Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (283, 37, 'Bortezomib/Thalidomide/Dexamethasone (VTD)', '<b>Bortezomib/Thalidomide/Dexamethasone (VTD)</b>', '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV bolus, days 1, 4, 8, and 11<br> <b>Thalidomide</b> 100 mg PO daily for 14 days and 200 mg daily thereafter<br> <b>Dexamethasone</b> 40 mg PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12; total of 320 mg per cycle', 'Low', 'Cazo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. $Lancet. 2010;18;376(9758):2075-2085.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>', 'Bortezomib : Velcade<br>Thalidomide : Thalomid');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (284, 37, 'CyBorD', '<b>CyBorD</b>', '<b>Cyclophosphamide</b> 300 mg/m<sup>2</sup> PO days 1, 8, 15, 22<br> <b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV on days 1, 4, 8, and 11<br> <b>Dexamethasone</b> 40 mg PO days 1-4, 9-12, and 17-20<br> Repeat every 28 days', 'Moderate-High', 'Khan ML, Reeder CB, Kumar SK, et al. A comparison af lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethansone in newly diagnosed multiple myeloma. $Br J Haematol. 2011 [Epub ahead of print].$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Bortezomib : Velcade<br>Cyclophosphamide : Cytoxan<br>Dexamethasone : various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (285, 37, 'DT-PACE', '<b>DT-PACE</b>', '<b>Dexamethasone</b> 40 mg PO, days 1-4<br> <b> Thalidomide</b> 400 mg/d PO<br> <b>Cisplatin</b> 10 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Doxorubicin</b> 10 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Etoposide</b> 40 mg/m<sup>2</sup>/d CIVI, days 1-4', 'High', 'Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. $J Clin Oncol. 2003;21(14):2732-2739.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cisplatin : CDDP<br>Dexamethasone : various<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Thalidomide : Thalomid');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (286, 37, 'Lenalidomide/Dexamethasone', '<b>Lenalidomide/Dexamethasone</b>', '<b>Lenalidomide</b> 25 mg/d PO, days 1-21<br> <b>Dexamethasone</b> 40 mg/d PO, days 1-4, 9-12, 17-20<br> Repeat every 28 days for 4 cycles', 'Low', 'Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. $N Engl J Med. 2007;357(21):2123-2132.$', '<b>Hepatic Impairment</b><ul><li>Lenalidomide:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Lenalidomide:<br>Substantially excreted by kidney. Trials excluded patients with renal insufficiency </li></ul>', 'Dexamethasone : various<br>Lenalidomide : Revlimid');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (287, 37, 'Melphalan/Prednisone (MP)', '<b>Melphalan/Prednisone (MP)</b>', '<b>Melphalan</b> 8 - 10 mg per m<sup>2</sup>  on days 1 - 4<br> <b>Prednisone</b> 60 mg/m<sup>2</sup> days 1 - 4<br> Repeat cycle every 42 days', 'Low', ' $Southwest Oncology Group Study. Arch Intern Med 1975;135:147-152$', '<b>Hepatic Impairment</b><ul><li>Melphalan:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Melphalan:<br>PO: if CrCl < 30 mL/min, consider dose reduction  <br> IV: if BUN > 30 mg/dL, reduce dose by 50%</li></ul>', 'Melphalan : Alkeran<br>Prednisone : various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (288, 37, 'Melphalan/Prednisone/Talidomide (MPT)', '<b>Melphalan/Prednisone/Talidomide (MPT)</b>', '<b>Melphalan</b> 0.25 mg/kg PO, daily for 5 days<br> <b>Prednisone</b> 1 mg/kg PO, daily for 5 days<br> Repeat every 28 days for 8 cycles<br> <b>Thalidomide 50 - 100 mg PO, daily ', 'Low', ' $Palumbo A, et al. Lancet 2006;28:367-835.$', '<b>Hepatic Impairment</b><ul><li>Melphalan:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Melphalan:<br>PO: if CrCl < 30 mL/min, consider dose reduction  <br> IV: if BUN > 30 mg/dL, reduce dose by 50%</li></ul>', 'Melphalan : Alkeran<br>Prednisone : various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (289, 37, 'RVD', '<b>RVD</b>', '<b>Lenalidomide</b> 25 mg/d PO, days 1-14<br> <b> Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11<br> <b>Dexamethasone</b> 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 (cycles 1-4)<br> Repeat every 21 days for 8 cycles', 'Low', 'Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. $Blood. 2010;116(5):679-686.$', '<b>Hepatic Impairment</b><ul><li>Lenalidomide:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li><li>Lenalidomide:<br>Substantially excreted by kidney. Trials excluded patients with renal insufficiency </li></ul>', 'Bortezomib : Velcade<br>Dexamethasone : various<br>Lenalidomide : Revlimid');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (290, 37, 'VAD', '<b>VAD</b>', '<b>Vincristine</b> 0.4 mg/d CIVI, days 1-4<br> <b>Doxorubicin</b> 9 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Dexamethasone</b> 40 mg/d PO, days 1-4, 9-12, 17-20<br> Repeat every 25 days', 'Moderate', 'Segeren CM, Sonneveld P, Holt V, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. $Br J Haematol. 1999;105(1):127-130.$', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Dexamethasone : various<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (291, 37, 'VMP', '<b>VMP</b>', '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11, 22, 25, 29, 32 cycles 1-4<br> <b>FOLLOWED BY</b><br> <b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 8, 22, 29 cycles 5-9<br> <b>Melphalan</b> 9 mg/m<sup>2</sup> PO, days 1-4<br> <b>Prednisone</b> 60 mg/m<sup>2</sup> PO, days 1-4<br> Repeat every 6 weeks for 9 cycles', 'Low', 'San Miguel JF, Schalg R, Khuageva NK, et al. MMY-3002 a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. $Blood. 2007;110(11 pt 1): Abstract 78.$<br> San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. $N Engl J Med. 2008;359(9):906-917.$', '<b>Hepatic Impairment</b><ul><li>Melphalan:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li><li>Melphalan:<br>PO: if CrCl < 30 mL/min, consider dose reduction  <br> IV: if BUN > 30 mg/dL, reduce dose by 50%</li></ul>', 'Bortezomib : Velcade<br>Melphalan : Alkeran<br>Prednisone : various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (292, 37, 'Bortezomib', '<b>Bortezomib</b>', '<b>Bortezomib</b> 1.3 mg/m<sup>2</sup>/d IV bolus, days 1, 4, 8, 11<br> Repeat every 21 days ', 'Low', 'Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. $N Engl J Med. 2003;348(26):2609-2617.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>', 'Bortezomib : Velcade');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (293, 37, 'Dexamethasone', '<b>Dexamethasone</b>', '<b>Dexamethasone</b> 20 mg/m<sup>2</sup>/d PO, days 1-4, 9-12, 17-20<br> Repeat after 14-day rest period', 'N/A', 'Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. $Blood. 1992;80(4):887-890.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Dexamethasone : various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (294, 37, 'Thalidomide', '<b>Thalidomide</b>', '<b>Thalidomide</b> 200 mg/d PO at bedtime (increased dose every 2 weeks for 6 weeks up to a dose of 800 mg/d)', 'Low', 'Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. $N Engl J Med. 1999;341(21):1565-1571.$ $ Erratum in N Engl J Med. 2000;342(5):364.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Thalidomide : Thalomid');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (295, 37, 'Carfilzomib', '<b>Carfilzomib</b>', '<b>Carfilzomib</b> 20 mg/m<sub>2</sub>, Days 1,2,8,9,15, and 16, followed by a 12 day rest period<br> Repeat cycle every 28 days', 'Low', 'Siegel DS, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.$Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25$', '<b>Hepatic Impairment</b><ul><li>Carfilzomib:<br>The safety, efficacy and pharmacokinetics of Carfilzomib have not been evaluated in patients with baseline hepatic impairment.<br> Patients with the following laboratory values were excluded from the KYPROLIS clinical trials: ALT/AST = 3 × upper limit of normal (ULN) and bilirubin = 2 × ULN</li></ul><b>Renal Impairment</b><ul><li>Carfilzomib:<br>No dose adjustment recommended</li></ul>', 'Carfilzomib : Kyprolis');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (296, 37, 'Pomalidamide', '<b>Pomalidamide</b>', '<b>Pomalidamide</b>4 mg PO daily, from Day 1-21 <br>Repeat cycle every 28 days', 'Low', 'Leleu X, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.$Blood. 2013 Mar 14;121(11):1968-75. doi: 10.1182/blood-2012-09-452375. Epub 2013 Jan 14$', '<b>Hepatic Impairment</b><ul><li>Pomalidamide:<br>Avoid POMALYST in patients with serum bilirubin greater than 2.0 mg/dL and AST/ALTgreater than 3.0 x ULN.</li></ul><b>Renal Impairment</b><ul><li>Pomalidamide:<br>Avoid Pomalidamide in patients with a serum creatinine greater than 3.0 mg/dL.</li></ul>', 'Pomalidamide : Pomalyst');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (297, 38, 'CDDP/VP-16', '<b>CDDP/VP-16</b>', '<b>Cisplatin</b> 90 mg/m<sup>2</sup> IV, day 1<br> <b>Etoposide</b> 150 mg/m<sup>2</sup>/d IV, days 3, 4<br> Repeat every 21 days for 4 courses', 'High', 'Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. $J Clin Oncol. 1990;8(2):330-336.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cisplatin : CDDP<br>Etoposide : VP-16');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (298, 38, 'COPE or "Baby Brain I"', '<b>COPE or "Baby Brain I"</b>', '<u>CYCLE A</u><br> <b>Vincristine</b> 0.065 mg/kg/d (maximum, 1.5 mg) IV, days 1, 8<br> <b>Cyclophosphamide</b> 65 mg/kg/d IV over 30 minutes, day 1<br> <u>CYCLE B</u><br> <b>Cisplatin</b> 4 mg/kg/d IV over 6 hours, day 1<br> <b>Etoposide</b> 6.5 mg/kg/d IV over 1 hour, days 3, 4<br> Regimens given in alternating 28-day cycles in the sequence AABAAB', 'High', 'Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than 3 years of age with malignant brain tumors. $N Engl J Med. 1993;328(24):1725-1731.', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Etoposide : VP-16<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (299, 38, 'Vincristine/Cyclophosphamide/Cisplatin', 'Vincristine/Cyclophosphamide/Cisplatin', '<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 1,000 mg/m<sup>2</sup> IV, day 1<br> Repeat every 6 weeks for 8 cycles', 'High', 'Douglas JG, Barker JL, Ellenbogen RG, et al. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure. $Int J Radiat Oncol Biol Phys. 2004;58(4):1161-1164.$<br> National Cancer Institute. Phase III randomized study of adjuvant lomustine/cisplatin/vincristine vs cyclophosphamide/cisplatin/vincristine following craniospinal radiotherapy in children with newly diagnosed, average-risk medulloblastoma. $http://cancer.gov.clinicaltrials.CCG-A9961. Accessed January 27, 2012.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (300, 38, 'Carbo/VP-16/Vincristine', '<b>Carbo/VP-16/Vincristine</b>', '<u>CYCLES 1 AND 3 (3-WEEK CYCLES)</u><br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 1, 7, 14<br> <b>Etoposide</b> 100 mg/m<sup>2</sup> IV, days 1-3<br> <b>Carboplatin</b> 500 mg/m<sup>2</sup> IV, days 1, 2<br><br> <u>CYCLES 2 AND 4 (3-WEEK CYCLES)</u><br> <b>Vincristine<sup>d</sup></b> 1.5 mg/m<sup>2</sup> IV, days 1, 7, 14<br> <b>Etoposide</b> 100 mg/m<sup>2</sup> IV, days 1-3<br> <b>Cyclophosphamide</b> 1,500 mg/m<sup>2</sup> IV, day 1<br> <b>Mesna</b> 750 mg/m<sup>2</sup> IV, 15 minutes before and 4 and 8 hours after cyclophosphamide', 'High', 'Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children''s Cancer Study Group PNET-3 study. $J Clin Oncol. 2003;21(8):1581-1591.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Carboplatin : Paraplatin<br>Cyclophosphamide : Cytoxan<br>Etoposide : VP-16<br>Mesna : Mesnex, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (301, 38, 'POC', '<b>POC</b>', '<b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Lomustine</b> 100 mg/m<sup>2</sup> PO, day 1<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup>/d IV, days 1, 8, 15', 'Moderate', 'Finlay JL, Bayett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. $J Clin Oncol. 1995;13(1):112-123.$', '<b>Hepatic Impairment</b><ul><li>Lomustine:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Lomustine:<br>If CrCl < 60 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Lomustine : CCNU<br>Prednisone : various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (302, 38, 'Carboplatin', '<b>Carboplatin</b>', '<b>Carboplatin</b> 560 mg/m<sup>2</sup> IV over 1 hour<br> Repeat every 28 days', 'High', 'Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. $J Clin Oncol. 2000;18(22):3819-3828.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li></ul>', 'Carboplatin : Paraplatin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (303, 39, 'A<sub>1</sub>', '<b>A<sub>1</sub></b>', '<b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 3<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 90 mg/m<sup>2</sup> IV, day 5', 'High', 'Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. $J Pediatr Hematol Oncol. 2002;24(8):613-621.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (304, 39, 'A<sub>3</sub>', '<b>A<sub>3</sub></b>', '<b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup>/d IV, days 1, 2<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 3<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d CIVI, days 1-5', 'High', 'Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. $J Pediatr Hematol Oncol. 2002;24(8):613-621.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (305, 39, 'CAV + P/VP', '<b>CAV + P/VP</b>', '<u>CAV (COURSES 1, 2, 4, 6)</u><br> <b>Cyclophosphamide</b> 70 mg/kg/d IV over 6 hours, days 1, 2<br> <b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d CIVI for 72 hours<br><b>Vincristine</b>0.033mg/kg/d CIVI for 72 hours<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV bolus, day 9<br> <br><u>P/VP (COURSES 3, 5, 7)</u><br> <b>Etoposide</b> 200 mg/m<sup>2</sup>/d IV over 2 hours, days 1-3<br> <b>Cisplatin</b> 50 mg/m<sup>2</sup>/d IV over 1 hour, days 1-4', 'High', 'Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. $J Clin Oncol. 1994;12(12):2607-2613.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (306, 39, 'High-risk neuroblastoma', '<b>High-risk neuroblastoma</b>', '<b>Cisplatin</b> 60 mg/m<sup>2</sup> IV over 6 hours, day 0<br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV, day 2<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 2, 5<br> <b>Cyclophosphamide</b> 1,000 mg/m<sup>2</sup>/d IV, days 3, 4<br> Repeat every 28 days for 5 cycles', 'High', 'Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. $N Engl J Med. 1999;341(16):1165-1173.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cisplatin : CDDP<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (307, 40, 'Chemoreduction', '<b>Chemoreduction</b>', '<b>Vincristine</b> 0.05 mg/kg (for age <12 months)<br> <b>OR</b> 1.5-2 mg/m<sup>2</sup> (for age >12 months)<br> <b>Carboplatin</b> 20 mg/kg (for age <12 months)<br> <b>OR 550-600 mg/m<sup>2</sup> (for age >12 months)<br> <b>Etoposide phosphate</b> 5 mg/kg (for age <12 months) or 150 mg/m2 (for age >12 months)', 'High', 'Sussman DA, Escalona-Benz E, Benz MS, et al. Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. $Arch Ophthalmol. 2003;121(7):979-984.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Carboplatin : Paraplatin<br>Etoposide : VP-16<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (308, 41, 'CD', '<b>CD</b>', '<b>Cisplatin</b> 80 mg/m<sup>2</sup> CI over 24 hours (>1 year of age) <b>OR</b> 3 mg/kg (<1 year of age) IV over 6 hours with post-hydration fluid<br> <br>Doxorubicin</b> 30 mg/m<sup>2</sup>/d CIVI over 48 hours, days 2, 3<br> Administer 4 cycles before surgery, 2 cycles after surgery', 'High', 'Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach- results of the first prospective study of the International Society of Pediatric Oncology. $J Clin Oncol. 2000;18(22):3819-3828.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (309, 42, 'VAD', '<b>VAD</b>', '<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV weekly for 10 weeks, then every 3 weeks for 15 weeks<br> <b>Dactinomycin</b> 1.5 mg/m<sup>2</sup> IV every 6 weeks for 26 weeks<br> <b>ALTERNATING WITH</b><br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV every 6 weeks for 1 year (stage III)<br> <b>OR</b><br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, day 1<br> <b>Dactinomycin</b> 15 mcg/kg/d IV, days 1-5 or 60 mcg/kg IV, day 1<br> Repeat every 6 weeks; if stage III or IV, add:<br> <b>Doxorubicin</b> 20 mg/m<sup>2</sup> IV, day 1, and RT', 'Vincristine plus dactinomycin, high; vincristine plus doxorubicin, or doxorubicin-containing, moderate', 'Pritchard J, Imeson J , Barnes J, et al. Results of the United Kingdom Children''s Cancer Study Group first Wilms'' tumor study. $J Clin Oncol. 1995; 13(1):124-133.$<br>  de Camargo B, Franco EL. A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of Wilms'' tumor. $Cancer. 1994;73(12):3081-3086.$', '<b>Hepatic Impairment</b><ul><li>Dactinomycin:<br>If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Dactinomycin : Actinomycin<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (310, 43, 'IFoVP', '<b>IFoVP</b>', '<b>Ifosfamide</b> 1,800 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV over 1 hour, days 1-5<br> <b>Mesna</b> 2,880 mg/m<sup>2</sup>/d IV, days 1-5<br> Repeat every 21 days', 'High', 'Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. $J Clin Oncol. 1987;5(8):1191-1198.$', '<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (311, 43, 'MTX-CDDP/Adr', '<b>MTX-CDDP/Adr</b>', '<b>Methotrexate</b> 12,000 mg/m<sup>2</sup> IV weekly for 2 weeks; escalate dose by 1,000 mg/m<sup>2</sup> in subsequent courses until peak level of 10-8 M is reached (reduce dose to 8,000 mg/m<sup>2</sup> IV for patients >12 years)<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup> IV every 3 hours for 8 doses beginning 16 hours after completion of methotrexate, <b>THEN</b> every 6 hours PO for 8 doses<br> <b>ALTERNATING WITH</b><br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 15 of cycles 1-7,<br> <b>THEN</b> 120 mg/m<sup>2</sup> for cycles 8-10<br> <b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 15-17 of cycles 1-7', 'High', 'Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma. $Cancer Treat Rep. 1986;70(12):1431-1432.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Leucovorin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Leucovorin:<br>No dose reduction</li></ul>', 'Cisplatin : CDDP<br>Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (312, 43, 'VP/high-dose Ifos', '<b>VP/high-dose Ifos</b>', '<b>Etoposide</b> 100 mg/m<sup>2</sup> days 1-5<br> <b>Ifosfamide</b> 3,500 mg/m<sup>2</sup> days 1-5<br> <b>Mesna</b> 700 mg/m<sup>2</sup> over 4 hours, <b>THEN</b> mesna 700 mg/m<sup>2</sup> at hour 4, 7, 10, 13, days 1-5<br> <b>GCF</b> 5 mcg/kg/d begin day 6<br> Repeat in 3 weeks for a total of 2 courses', 'High', 'Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. $J Clin Oncol. 2002;20(2):426-433.', '<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Etoposide : VP-16<br>Ifosfamide : Ifex<br>Mesna : Mesnex, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (313, 44, 'ICE', '<b>ICE</b>', '<b>Ifosfamide</b> 1,800 mg/m<sup>2</sup>/d IV over 1 hour, days 0-4<br> <b>Carboplatin</b> 400 mg/m<sup>2</sup>/d IV over 1 hour, days 0, 1<br> <b>Etoposide 100 mg/m<sup>2</sup>/d IV over 1 hour, days 0-4', 'High', 'Cairo MS. The use of ifosfamide, carboplatin, and etoposide in children with solid tumors. $Semin Oncol. 1995;22(3 suppl 7):23-27.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Carboplatin : Paraplatin<br>Etoposide : VP-16<br>Ifosfamide : Ifex');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (314, 44, 'VCR/Cyclophosphamide', '<b>VCR/Cyclophosphamide</b>', '<b>Vincristine</b> 2 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 75 mg/m<sup>2</sup> IV bolus, day 1<br> <b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days', 'High', 'Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing''s sarcoma and primitive neuroectodermal tumor of bone. $N Engl J Med. 2003;348(8):694-701.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (315, 44, 'P6', '<b>P6</b>', '<u>CYCLES 1, 2, 3 AND 6</u><br> <b>Cyclophosphamide</b> 2,100 mg/m<sup>2</sup>/d IV, days 1, 2<br> <b>Doxorubicin</b> 25 mg/m<sup>2</sup> CIVI, days 1-3<br> <b>Vincristine</b> 0.67 mg/m2 (maximum, 2 mg/cycle0 CIVI, days 1-3<br><br> <u>CYCLES 4, 5 AND 7</u><br> <b>Ifosfamide</b> 1,800 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5', 'High', 'Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing''s family of tumors in children and young adults. $J Clin Oncol. 2003;21(18):3423-3430.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Ifosfamide : Ifex<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (316, 44, 'Topo/CTX', '<b>Topo/CTX</b>', '<b>Cyclophosphamide</b> 250 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>FOLLOWED BY</b><br> <b>Topotecan</b> 0.6-0.75 mg/m<sup>2</sup>/d IV as an escalating dose, days 1-5', 'High', 'Saylors RL, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncolgy Group study. $J Clin Oncol. 1998;16(3):945-952.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>', 'Cyclophosphamide : Cytoxan<br>Topotecan : Hycamtin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (317, 44, 'VAC', '<b>VAC</b>', '<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV weekly for 3 weeks<br> <b>Dactinomycin</b> 0.015 mg/kg/d (maximum, 0.5 mg/kg/d) IV for 5 days<br> <b>Cyclophosphamide</b> 2,200 mg/m<sup>2</sup> IV, day 1', 'High', 'Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. $J Clin Oncol. 2001;19(12):3091-3102.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Dactinomycin:<br>If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Dactinomycin : Actinomycin<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (318, 45, 'ABVD', '<b>ABVD</b>', '<b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Bleomycin</b> 10 units/m<sup>2</sup>/d IV, days 1, 15<br> <b>Vinblastine</b> 6 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Dacarbazine</b> 375 mg/m<sup>2</sup>/d IV, days 1, 15<br> Repeat every 14 days for 12 courses', 'High', 'Fryer CJ, Hutchinson RJ, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD therapy followed by low-dose regional radiation in advanced Hodgkin''s disease in children: a report from the Children''s Cancer Study Group. $J Clin Oncol. 1990;8(12):1971-1980.$', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vinblastine:<br>No dose reduction </li></ul>', 'Bleomycin : Blenoxane<br>Dacarbazine : DTIC<br>Doxorubicin : Adriamycin, various<br>Vinblastine : Velban');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (319, 45, 'BEACOPP', '<b>BEACOPP</b>', '<b>Bleomycin</b> 10 units/m<sup>2</sup> IV, day 7<br> <b>Etoposide</b> 200 mg/m<sup>2</sup>/d IV, days 0-2<br> <b>Doxorubicin</b> 35 mg/m<sup>2</sup> IV, day 0<br> <b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 0<br> <b>Vincristine</b> 2 mg/m<sup>2</sup> IV, day 7<br> <b>Procarbazine</b> 100 mg/m<sup>2</sup>/d PO, days 0-6<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO, days 0-13<br> Repeat every 21 days', 'High', 'Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin''s lymphoma: preliminary results from the Children''s Cancer Group Study Ccg-59704. $Ann Oncol. 2002;13(suppl 1):107-111.', '<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Procarbazine:<br>If CrCl < 30 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Bleomycin : Blenoxane<br>Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Etoposide : VP-16<br>Prednisone : various<br>Procarbazine : Matulane<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (320, 45, 'CHOP', '<b>CHOP</b>', '<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup>/d IV, days 1, 22<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup>/d IV, days 1, 22<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV weekly for 6 doses<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO for 28 days', 'Moderate', 'Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy JB. Results of treatment of childhood localized non-Hodgkin''s lymphoma with combination chemotherapy with or without radiotherapy. $N Engl J Med. 1990;322(17):1169-1174.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Doxorubicin : Adriamycin, various<br>Prednisone : various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (321, 46, 'SNCCL/B-ALL', '<b>SNCCL/B-ALL</b>', '<u>INITIAL PHASE</u><br> <b>Cytarabine</b> 50 mg/m<sup>2</sup>/d (maximum, 50 mg/d) IT, days 1, 2, 3, 11<br> <b>Methotrexate</b> 12 mg/m<sup>2</sup>/d (maximum, 12 mg/d) IT, days 4, 11<br> <b>Cyclophosphamide</b> 300 mg/m<sup>2</sup> IV push every 12 hours for 6 doses, days 1-3<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV, day 4<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup>/d IV, days 4, 11<br> <b>ALTERNATING WITH</b><br><br> <u>SECONDARY PHASE</u><br> <b>Cytarabine</b> 50 mg/m<sup>2</sup> (maximum, 50 mg) IT, day 1<br> <b>Methotrexate</b> 12 mg/m<sup>2</sup> (maximum, 12 mg) IT, day 1<br> <b>Methotrexate</b> 200 mg/m<sup>2</sup> IV bolus,<br> <b>THEN</b> 800 mg/m<sup>2</sup> CIVI<br> <b>Cytarabine</b> 3,000 mg/m<sup>2</sup> IV over 3 hours every 12 hours for 4 doses, days 2, 3<br> <b>Leucovorin calcium</b> 30 mg/m<sup>2</sup> IV at hour 42, then 3 mg/m<sup>2</sup> IV at hours 54, 66, 78', 'High', 'Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study. $J Clin Oncol. 1996;14(4):1252-1261.$', '<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Cyclophosphamide : Cytoxan<br>Cytarabine : Ara-C<br>Doxorubicin : Adriamycin, various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (322, 47, 'VCR/Asparaginase/Dex/MTX', '<b>VCR/Asparaginase/Dex/MTX</b>', '<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 0,7, 14, 21<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> IM, 3 times weekly for 9 doses, starting on days 2-4<br> <b>Dexamethasone</b> 6 mg/m<sup>2</sup>/d PO in 3 equal doses (was substituted for prednisone)<br> <b>Methotrexate</b> 8, 10, or 12 mg IT, age-adjusted, days 0, 14 (also days 7, 21 for patients with CNS disease at diagnosis)<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO', 'Moderate for MTX agent IT, minimal for others', 'Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children''s Cancer Group. $Blood 2003;101(10):3809-3817.$', '<b>Hepatic Impairment</b><ul><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>', 'Dexamethasone : various<br>Prednisone : various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (323, 47, 'VCR/Prednisone/Pegaspargase/Cytarabine/MTX', '<b>VCR/Prednisone/Pegaspargase/Cytarabine/MTX</b>', '<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 0, 7, 14, 21<br> <b>Prednisone</b> 40 mg/m<sup>2</sup> PO, days 0-28, then 10-day taper<br> <b>Pegaspargase</b> 2,500 units/m<sup>2</sup> IM, day 3<br> <b>Cytarabine</b> 30, 50, or 70 mg IT, age-adjusted, day 0<br> <b>Methotrexate</b> 8, 10, <b>OR</b> 12 mg IT, age-adjusted, days 7, 28', 'Moderate for MTX agent IT, minimal for others', 'Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children''s Cancer Group Study. $Blood. 2002;99(6):1986-1994.$ $Erratum in: Blood. 2002; 100(6):1531.$', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>', 'Cytarabine : Ara-C<br>Prednisone : various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (324, 47, 'Nelarabine', '<b>Nelarabine</b>', '<b>Nelarabine</b> 650 mg/m<sup>2</sup>/d IV, over 1 hour for 5 consecutive days<br> Repeat every 21 days', 'Low', 'Arranon [package insert]. $Research Triangle Park, NC: GlaxoSmithKline; 2011.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (325, 47, 'OD', '<b>OD</b>', '<b>Dexamethasone</b> 6 mg/m<sup>2</sup>/d PO, days 1-28<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> IM, 3 times weekly for 9 doses<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 0, 7, 14, 21<br> <b>Methotrexate</b> 8-12 mg IT, age-adjusted dosing schedule', 'Moderate', 'Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children''s Cancer Group. $Blood 2003;101(10):3809-3817.$', '<b>Hepatic Impairment</b><ul><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>', 'Dexamethasone : various<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (326, 47, 'PVDA', '<b>PVDA</b>', '<b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO, days 1-28<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup>/d IV, days 2, 8, 15, 22<br> <b>Daunorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 2, 8, 15, 22<br> <b>Asparaginase</b> 5,000 units/m<sup>2</sup>/d IM, days 2, 5, 8, 12, 15, 19', 'Moderate', 'Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of hgh-risk chidhood acute lymphoblastic leukemia. Apediatric Oncology Group pilot study. $Cancer. 1993;71(9):2854-2861.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (327, 47, 'TIT (CNS Prophylaxis)', '<b>TIT (CNS Prophylaxis)</b>', '<u>Regimen <%0B>Age 1y <%0B>Age 2y <%0B>Age>=3y</u><br> <b>Methotrexate</b> <%0B>10 mg <%0B>12.5 mg <%0B>15 mg<br> <b>Cytarabine</b> <%0B>20 mg <%0B>25 mg <%0B>30 mg<br> <b>Hydrocortisone</b> <%0B>10 mg <%0B>12.5 mg <%0B>15 mg<br> <b>Administer</b> IT on day 1, then at weeks 1, 2, 3, 6, 11, 16, 21, 26, 31, then every 12 weeks', 'Moderate', 'Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of hgh-risk chidhood acute lymphoblastic leukemia. Apediatric Oncology Group pilot study. $Cancer. 1993;71(9):2854-2861.$', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>', 'Cytarabine : Ara-C<br>Hydrocortisone : various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (329, 47, 'IDMTX', '<b>IDMTX</b>', '<u>WEEK 1</u><br> <b>Methotrexate</b> 1,000 mg/m<sup>2</sup> IV over 24 hours<br> <b>FOLLOWED BY</b><br> <b>Mercaptopurine</b> 1,000 mg/m<sup>2</sup> IV over 6 hours<br> <b>THEN</b> (48 hours after the start of Methotrexate)<br> <b>Leucovorin calcium</b> 5 mg/m<sup>2</sup> IV every 6 hours for at least 5 doses<br> <u>WEEK 2</u><br> <b>Methotrexate</b> 20 mg/m<sup>2</sup> IM, day 1<br> <b>Mercaptopurine</b> 50 mg/m<sup>2</sup>/d PO, days 1-7<br> Repeat 2-week cycle times 12', 'Week 1, high; week 2, minimal', 'Mahoney DH, Shuster JJ, Nitschke R, et al. Intensification with intermediate-dose intravenous methotrexate is effectie therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. $J Clin Oncol. 2000;18(6):1285-1294.$', '<b>Hepatic Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (330, 47, '6-MP/ MTX', '<b>6-MP/ MTX</b>', '<b>Mercaptopurine</b> 25 mg/m<sup>2</sup>/d PO, days 1-56<br> <b>Methotrexate</b> 5,000 mg/m<sup>2</sup> IV over 24 hours, days 8, 22, 36, 50<br> <b>Methotrexate</b> 12 mg/d IT (adjust dose for children<3 years), days 8, 22, 36, 50', 'Moderate', 'Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. $Blood. 2000;95(11):3310-3322.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (331, 47, 'MTX/6-MP', '<b>MTX/6-MP</b>', '<b>Methotrexate</b> 20 mg/m<sup>2</sup> IM weekly, weeks 25-130<br> <b>Mercaptopurine</b> 50 mg/m<sup>2</sup>/d PO, weeks 25-130', 'Low', 'Camitta B, Leventhal B, Lauer S, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of chldhood: a Pediatric Oncology Group study. $J Clin Oncol. 1989;7(10):1539-1544.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (332, 48, 'CA', '<b>CA</b>', '<b>Cytarabine</b> 3,000 mg/m<sup>2</sup> IV over 3 hours every 12 hours for 4 doses<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> IM 3 hours after last dose of cytarabine<br> Repeat 28 days after initial cycle or after recovery of blood counts, whichever is later', 'high', 'Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. $Cancer. 2006;66(6):1106-1113.$', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>', 'Cytarabine : Ara-C');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (333, 48, 'DA', '<b>DA</b>', '<b>Daunorubicin</b> 45 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cytarabine</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-7', 'Moderate', 'Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. $Cancer. 2006;66(6):1106-1113.$', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li></ul>', 'Cytarabine : Ara-C');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (334, 48, 'DAT', '<b>DAT</b>', '<b>Daunorubicin</b> 45 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cytarabine</b> 100 mg/m<sup>2</sup>/d IV, days 1-7<br> <b>Thioguanine</b> 100 mg/m<sup>2</sup>/d PO, days 1-7', 'Moderate', 'Ravindranath Y, Steuber CP, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. $J Clin Oncol. 1991;9(4):572-580.$', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Thioguanine:<br>If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li></ul>', 'Cytarabine : Ara-C<br>Thioguanine : 6-TG');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (335, 48, 'DCTER', '<b>DCTER</b>', '<b>Dexamethasone</b> 6 mg/m<sup>2</sup>/d (if age < 3 yeras 0.2mg/kg/d) PO tid, days 0-4<br> <b>Cytarabine</b> 200 mg/m<sup>2</sup>/d (if age < 3 yeras 6.7 mg/kg/d) CIVI, days 0-4<br> <b>Thioguanine</b> 100 mg/m<sup>2</sup>/d (if age < 3 yeras 3.3 mg/kg/d) PO bid, days 0-4<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d (if age < 3 yeras 3.3 mg/kg/d) CIVI, days 0-4<br> <b>Daunorubicin</b> 20 mg/m<sup>2</sup>/d (if age < 3 yeras 0.67 mg/kg/d) CIVI, days 0-4<br> <b>Cytarabine</b> IT (age-based doses)<br> Doses in parentheses used for children <3 years of age', 'Moderate', 'Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children''s Cancer Group. $Blood. 1996;87(12):4979-4989.$', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Thioguanine:<br>If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Cytarabine : Ara-C<br>Dexamethasone : various<br>Etoposide : VP-16<br>Thioguanine : 6-TG');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (336, 48, 'HI-C DAZE', '<b>HI-C DAZE</b>', '<b>Daunorubicin</b> 30 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cytarabine</b> 3,000 mg/m<sup>2</sup>/d IV every 12 hours, days 1-4<br> <b>Etoposide</b> 200 mg/m<sup>2</sup>/d IV, days 1-3, 6-8<br> <b>Azacitidine</b> 150 mg/m<sup>2</sup>/d IV, days 3-5, 8-10', 'High', 'Hurwitz CA, Mounce KG, Grier HE. Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. $J Pediatr Hematol Oncol. 1995;17(3):185-197.$', '<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>', 'Azacitidine : Vidaza<br>Cytarabine : Ara-C<br>Etoposide : VP-16');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (337, 48, 'MACE/consolidation', '<b>MACE/consolidation</b>', '<b>Amsacrine</b> 100 mg/m<sup>2</sup> IV (1-hour infusion), days 1-5<br> <b>Cytarabine</b> 200 mg/m<sup>2</sup> CIVI, days 1-5<br> <b>Etoposide</b> 100 mg/m<sup>2</sup> IV (1-hour infusion), days 1-5', 'Low', 'Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council''s 10th AML trial. $Br J Haematol. 1998;101(1):130-140.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (338, 48, 'MidAC', '<b>MidAC</b>', '<b>Mitoxantrone</b> 10 mg/m<sup>2</sup> IV (short infusion), days 1-5<br> <b>Cytarabine</b> 1,000 mg/m<sup>2</sup> IV (2-hour infusion), every 12 hours, days 1-3', 'Moderate', 'Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council''s 10th AML trial. $Br J Haematol. 1998;101(1):130-140.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');



create table gen2brand(generic TEXT, brand_name TEXT);
insert into gen2brand(generic, brand_name) values ('Obinutuzumab','Gazyva');
insert into gen2brand(generic, brand_name) values ('Ibrutinib','Imbruvica');
insert into gen2brand(generic, brand_name) values ('Ofatumumab','Arzerra');
insert into gen2brand(generic, brand_name) values ('Blinatumomab','Blincyto');
insert into gen2brand(generic, brand_name) values ('Ixazomib','Ninlaro');
insert into gen2brand(generic, brand_name) values ('Daratumumab','Darzalex');
insert into gen2brand(generic, brand_name) values ('Nivolumab','Opdivo');
insert into gen2brand(generic, brand_name) values ('Axitinib','Inlyta');
insert into gen2brand(generic, brand_name) values ('Vemurafinib','Zelboraf');
insert into gen2brand(generic, brand_name) values ('Ipilumimab','Yervoy');
insert into gen2brand(generic, brand_name) values ('Dabrafenib','Tafinlar');
insert into gen2brand(generic, brand_name) values ('Trametinib','Mekinist');
insert into gen2brand(generic, brand_name) values ('Cobimetinib','Cotellic');
insert into gen2brand(generic, brand_name) values ('Pembrolizumab','Keytruda');
insert into gen2brand(generic, brand_name) values ('Trifluridine/Tiparcil','Lonsurf');
insert into gen2brand(generic, brand_name) values ('Elotuzumab','Empliciti');
insert into gen2brand(generic, brand_name) values ('Ramucirumab','Cyramza');
insert into gen2brand(generic, brand_name) values ('Nab-Paclitaxel','Abraxane');
insert into gen2brand(generic, brand_name) values ('Irinotecan liposome','Onivyde');
insert into gen2brand(generic, brand_name) values ('Everolimus','Afinitor');
insert into gen2brand(generic, brand_name) values ('Idelalisib','Zydellig');
insert into gen2brand(generic, brand_name) values ('Pertuzumab','Perjeta');
insert into gen2brand(generic, brand_name) values ('Ado-trastuzumab','Kadcyla');
insert into gen2brand(generic, brand_name) values ('Ceritinib','Zykadia');
insert into gen2brand(generic, brand_name) values ('Necitumumab','Portrazza');
insert into gen2brand(generic, brand_name) values ('Osimertinib','Tagrisso');
insert into gen2brand(generic, brand_name) values ('Afatinib','Gilotrif');
insert into gen2brand(generic, brand_name) values ('Gefitinib','Iressa');
insert into gen2brand(generic, brand_name) values ('Belinostat','Beleodaq');
insert into gen2brand(generic, brand_name) values ('Brentuximabvedotin','Adcetris');
